
<html lang="en"     class="pb-page"  data-request-id="26cdfa85-839e-472f-a544-48033686a242"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2017.60.issue-1;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.6b01310;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms" /></meta><meta name="dc.Creator" content="Ling  Tong" /></meta><meta name="dc.Creator" content="Wensheng  Yu" /></meta><meta name="dc.Creator" content="Lei  Chen" /></meta><meta name="dc.Creator" content="Oleg  Selyutin" /></meta><meta name="dc.Creator" content="Michael P.  Dwyer" /></meta><meta name="dc.Creator" content="Anilkumar G.  Nair" /></meta><meta name="dc.Creator" content="Robert  Mazzola" /></meta><meta name="dc.Creator" content="Jae-Hun  Kim" /></meta><meta name="dc.Creator" content="Deyou  Sha" /></meta><meta name="dc.Creator" content="Jingjun  Yin" /></meta><meta name="dc.Creator" content="Rebecca T.  Ruck" /></meta><meta name="dc.Creator" content="Ian W.  Davies" /></meta><meta name="dc.Creator" content="Bin  Hu" /></meta><meta name="dc.Creator" content="Bin  Zhong" /></meta><meta name="dc.Creator" content="Jinglai  Hao" /></meta><meta name="dc.Creator" content="Tao  Ji" /></meta><meta name="dc.Creator" content="Shuai  Zan" /></meta><meta name="dc.Creator" content="Rong  Liu" /></meta><meta name="dc.Creator" content="Sony  Agrawal" /></meta><meta name="dc.Creator" content="Ellen  Xia" /></meta><meta name="dc.Creator" content="Stephanie  Curry" /></meta><meta name="dc.Creator" content="Patricia  McMonagle" /></meta><meta name="dc.Creator" content="Karin  Bystol" /></meta><meta name="dc.Creator" content="Frederick  Lahser" /></meta><meta name="dc.Creator" content="Donna  Carr" /></meta><meta name="dc.Creator" content="Laura  Rokosz" /></meta><meta name="dc.Creator" content="Paul  Ingravallo" /></meta><meta name="dc.Creator" content="Shiying  Chen" /></meta><meta name="dc.Creator" content="Kung-I  Feng" /></meta><meta name="dc.Creator" content="Mark  Cartwright" /></meta><meta name="dc.Creator" content="Ernest  Asante-Appiah" /></meta><meta name="dc.Creator" content="Joseph A.  Kozlowski" /></meta><meta name="dc.Description" content="We describe the research that led to the discovery of compound 40 (ruzasvir, MK-8408), a pan-genotypic HCV nonstructural protein 5A (NS5A) inhibitor with a “flat” GT1 mutant profile. This NS5A inhi..." /></meta><meta name="Description" content="We describe the research that led to the discovery of compound 40 (ruzasvir, MK-8408), a pan-genotypic HCV nonstructural protein 5A (NS5A) inhibitor with a “flat” GT1 mutant profile. This NS5A inhi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 15, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01310" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01310" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01310" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01310" /></link>
        
    
    

<title>Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01310" /></meta><meta property="og:title" content="Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0024.jpeg" /></meta><meta property="og:description" content="We describe the research that led to the discovery of compound 40 (ruzasvir, MK-8408), a pan-genotypic HCV nonstructural protein 5A (NS5A) inhibitor with a “flat” GT1 mutant profile. This NS5A inhibitor contains a unique tetracyclic indole core while maintaining the imidazole–proline–valine Moc motifs of our previous NS5A inhibitors. Compound 40 is currently in early clinical trials and is under evaluation as part of an all-oral DAA regimen for the treatment of chronic HCV infection." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01310"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01310">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01310&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01310&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01310&amp;href=/doi/10.1021/acs.jmedchem.6b01310" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 290-306</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01290" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01284" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ling++Tong">Ling Tong</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-3302-8184" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wensheng++Yu">Wensheng Yu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-5978-9454" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Chen">Lei Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Oleg++Selyutin">Oleg Selyutin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+P.++Dwyer">Michael P. Dwyer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anilkumar+G.++Nair">Anilkumar G. Nair</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert++Mazzola">Robert Mazzola</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jae-Hun++Kim">Jae-Hun Kim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deyou++Sha">Deyou Sha</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jingjun++Yin">Jingjun Yin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rebecca+T.++Ruck">Rebecca T. Ruck</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ian+W.++Davies">Ian W. Davies</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bin++Hu">Bin Hu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bin++Zhong">Bin Zhong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jinglai++Hao">Jinglai Hao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tao++Ji">Tao Ji</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shuai++Zan">Shuai Zan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rong++Liu">Rong Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sony++Agrawal">Sony Agrawal</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ellen++Xia">Ellen Xia</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephanie++Curry">Stephanie Curry</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patricia++McMonagle">Patricia McMonagle</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karin++Bystol">Karin Bystol</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Frederick++Lahser">Frederick Lahser</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Donna++Carr">Donna Carr</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Laura++Rokosz">Laura Rokosz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Ingravallo">Paul Ingravallo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shiying++Chen">Shiying Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kung-I++Feng">Kung-I Feng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Cartwright">Mark Cartwright</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ernest++Asante-Appiah">Ernest Asante-Appiah</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+A.++Kozlowski">Joseph A. Kozlowski</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Department of Medicinal Chemistry, <sup>‡</sup>Department of Discovery Biology, <sup>§</sup>Department of Pharmacokinetics, and <sup>∥</sup>Department of Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div><div class="aff-info" id="aff2"><span class="aff-text"><sup>⊥</sup>Department of Process and Analytical Chemistry, and <sup>#</sup>Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">∇</span> <span class="aff-text">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div><div class="corresp-info"><strong>*</strong>Phone: 908-740-3383. E-mail: <a href="/cdn-cgi/l/email-protection#d6babfb8b1f8a2b9b8b196bbb3a4b5bdf8b5b9bb"><span class="__cf_email__" data-cfemail="600c090e074e140f0e07200d0512030b4e030f0d">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01310&amp;href=/doi/10.1021%2Facs.jmedchem.6b01310" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 290–306</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 3, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 August 2016</li><li><span class="item_label"><b>Published</b> online</span>15 November 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 January 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01310" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01310</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01310"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3496</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">33</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01310" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ling&quot;,&quot;last_name&quot;:&quot;Tong&quot;},{&quot;first_name&quot;:&quot;Wensheng&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Oleg&quot;,&quot;last_name&quot;:&quot;Selyutin&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;P. Dwyer&quot;},{&quot;first_name&quot;:&quot;Anilkumar&quot;,&quot;last_name&quot;:&quot;G. Nair&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Mazzola&quot;},{&quot;first_name&quot;:&quot;Jae-Hun&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Deyou&quot;,&quot;last_name&quot;:&quot;Sha&quot;},{&quot;first_name&quot;:&quot;Jingjun&quot;,&quot;last_name&quot;:&quot;Yin&quot;},{&quot;first_name&quot;:&quot;Rebecca&quot;,&quot;last_name&quot;:&quot;T. Ruck&quot;},{&quot;first_name&quot;:&quot;Ian&quot;,&quot;last_name&quot;:&quot;W. Davies&quot;},{&quot;first_name&quot;:&quot;Bin&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Bin&quot;,&quot;last_name&quot;:&quot;Zhong&quot;},{&quot;first_name&quot;:&quot;Jinglai&quot;,&quot;last_name&quot;:&quot;Hao&quot;},{&quot;first_name&quot;:&quot;Tao&quot;,&quot;last_name&quot;:&quot;Ji&quot;},{&quot;first_name&quot;:&quot;Shuai&quot;,&quot;last_name&quot;:&quot;Zan&quot;},{&quot;first_name&quot;:&quot;Rong&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Sony&quot;,&quot;last_name&quot;:&quot;Agrawal&quot;},{&quot;first_name&quot;:&quot;Ellen&quot;,&quot;last_name&quot;:&quot;Xia&quot;},{&quot;first_name&quot;:&quot;Stephanie&quot;,&quot;last_name&quot;:&quot;Curry&quot;},{&quot;first_name&quot;:&quot;Patricia&quot;,&quot;last_name&quot;:&quot;McMonagle&quot;},{&quot;first_name&quot;:&quot;Karin&quot;,&quot;last_name&quot;:&quot;Bystol&quot;},{&quot;first_name&quot;:&quot;Frederick&quot;,&quot;last_name&quot;:&quot;Lahser&quot;},{&quot;first_name&quot;:&quot;Donna&quot;,&quot;last_name&quot;:&quot;Carr&quot;},{&quot;first_name&quot;:&quot;Laura&quot;,&quot;last_name&quot;:&quot;Rokosz&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Ingravallo&quot;},{&quot;first_name&quot;:&quot;Shiying&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Kung-I&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Cartwright&quot;},{&quot;first_name&quot;:&quot;Ernest&quot;,&quot;last_name&quot;:&quot;Asante-Appiah&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;A. Kozlowski&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;290-306&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01310&quot;},&quot;abstract&quot;:&quot;We describe the research that led to the discovery of compound 40 (ruzasvir, MK-8408), a pan-genotypic HCV nonstructural protein 5A (NS5A) inhibitor with a “flat” GT1 mutant profile. This NS5A inhibitor contains a unique tetracyclic indole core while maintaining the imidazole–proline–valine Moc motifs of our previous NS5A inhibitors. Compound 40 is currently in early clinical trials and is under evaluation as part of an all-oral DAA regimen for the treatment of chronic HCV infection.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01310&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01310" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01310&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01310" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01310&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01310" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01310&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01310&amp;href=/doi/10.1021/acs.jmedchem.6b01310" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01310" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01310" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01310%26sid%3Dliteratum%253Aachs%26pmid%3D27808515%26genre%3Darticle%26aulast%3DTong%26date%3D2017%26atitle%3DDiscovery%2Bof%2BRuzasvir%2B%2528MK-8408%2529%253A%2BA%2BPotent%252C%2BPan-Genotype%2BHCV%2BNS5A%2BInhibitor%2Bwith%2BOptimized%2BActivity%2Bagainst%2BCommon%2BResistance-Associated%2BPolymorphisms%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D1%26spage%3D290%26epage%3D306%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291749" title="Thiophenes">Thiophenes</a>,</li><li><a href="/action/doSearch?ConceptID=291430" title="Infectious diseases">Infectious diseases</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=291862" title="Indoles">Indoles</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/1" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/jmcmar.2017.60.issue-1/20170112/jmcmar.2017.60.issue-1.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01310&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We describe the research that led to the discovery of compound <b>40</b> (ruzasvir, MK-8408), a pan-genotypic HCV nonstructural protein 5A (NS5A) inhibitor with a “flat” GT1 mutant profile. This NS5A inhibitor contains a unique tetracyclic indole core while maintaining the imidazole–proline–valine Moc motifs of our previous NS5A inhibitors. Compound <b>40</b> is currently in early clinical trials and is under evaluation as part of an all-oral DAA regimen for the treatment of chronic HCV infection.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33621" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33621" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hepatitis C virus (HCV) infection has become the most common blood-born infection in developed countries.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Recent estimates of disease burden show an increase in seroprevalence over the period of 15 years (between 1990 and 2005) to ∼2.8% of the global population, more than 185 million infections worldwide.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> HCV infection is initially asymptomatic; as the duration of chronic infection increases, symptoms become manifested as increased liver disease including fibrosis, cirrhosis (compensated and decompensated), and hepatocellular carcinoma.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Advances in treatment regimens have resulted in significantly improved outcomes for many patients. However, not every patient becomes cured; hence, there remains a medical need in the treatment of these patient populations.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a></div><div class="NLM_p">The challenge in treating HCV originates from the diversity present in the virus where it is classified into seven major genotypes, with more than 50 subtypes known.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Early treatment options such as interferon and ribavirin were poorly tolerated and showed limited efficacy due to the emergence of resistance-associated variants (RAVs). Over time, a consensus emerged that a better tolerated, more efficacious treatment was needed and that the diversity of HCV infection might best be addressed through administration of a combination of several direct-acting antiviral agents (DAAs), each targeting a different step in the replication cycle of the virus.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> This approach provides a chance to overcome poor treatment outcomes by allowing the combination of multiple mechanisms to suppress the emergence of RAVs escaping from any single mechanism. This approach has become the current treatment paradigm and has led to the improvement in patient outcomes. From this strategy, three major categories of drugs have been developed including NS3/4A protease inhibitors, NS5A replication complex inhibitors, and NS5B polymerase nucleotide and non-nucleotide inhibitors. The ideal profile for each component of the DAA regimen includes high potency, high barrier to resistance, pan-genotype activity, few drug–drug interactions (DDIs), minimal toxicity, and a pharmacokinetic profile that allows once-daily oral dosing.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">An area of high interest for Merck & Co., Inc. has been the identification and development of potent NS5A inhibitors to be used as part of an all-oral DAA regimen.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9 ref10 ref11">(6-11)</a> The exact mechanism of NS5A inhibition remains unclear and is poorly understood; however, NS5A plays a critical role in viral ribonucleic acid (RNA) synthesis and virion assembly.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> As a therapeutic target, NS5A has been validated clinically, where multiple inhibitors were shown to be well tolerated and to produce rapid and robust viral load declines in patients.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13-15)</a> Today NS5A inhibitors have become an integral part of DAA regimens with five NS5A inhibitors currently used in clinical practice for HCV treatment including daclatasvir (BMS-790052),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> ledipasvir (GS-5885),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> ombitasvir (ABT-267),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> elbasvir (MK-8742, <b>1</b>),<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and velpatasvir (GS-5816).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0022.gif" alt="" id="GRAPHIC-d171e529-autogenerated" /></img><div class="NLM_p">In a continued effort to develop NS5A inhibitors, we asked the question: Is it possible to identify an inhibitor with potent activity against all genotypes and a minimal potency shift from the wild type virus to previously identified RAVs, selected by existing NS5A inhibitors, particularly in the most prevalent GT1a? We use the term “flat compound” to describe such a pan-genotype inhibitor with a minimal potency loss (∼10-fold) between the wild-type virus and clinically relevant polymorphisms. In addition, the desired flat compound should also maintain sufficiently good pharmacokinetic parameters to support once-daily dosing and suitable pharmaceutical properties in order to enable a fixed-dose combination (FDC) with partner DAAs. We now describe the structural modifications to the core structure of <b>1</b> that led to the discovery of MK-8408 (<b>40</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>),<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> also known as ruzasvir, a potent NS5A inhibitor with a flat in vitro profile. Compound <b>40</b> is currently undergoing clinical testing as part of an all-oral, interferon-free DAA regimen for the treatment of chronic HCV infection.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Compound <b>40</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01310&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21145" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21145" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">From our experience in the development of NS5A inhibitors, we observed that the GT 1a RAV 1aY93H consistently conferred a high level of resistance across a range of different molecules.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9 ref10 ref11">(6-11)</a> However, we also observed that molecules with improved inhibition of GT1a_Y93H often resulted in similar or better inhibition of other GT1 variants. We hypothesized that gaining the ability to better inhibit this RAV might provide a path toward the flat profile we desired, and therefore GT1a_Y93H was selected as a part of the screening set for SAR optimization. Concurrent with the selection of GT1a_Y93H, GT1a_L31V was also picked for optimization, as it offered diversity in a mutation at a different location in the protein. GT2b(31M) was also added to the screening set, as it represented a clinically important non-genotype 1 example. Inclusion of GT3a and GT4a offered verification of performance against additional genotypes. Acknowledging the risk associated with defining SAR with a focus on GT1a_Y93H, GT1a_L31V, and 2b, where the SAR may not translate to other genotypes and RAVs, we proceeded with the strategy and decided to validate it by periodically checking the full virologic profile of key compounds. The discussion herein is restricted to replicon EC<sub>90</sub> values unless otherwise noted. The stereochemistry at the aminal position for compound <b>40</b> was determined as (<i>S</i>), which was more potent than the corresponding (<i>R</i>) configuration. Compounds reported in this paper were separated and assayed as single enantiomers with the potency for the most active isomer reported, unless otherwise noted.</div><div class="NLM_p">For the purposes of this discussion, we arbitrarily designated the aminal-phenyl group as the “Z-group”, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. From our earlier results we observed sensitivity of the mutant profiles toward changes at the Z-group, as illustrated by compound <b>2</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> Numbers in parentheses were potency shift of mutants relative to GT1a, which was used as a measurement of flatness of the profile. We also observed that improvement in the mutant profiles was achievable through addition of a fluorine atom at R<sub>1</sub> shown by comparison of compound <b>3</b><a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> versus compound <b>4</b>.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The combination of a chromane Z group and a fluorine atom at R<sub>1</sub> could give a modest reduction in the shift in potency against key mutants to <200-fold shown by compound <b>5</b>,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a><a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Potency and Shift Comparison of <b>1</b>–<b>5</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0008.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0009.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><p class="first last"><sup>†</sup>Fold-shift is relative to the WT activity, set = 1.</p></div></div><div></div></div><div class="NLM_p">While these modifications did not produce NS5A inhibitors with the “flat” profile that we desired, it suggested a path forward on how we might obtain an NS5A inhibitor with a flat profile. While substitutions on the phenyl group of the tetracyclic indole core had been described previously<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and improvements in the ”flatness” of the inhibitors were observed, we did not feel that this approach by itself would lead to a flat compound. Thus, we looked for wider variations in the Z-group, and upon review of the previous SAR, we noticed that the isosteric replacement of the phenyl ring with a thiophene ring had not been examined, so compound <b>6</b> was prepared. We observed improved inhibitory activities in GT1a_Y93H over compound <b>1</b>, as shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. Additionally, compound <b>6</b> demonstrated a balanced potency shift profile toward both GT1a_Y93H (100X) and 2b (267X) (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Verification of this trend was observed with compound <b>7</b>, which displayed a similar profile to compound <b>6</b>, giving us confidence that substitution on the thiophene ring could be beneficial. The addition of simple alkyl groups such as ethyl and cyclopropyl (compounds <b>8</b> and <b>10</b>) onto the thiophene ring further improved GT2b potency to subnanomolar range. The addition of a R<sub>1</sub> fluorine atom demonstrated significant improvement on GT 1a_Y93H potency for the matched pairs (compounds <b>9</b> and <b>11</b>). In both cases where the additional fluorine atom is located at R<sub>1</sub> position, the potency shift against key mutant GT1a_Y93H was below 50-fold (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). We were encouraged by these results, and additional efforts were undertaken to explore a broader substitution patterns on the thiophene ring while retaining the R<sub>1</sub> fluoro group.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Key Mutant Profile of Compounds <b>6</b>–<b>11</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0010.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0011.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><p class="first last"><sup>†</sup>Fold-shift is relative to the WT activity, set = 1.</p></div><div class="footnote" id="t2fn2"><sup>Table a</sup><p class="last">Denotes mixture of diastereomers at the aminal carbon.</p></div></div><div></div></div><div class="NLM_p"><a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> summarizes the SAR results for substituted thiophene derivatives. The attachment point of the thiophene ring to the aminal carbon was examined with the 2-thiophene (<b>6</b>) and 3-thiophene (<b>12</b>) analogs, with both possessing very similar profiles. The lack of a preferred regiochemistry around the thiophene ring was again supported by the cyclopropyl-substituted analogs <b>11</b> and <b>13</b>, which had similar activities. Given the lack of differentiation for 2- versus 3-attachment of the thiophene ring and a preference toward the 2,5-substitution pattern, for potential metabolic stability,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> the 2-position was selected as the attachment point to the aminal-carbon for the further investigation of substituting different positions of the thiophene ring.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Virologic Profile of Substituted Thiophene Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0012.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0013.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Mixture of diastereomers.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Single diastereomer.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">EC<sub>50</sub> value.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">R<sub>1</sub> = H.</p></div><div class="footnote" id="t3fn5"><p class="first last"><sup>†</sup>The replicon bears methionine at position 31.</p></div></div><div></div></div><div class="NLM_p">Moving the cyclopropyl group to the 3- and 4-position of the ring (<b>14</b> and <b>15</b>) did reveal potency differences in comparison to compound <b>11</b> with compound <b>15</b> showing a very dramatic loss in activity. Next, a series of substituents were installed in the 5-positon ranging from alkyl, branched alkyl, fluorinated alkyl, as well as heteroatom containing groups substitutions (<b>9</b>, <b>16</b>–<b>25</b>) shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. These substituents were all well-tolerated demonstrating comparable wild-type and mutant profiles with the exception of <b>23</b> which was found to be weaker at both GT1a_Y93H and GT2b(31M). Unfortunately, none of these analogs demonstrated an improvement in the overall “flatness” of the profile compared to compound <b>11</b>. A second substituent was introduced on the thiophene ring to assess if it would impact inhibitory activity (<b>26</b>–<b>28</b>). These derivatives were very similar in potency and showed no meaningful improvement over the monosubstituted compound <b>11</b>. Several 4,5-fused bicyclic thiophenes were prepared including benzothiophene <b>29</b> (R<sub>1</sub> = H and <i>R</i>-fluoroproline on the right-hand side) to explore the impact of fusing an aryl group onto the thiophene ring. While compound <b>29</b> demonstrated modest improvement on mutant profiles, it did show decreased potency on GT3a when compared to the unsubstituted thiophene analog <b>6</b> as well as related 2,5-disubstituted thiophene analogs. By comparison, the saturated fused bicyclic thiophene compounds <b>30</b> and <b>31</b> had profiles comparable to <b>11</b>.</div><div class="NLM_p">The SAR data summarized in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> demonstrated that introduction of a substituted thiophene group into the tetracyclic indole core has a surprisingly positive effect on flattening variant profiles. Many of the compounds in this series exhibited potent in vitro profiles including high potency toward key variants, which were difficult to achieve in the Z = phenyl series.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9 ref10 ref11">(6-11)</a> While the data summarized in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> represented significant improvement in key mutant profiles, the goal of flatness was not reached and further optimization was explored. Inspired by these results, we carried out further variation of five-membered heterocycles at the Z group, preparing both thiophene variants and those lacking the sulfur atom of thiophene. <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> summarizes the virologic profiles of these additional five-membered heterocycle derivatives.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro Profile of Heterocycles Z Group</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0014.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0015.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><p class="first last"><sup>†</sup>The replicon bears methionine at position 31.</p></div></div><div></div></div><div class="NLM_p">Replacement of the thiophene ring of <b>11</b>, with a 5-substituted oxazole, yielded compound <b>32</b> which possessed a much weaker potency profile. Addition of a cyclopropyl group to the 2-position of the oxazole (<b>33</b>) improved the potency profile compared to the 2-H analog but was not comparable to the thiophene derivative. While this trend was consistent with observations made in the thiophene series, the key mutant GT1a_Y93H potency was weaker by 10-fold with the oxazole scaffold compared to <b>11</b>. Benzoxazole analog <b>34</b> demonstrated further potency improvement on the GT1a_Y93H to 0.32 nM but at the expense of the 2b profile which was ∼10× weaker than compound <b>11</b>. Isooxazole analog <b>35</b> exhibited a promising potency profile, as all of the key mutant potencies were in subnanomolar range while the most shifted genotype was GT2b (460X). Thiadiazole <b>36</b> showed a poor GT1a_Y93H mutant profile which could be improved by incorporation of the 1,2,3-thiadiazole instead to give <b>37</b>, which was better tolerated (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). The thiazole analogs, <b>38</b>–<b>40</b>, demonstrated that the position of the nitrogen within the heterocycle as well as the placement of the cyclopropyl group can modulate the mutant profiles significantly. By placement of the nitrogen atom further away from the aminal position, as in compound <b>40</b>, the virologic profile was significantly improved compared to the other regioisomeric thiazole variants, <b>38</b> and <b>39</b>. The verification of the importance of the cyclopropyl substitution on the thiazole ring in <b>40</b> was demonstrated by the parental thiazole compound <b>41</b>, which showed significantly reduced inhibitory activies against key mutants GT1a_Y93H and GT2b(31M).</div><div class="NLM_p">Having shown the potential value of the Z = cyclopropyl thiazole ring and the position of the nitrogen in the thiazole ring, it remained to determine if further improvements in the virologic profile of <b>40</b> could be obtained. <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a> summarizes the virologic profile of thiazole analogs <b>40</b>, <b>42</b>–<b>50</b>, where the cyclopropyl group has been modified. Adding a methyl group onto the cyclopropyl group gave <b>42</b> which showed weak GT2b(31M) potency compared to the cyclopropyl derivative <b>40</b>. Similarly, opening up the cyclopropyl ring to give the <i>n</i>-propyl compound <b>44</b> or changing the cyclopropyl to an ethyl (<b>43</b>) or to an isopropyl, compound <b>45</b>, resulted in slightly weaker activity vs GT2b(31M). Changing the cyclopropyl to a trifluoroethyl again resulted in slightly weaker activity in GT2b(31M), but the difluoromethyl analog <b>47</b> was comparable to <b>40</b>. Introduction of polar functionality (<b>48</b> and <b>49</b>) was tolerated with both compounds demonstrating good activity across genotypes. Interestingly, additional substitution on the thiazole ring, as found in compound <b>50</b>, proved to be detrimental to both GT1a_Y93H and GT2b(31M) activity. With the identification of a number of compounds with excellent in vitro profiles that were very similar to one another (<a class="ref internalNav" href="#tbl4" aria-label="Tables 4">Tables 4</a> and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>), a number of analogs were taken into broader mutant profiling and PK experiments to aid in differentiation.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. SAR of Substituted Thiazole Series</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0016.gif" alt="" id="fx9" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0017.gif" alt="" id="fx10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><p class="first last"><sup>†</sup>The replicon bears methionine at position 31.</p></div></div><div></div></div><div class="NLM_p">On the basis of structural diversity, in vitro potency, and apparent flatness of mutant profiles vs wild-type, a small group of compounds was selected for pharmacokinetic evaluation in both rat and dog, as shown in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>. In rat, the thiophene and thiazole derivatives exhibited moderate oral exposure and bioavailability. However, the oral exposure of total compound in dog was generally higher than the rat, and similarly the bioavailability was also better than the rat. Among these compounds, <b>9</b> showed the highest oral exposure in dog (13.8 μM·h). Further analysis of the in vitro profiles of these compounds, with respect to flatness, is described in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vivo Pharmacokinetic Parameters of Selected Compounds in Rat and Dog<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0018.gif" alt="" id="fx11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">See <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for details.</p></div><div class="footnote" id="t6fn2"><sup>Table b</sup><p class="last">2 mpk.</p></div><div class="footnote" id="t6fn3"><sup>Table c</sup><p class="last">1 mpk.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Flatness Comparison of Selected Thiophene and Thiazole Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0019.gif" alt="" id="fx12" /></img><div></div></div><div class="NLM_p">The values shown in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a> are the fold shift, or the ratio of the mutant or genotype EC<sub>90</sub> divided by the 1a wild type potency which would provide a measure of “flatness” of the profile. Our goal was to identify inhibitors with ∼10-fold of shift of wild-type virus against GT1a clinically relevant mutants and other genotypes as previously mentioned. At the first glance, all of the compounds in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a> showed significant improvements in fold shift, in key mutants and genotypes. Happily, all of the selected compounds listed were shifted <200×. In particular, compounds <b>9</b> and <b>40</b> demonstrated the least shift in GT1a_Y93H, approximately 20×. Moreover, compound <b>40</b> exhibited ∼12× shift in genotype 2b.</div><div class="NLM_p">In an effort to determine if the virologic profiles of the NS5A inhibitors described thus far could be further improved, we applied lessons that we learned in previous studies. We had observed that introduction of a fused cyclopropyl proline moiety to the left-hand side of the molecule, in certain cases, could improve both the 2b potency and the rat oral exposure.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> In the application of this learning to the current series described above, a couple of these analogs, bearing either a thiazole or thiophene Z group, were studied and their virologic profiles are summarized in <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>. In most examples, fusing a cyclopropyl group to the left-side proline gave a slight potency loss toward GT2b(31M) (<b>52</b>–<b>57</b>). However, compound <b>51</b>, bearing the cyclopropyl thiazole Z group, showed a mutant and genotype profile similar to, or better than, that of compound <b>40</b>. Further evaluation of <b>51</b> in rat PK did not real an overall improvement over <b>40</b> (<a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a>).</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Proline Modification on Thiazole/Thiophene Series</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0020.gif" alt="" id="fx13" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0021.gif" alt="" id="fx14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><p class="first last"><sup>†</sup>The replicon bears methionine at position 31.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Rat PK Profile for Compound <b>51</b><a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">iv</th><th class="rowsep1 colsep0" colspan="4" align="center">po</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">dose (mpk)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">CLp (mL min<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center">dose (mpk)</th><th class="colsep0 rowsep0" align="center">AUC<sub>(0–<i>t</i>)</sub> (μM·h)</th><th class="colsep0 rowsep0" align="center">C<sub>24</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">3.9</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">0.52</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">See <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for details.</p></div></div></div><div class="NLM_p">Although many of the NS5A inhibitors described within show surprisingly and significantly improved in vitro profiles, with minimal potency shifts, many of them did not differ greatly from one another. We selected <b>40</b> for further study, based on its replicon potency profiles, which were flat or nearly flat, and its demonstrated improvements on key mutants GT1a_Y93H, L31V and GT2b(31M). A summary of the pharmacokinetic parameters of compound <b>40</b> in rhesus monkey is presented in <a class="ref internalNav" href="#tbl10" aria-label="Table 10">Table 10</a>.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Rhesus Monkey PK Profile for Compound <b>40</b><a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">iv</th><th class="rowsep1 colsep0" colspan="4" align="center">po</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">dose (mpk)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">CLp (mL min<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center">dose (mpk)</th><th class="colsep0 rowsep0" align="center">AUC<sub>(0–<i>t</i>)</sub> (μM·h)</th><th class="colsep0 rowsep0" align="center">C<sub>24</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">10.2</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">3.9</td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup>a</sup><p class="last">See <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for details.</p></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85404" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85404" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In summary, building from the knowledge base of our existing NS5A program and applying rationale SAR development to the tetracyclic indole based template, we discovered compounds with significantly improved in vitro virologic profiles. Multiple compounds with either “flat” or “nearly flat” profiles were identified. In particular, compound <b>40</b> was selected for preclinical and later clinical evaluation; compound <b>40</b> is now known as ruzasvir. The in vitro profile of this compound (<a class="ref internalNav" href="#tbl11" aria-label="Table 11">Table 11</a>) represents an example of an HCV NS5A inhibitor with a “flat” GT1, pan-genotypic profile. Ruzasvir (<b>40</b>) is currently in clinical trials as part of an all-oral DAA regimen for the treatment of chronic HCV infection. The full characterization of ruzasvir (<b>40</b>) will be communicated in future publications.</div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. In vitro potency profiles of compound <b>40</b> vs. <b>1</b> against GT1-6 and key GT1 variants</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">EC<sub>90</sub> (nM)<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">EC<sub>90</sub> (nM)<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">replicon</th><th class="colsep0 rowsep0" align="center"><b>1</b></th><th class="colsep0 rowsep0" align="center"><b>40</b></th><th class="colsep0 rowsep0" align="center">replicon</th><th class="colsep0 rowsep0" align="center"><b>1</b></th><th class="colsep0 rowsep0" align="center"><b>40</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT1b</td><td class="colsep0 rowsep0" align="left">0.006</td><td class="colsep0 rowsep0" align="left">0.003</td><td class="colsep0 rowsep0" align="left">GT2a</td><td class="colsep0 rowsep0" align="left">0.019</td><td class="colsep0 rowsep0" align="left">0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Y93H</td><td class="colsep0 rowsep0" align="left">0.89</td><td class="colsep0 rowsep0" align="left">0.009</td><td class="colsep0 rowsep0" align="left">GT2b</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">0.036</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT1a</td><td class="colsep0 rowsep0" align="left">0.006</td><td class="colsep0 rowsep0" align="left">0.003</td><td class="colsep0 rowsep0" align="left">GT3a</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Q30R</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">0.011</td><td class="colsep0 rowsep0" align="left">GT4a</td><td class="colsep0 rowsep0" align="left">0.016</td><td class="colsep0 rowsep0" align="left">0.011</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">L31V</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">0.016</td><td class="colsep0 rowsep0" align="left">GT5a</td><td class="colsep0 rowsep0" align="left">0.002</td><td class="colsep0 rowsep0" align="left">0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Y93C</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">0.002</td><td class="colsep0 rowsep0" align="left">GT6</td><td class="colsep0 rowsep0" align="left">0.017</td><td class="colsep0 rowsep0" align="left">0.007</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Y93H</td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">0.067</td><td class="colsep0 rowsep0" align="left">GT6d</td><td class="colsep0 rowsep0" align="left">0.008</td><td class="colsep0 rowsep0" align="left">0.027</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup>a</sup><p class="last">See <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for details.</p></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53372" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53372" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Final compounds were prepared according to published procedures.<a onclick="showRef(event, 'ref19 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref19 ref21 ref22">(19, 21, 22)</a> The absolute configuration of the aminal carbon for compound <b>40</b> is unambiguously assigned to be “<i>S</i>” by single crystal X-ray analysis.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The remaining stereocenters present in the final molecules were derived from the commercially available starting materials.</div><div class="NLM_p">The intermediate cores <b>69</b> and <b>70</b> were synthesized according to the chemistry shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Treatment of ketone <b>62</b> with hydrazine <b>63</b> or <b>64</b> afforded the intermediate hydrazones (<b>65</b> and <b>66</b>) which could be cyclized to afford indole derivatives <b>67</b> and <b>68</b>. Reduction with zinc in TFA afforded the indoline derivatives <b>69</b> and <b>70</b>. The indole based tetracyclic core <b>74</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) was synthesized either through cyclization of indoline derivative <b>71</b> with various thiophene aldehydes <b>72</b> followed by oxidation of the indoline ring or through cyclization of dichloromethyl thiophene <b>76</b> with intermediate such as <b>67</b>. The dibromo compound <b>74</b> was converted to the corresponding bis-boronic ester <b>77</b>. <b>77</b> could undergo a double Suzuki coupling reaction either with the imidazole proline intermediate <b>58</b> to afford the racemic form of the final compound <b>78</b> or with the Boc-protected imidazole proline intermediate <b>59</b> followed by global deprotection of the Boc groups and HATU promoted double amide coupling with Moc-<span class="smallcaps smallerCapital">l</span>-valine to get to <b>78</b>. <b>78</b> was subjected to chiral separation to afford the final products (<b>8</b>–<b>35</b> in <a class="ref internalNav" href="#tbl2" aria-label="Tables 2">Tables 2</a>–<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> were synthesized with the same approach). In the case of compound <b>6</b>, compound <b>81</b> was synthesized following the route illustrated in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Advance intermediate <b>81</b> was subjected to a Suzuki coupling with cyclopropyl boronic acid shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Analog <b>82</b> (racemate) was obtained as the major product and <b>81</b> was dehalogenated to afford <b>6</b> as a side product. Chiral SFC separation afforded compound <b>11</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Common Intermediates <b>69</b> and <b>70</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01310&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) AcOH/EtOH/40 °C to reflux, 6 h; (b) PPA/xylene, 100 °C, 2 h; (c) Zn/TFA, 70–76 °C, 17 h.</p></p></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthetic Approach to Thiophene/Thiazole Analogs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01310&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TFA/CH<sub>3</sub>CN, 25 °C, 6 h; (b) DDQ, toluene, reflux, 2 h; (c) bis(pinacolato)diboron, KOAc, Pd(dppf)Cl<sub>2</sub>, dioxane, 100 °C, overnight; (d) <b>58</b>, Na<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, THF/H<sub>2</sub>O, 80 °C, overnight; (e) <b>59</b>, K<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, THF/H<sub>2</sub>O, 80 °C, overnight; (f) HCl in dioxane/CH<sub>2</sub>Cl<sub>2</sub>, 20 °C, 1 h; (g) HATU, Moc-<span class="smallcaps smallerCapital">l</span>-valine, DIPEA, DMF, 0 °C, 40 min; (h) pyridine/PCl<sub>5</sub>/CH<sub>2</sub>Cl<sub>2</sub>, −10 °C, 0.5 h; (i) Cs<sub>2</sub>CO<sub>3</sub>/DMSO, 100 °C, 1 h; (j) chiral SFC separation.</p></p></figure><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>6</b> and <b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01310&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) cyclopropyl boronic acid, Pd<sub>2</sub>(dba)<sub>3</sub>, X-Phos, K<sub>2</sub>CO<sub>3</sub>/dioxane, 110 °C, 16 h, 46% for <b>82</b> and 18% for <b>6</b>; (b) chiral SFC separation.</p></p></figure><div class="NLM_p">Thiazole analogs <b>38</b>–<b>50</b> and hetercyclic analogs <b>32</b>-<b>37</b> were prepared following the same approach shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. A representative example of synthetic approach to <b>40</b> was shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01310&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd(OAc)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, <i>n</i>-BuPdCl<sub>2</sub>, toluene/H<sub>2</sub>O, 100 °C, overnight, 32%; (b) <i>n</i>-BuLi, DMF, −78 °C, 3 h, 49% (c) TFA/CH<sub>3</sub>CN, 25 °C, 6 h, 68%; (d) DDQ, toluene, reflux, 2 h, 82%; (e) bis(pinacolato)diboron, KOAc, Pd(dppf)Cl<sub>2</sub>, dioxane, 110 °C, overnight, 82%; (f) <b>58</b>, Na<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, THF/H<sub>2</sub>O, 95 °C, overnight; (g) SFC chiral separation, 10% over two steps.</p></p></figure><div class="NLM_p">2-Bromothiazole (<b>83</b>) was subjected to Suzuki coupling with cyclopropyl boronic acid to afford <b>84,</b> which was converted to aldehyde <b>85</b>. Acid-catalyzed cyclization of <b>85</b> with <b>69</b> afforded <b>86</b> which was treated with DDQ to afford indole analog <b>87</b>. The dibromo compound <b>87</b> was converted to the bis-boronic ester <b>88</b> which was subjected to double Suzuki coupling with Moc-valine fragment <b>58</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) to afford <b>89</b>. The racemate mixture of aminal diastereomers was subjected to SFC chiral separation to provide compound <b>40</b>.</div><figure id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Common intermediates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01310&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds <b>51</b>–<b>57</b> (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>) were obtained using the preparation illustrated in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> for compound <b>56</b>. 5-Cyclopropylthiophene-2-carbaldehyde (<b>90</b>) was subjected to a Pd-mediated Suzuki coupling with cyclopropyl boronic acid to afford <b>91</b>. Cyclization of aldehyde <b>91</b> with indoline intermediate <b>70</b> afforded the tetracyclic indoline intermediate <b>92</b> which was oxidized to the corresponding dihalogenated indole analog <b>93</b> upon treatment of DDQ in toluene. The bromine atom on <b>93</b> underwent a selective Pd-mediated coupling with bis(pinacolato)diboron to afford monoboronic ester <b>94</b> which was then coupled with Moc-<span class="smallcaps smallerCapital">l</span>-valine capped imidazole proline intermediate <b>58</b> via Suzuki coupling to afford <b>95</b>. The chlorine on <b>95</b> was converted to the intermediate boronic ester <b>96</b> which upon treatment with cyclopropyl fused proline intermediate <b>61</b> under Suzuki coupling conditions afforded <b>97</b>. After deprotection of Boc group, HATU promoted amide coupling with Moc-<span class="smallcaps smallerCapital">l</span>-valine intermediate <b>58</b> afforded the racemate <b>99</b>. The racemate mixture of aminal diastereomers was subjected to SFC chiral separation to provide compound <b>56</b>.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>56</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01310&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd(OAc)<sub>2</sub>, cataCXiumA, Cs<sub>2</sub>CO<sub>3</sub>, toluene/H<sub>2</sub>O, 100 °C, 16 h, 95%; (b) TFA, rt, CH<sub>3</sub>CN, 6 h, 78%; (c) DDQ, toluene, reflux, 2 h, 82%; (d) bis(pinacolato)diboron, KOAc, Pd(dppf)Cl<sub>2</sub>, dioxane, 100 °C, 82%; (e) <b>58</b>, K<sub>2</sub>CO<sub>3</sub> aq, Pd(dppf)Cl<sub>2</sub>, dioxane, 90 °C, overnight, 70%; (f) Pd<sub>2</sub>(dba)<sub>3</sub>, X-Phos, KOAc/dioxane, 110 °C, overnight, 99%; (g) <b>61</b>, 1 M K<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, dioxane/H<sub>2</sub>O, 85 °C, overnight, 28%; (h) 4 N HCl in dioxane, 25 °C, 3 h, 100%; (i) HATU, Moc-<span class="smallcaps smallerCapital">l</span>-valine, DIPEA, DMF, rt, 3 h 99%; (j) chiral SFC separation, 34%.</p></p></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16775" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16775" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Biological Evaluation. Virology Assay</h3><div class="NLM_p last">The tabulated activity data are mean values of at least two experiments, and in general, the replicon assay exhibits a maximum of 3-fold variation. Detailed replicon biological assays were described previously.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> Briefly, the resistance-associated variants in NS5A were each introduced into GT 1a-H77, GT 1b-Con1, or chimeric replicons. In the transient assay (GT1a RAV data for compound <b>40</b> in <a class="ref internalNav" href="#tbl10" aria-label="Table 10">Table 10</a>), the replicon containing the GT1a NS5A variant was transfected via electroporation into a Huh-7 derived cell line. The percent inhibition of HCV replicon replication as determined by decreased luciferase signal was calculated for each compound concentration, and the EC<sub>90</sub> values were calculated as described above.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> PK Assessment</h3><div class="NLM_p"><i>Rat and Dog PK Studies (24 h).</i> Compounds were dosed in overnight fasted rats and dogs via iv and po administration. Two animals were included in each dosing group. The iv dose was administered in 60% PEG200 at 2 mg/kg in rats and 1 mg/kg in dogs, whereas oral dose was administrated in 10% Tween at 10 mg/kg in rats and 5 mg/kg in dogs. Blood was collected up to 24 h, and plasma was obtained by centrifugation of the blood. Compound concentrations in plasma were detected by LC/MS analysis.</div><div class="NLM_p last"><i>Monkey PK Study.</i> Compound was dosed in overnight fasted monkeys via iv at 1 mg/kg in 60% PEG200 (<i>n</i> = 3) and via po at 5 mg/kg in 10% Tween (<i>n</i> = 3). Plasma samples were collected up to 48 h, and compound concentrations were analyzed by LC/MS/MS.</div></div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Chemistry. General Procedures</h3><div class="NLM_p">Reactions were conducted, purified, and analyzed according to methods widely practiced in the field while taking necessary precautions in the exclusion of moisture and/or oxygen where appropriate. Final compounds were tested in biological assays as TFA salts, HCl salts, or free bases. Although where relevant the exact salt content was not determined, its mole equivalent was assumed to be equal to the number of basic moieties residing in the molecule for purposes of yield and EC<sub>90</sub> calculations. For each final compound, single diastereomers were obtained from SFC chiral separation of the racemic mixture using TharSFC instrumentation using the following general method. Column, specified in each separation; mobile phase A, CO<sub>2</sub>; mobile phase B, specified in each separation; back pressure 100 bar; flow rate 2.4–2.5 mL/min, 35 °C; detection at 210–350 nm. The more potent diastereomer was reported unless noted otherwise. Conditions for SFC chiral separation varied according to compounds. Wherever possible, SFC chiral separation conditions were reported. LC/MS analyses were performed on Agilent 1200 series HPLC equipped with DAD and 6110 single quadrupole MSD and ELSD with Agilent TC-C18, 50 mm × 2.1 mm, 5 μm for acid methods, Waters X-Bridge Shield RP18, 50mm × 2.1 mm, 5 μm for basic methods. All tested compounds exhibited >95% purity under the LC conditions except for compound <b>7</b>. UHPLC/HRMS analysis of compound <b>40</b> was performed using the following condition: LC/MS analysis was performed on a Waters Acquity UPLC system, consisting of a binary pump, a sample manager, a TUV detector, and a Waters Synapt G1 mass spectrometer (Waters, Milford, MA) under positive or negative ESI conditions. The output signal was monitored and processed using MassLynx software designed by Waters (Milford, MA). NMR spectra were recorded on a Varian 400 MHz, 500 MHz or Bruker 400 MHz spectrometers. Residual protio-solvent was used as internal standard for chemical shift assignments. Coupling constants are provided in Hz, with the following spectral pattern designations: s, singlet; d, doublet; t, triplet; q, quartet; br, broad; m, multiplet, o, overlapped. IUPAC nomenclature was adopted for all final compounds and key intermediates.</div><div class="NLM_p last">Abbreviations used in the experimental descriptions are the following: DDQ, 2,3-dichloro-5,6-dicyano-1,4-benzoquinone; DEA, diethylamine; DIEA, <i>N</i>,<i>N</i>-diisopropylethylamine; EtOAc, ethyl acetate; IPA, isopropyl alcohol; HATU, 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate; MeOH, methanol; rt, room temperature; SFC, supercritical fluid chromatography.</div></div><div id="sec5_2_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Dimethyl <i>N</i>,<i>N</i>′-([(6<i>RS</i>)-1-Fluoro-6-(thiophen-2-yl)-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>6</b>) Mixture of Diastereomers</h3><div class="NLM_p last">Dimethyl <i>N</i>,<i>N</i>′-([6-(5-chlorothiophen-2-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>81</b>) (16 mg, 0.014 mmol), cyclopropyl boronic acid (11.8 mg, 0.137 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (2.51 mg, 2.74 μmol), and X-Phos (2.61 mg, 5.48 μmol) were added to a 10 mL sealed tube. After the flask was flashed with N<sub>2</sub>, dioxane (456 μL) and an aqueous solution of 1 M K<sub>2</sub>CO<sub>3</sub> (82 μL, 0.082 mmol) were added. The mixture was capped, heated to 110 °C, and stirred for 16 h. After cooling, the solution was concentrated and purified by prep-HPLC (0–80% acetonitrile in H<sub>2</sub>O over 15 min) to afford <b>82</b> (racemic form of compound <b>11</b>) (7.4 mg, 46% yield) as desired product and <b>6</b> (2.8 mg, 18% yield) as the dechlorinated product. <sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.16 (m,1H), 7.98 (m, 3 H), 7.80 (m, 1 H), 7.60 (m, 2 H), 7.40 (m, 2 H), 7.25 (m, 1 H), 6.90 (m, 1 H), 6.75 (m,1 H), 5.25 (m, 2 H), 4.25 (m, 2 H), 4.15 (m, 2 H), 3.85 (m, 2 H), 3.70 (s, 6 H), 2.60 (m, 2 H), 2.60–2.30 (m, 10 H), 0.96 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>47</sub>H<sub>52</sub>FN<sub>9</sub>O<sub>7</sub>S, 905.37, found 906.4.</div></div><div id="sec5_2_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Dimethyl <i>N</i>,<i>N</i>′-([(6<i>RS</i>)-6-(5-Chlorothiophen-2-yl)-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>7</b>) Mixture of Diastereomers</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.90 (m, 1 H), 7.70 (m, 1 H), 7.60 (s, 1 H), 7.20–7.45 (m, 5H), 7.05 (m, 1 H), 6.90 (m, 1 H), 6.70 (m, 1H), 6.40 (m,1H), 5.15 (m, 2H), 4.20 (m, 2H), 4.10 (m, 2H), 3.85 (m, 2H), 3.65 (s, 6 H), 2.0–2.45 (m, 10 H), 0.96 (m, 12H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>47</sub>H<sub>52</sub>ClN<sub>9</sub>O<sub>7</sub>S, 922.34, found 944.2 [M + Na]<sup>+</sup>.</div></div><div id="sec5_2_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Dimethyl <i>N</i>,<i>N</i>′-([6-(5-Ethylthiophen-2-yl)-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>8</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.90 (m, 2 H), 7.83 (s, 1 H), 7.68–7.71 (m, 2 H), 7.45 (m, 2 H), 7.38 (m, 2 H), 7.09 (s, 1 H), 6.49 (dd, <i>J</i> = 4 Hz, <i>J</i> = 12 Hz, 2 H), 5.17–5.24 (m, 2 H), 4.21 (t, <i>J</i> = 6.1 Hz, 2 H), 4.06 (bs, 2 H), 3.88 (m, 2 H), 3.62 (s, 6 H), 2.64 (q, <i>J</i> = 7.2 Hz, 2 H), 2.52 (m, 2 H), 2.00–2.30 (m, 8 H), 1.11 (t, <i>J</i> = 7.6 Hz, 3 H), 0.92 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>49</sub>H<sub>57</sub>N<sub>9</sub>O<sub>7</sub>S, 915.41; found 916.5.</div></div><div id="sec5_2_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Dimethyl <i>N</i>,<i>N</i>′-([6-(5-Ethylthiophen-2-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>9</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.01 (s, 1 H), 7.95 (s, 1 H), 7.81 (s, 1 H), 7.75 (s, 1 H), 7.51–7.57 (m, 1 H), 7.46–7.51 (m, 1 H), 7.39 (d, <i>J</i> = 10.8 Hz, 1 H), 7.30 (s, 1 H), 7.17 (d, <i>J</i> = 2.4 Hz, 1 H), 6.47–6.56 (m, 2 H), 5.22 (dt, <i>J</i> = 15.2, 7.2 Hz, 2 H), 4.21 (t, <i>J</i> = 7.2 Hz, 2 H), 4.08 (m, 2 H), 3.83–3.94 (m, 2 H), 3.64 (s, 6 H), 2.67 (q, <i>J</i> = 7.2 Hz, 2 H), 2.54 (d, <i>J</i> = 5.6 Hz, 2 H), 1.99–2.32 (m, 8 H), 1.13 (t, <i>J</i> = 7.2 Hz, 3 H), 0.85–1.00 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>49</sub>H<sub>56</sub>FN<sub>9</sub>O<sub>7</sub>S, 935.41; found 935.3.</div></div><div id="sec5_2_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Dimethyl <i>N</i>,<i>N</i>′-([6-(5-Cyclopropylthiophen-2-yl)-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>10</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.98 (s, 1 H), 7.93 (d, <i>J</i> = 7.6 Hz, 1 H), 7.88 (s, 1 H), 7.72 (d, <i>J</i> = 6.8 Hz, 2 H), 7.48 (d, <i>J</i> = 8.8 Hz, 1 H), 7.42 (d, <i>J</i> = 11.2 Hz, 2 H), 7.15 (s, 1 H), 6.47 (q, <i>J</i> = 3.6 Hz, 2 H), 5.21 (m, 2 H), 4.21 (t, <i>J</i> = 6.4 Hz, 2 H), 4.08 (m, 2 H), 3.87 (m, 2 H), 3.63 (s, 6 H), 2.55 (bs, 2 H), 2.16–2.26 (m, 6 H), 2.05 (m, 2 H), 1.91 (m, 1 H), 0.86–0.93 (m, 14 H), 0.51 (m, 2 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>57</sub>N<sub>9</sub>O<sub>7</sub>S, 927.41; found 928.7.</div></div><div id="sec5_2_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Dimethyl <i>N</i>,<i>N</i>′-([6-(5-Cyclopropylthiophen-2-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>11</b>)</h3><div class="NLM_p last">The title compound <b>11</b> was obtained from chiral SFC separation of the racemate (16.7 g) using the following conditions: column, Chiralpak AS-H, 150 mm × 4.6 mm, 5 μm; mobile phase B, 0.05% DEA in IPA, gradient, 5–40% B. Compound <b>11</b> (4.8 g, 29% yield). <sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.02 (s, 1 H), 7.95 (s, 1 H), 7.78 (d, <i>J</i> = 19.6 Hz, 2 H), 7.46–7.57 (m, 2 H), 7.39 (d, <i>J</i> = 10.8 Hz, 1 H), 7.31 (s, 1 H), 7.19 (d, <i>J</i> = 2.4 Hz, 1 H), 6.42–6.53 (m, 2 H), 5.21 (m, 2 H), 4.20 (t, <i>J</i> = 7.2 Hz, 2 H), 4.08 (m, 2 H), 3.79–3.92 (m, 2 H), 3.64 (s, 6 H), 2.55 (m, 2 H), 1.97–2.31 (m, 8 H), 1.89–1.96 (m, 1 H), 0.81–1.01 (m, 14 H), 0.53 (d, <i>J</i> = 3.5 Hz, 2 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>56</sub>FN<sub>9</sub>O<sub>7</sub>S, 946.40; found 946.3.</div></div><div id="sec5_2_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Dimethyl <i>N</i>,<i>N</i>′-([1-Fluoro-6-(thiophen-3-yl)-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>12</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.00 (s, 1 H), 7.88 (s, 1 H), 7.75 (s, 1H), 7.67 (s, 1 H), 7.52 (m, 1 H), 7.33–7.41 (m, 4 H), 7.17 (d, <i>J</i> = 3.2 Hz, 1 H), 6.93 (d, J = 5.2 Hz, 2 H), 5.22 (m, 2 H), 4.22 (t, <i>J</i> = 7.2 Hz, 2 H), 4.09 (m, 2 H), 3.86 (m, 2 H), 3.64 (s, 6 H), 2.54 (m, 2 H), 2.04–2.27 (m, 8 H), 0.91 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>47</sub>H<sub>52</sub>FN<sub>9</sub>O<sub>7</sub>S, 906.37; found 906.4.</div></div><div id="sec5_2_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Dimethyl <i>N</i>,<i>N</i>′-([6-(5-Cyclopropylthiophen-3-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>13</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.01 (s, 1 H), 7.89 (d, <i>J</i> = 5.6 Hz, 1 H), 7.75 (s, 1 H), 7.52 (m, 2 H), 7.30–7.40 (m, 3 H), 7.19 (d, <i>J</i> = 3.2 Hz, 1 H), 6.66 (s, 1 H), 6.55 (s, 1 H), 5.21 (m, 2 H), 4.20 (t, <i>J</i> = 8 Hz, 2 H), 4.08 (m, 2 H), 3.83 (m, 2 H), 3.64 (s, 6 H), 2.53 (m, 2 H), 1.94–2.26 (m, 8 H), 0.88–0.97 (m, 15 H), 0.50 (m, 2 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>56</sub>FN<sub>9</sub>O<sub>7</sub>S, 946.40; found 946.5.</div></div><div id="sec5_2_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Dimethyl <i>N</i>,<i>N</i>′-([6-(4-Cyclopropylthiophen-2-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>14</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.41–7.67 (m, 4 H), 7.08–7.29 (m, 4 H), 6.76–6.85 (m, 2 H), 6.43 (s, 1H), 5.18 (t, <i>J</i> = 7.2 Hz, 1 H), 5.08 (t, <i>J</i> = 6.8 Hz, 1H), 4.19 (m, 2 H), 4.00 (b, 2H), 3.85 (m, 2 H), 3.59 (s, 6 H), 2.45 (b, 1 H), 1.95–2.35 (m, 9 H), 1.64 (b, 1 H), 0.84–0.98 (m, 12 H), 0.69 (m, 2H), 0.35 (b,2 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>56</sub>FN<sub>9</sub>O<sub>7</sub>S, 946.40; found 946.5.</div></div><div id="sec5_2_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Dimethyl <i>N</i>,<i>N</i>′-([6-(3-Cyclopropylthiophen-2-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>15</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.98 (m, 2 H), 7.90 (s, 1 H), 7.74 (s, 1 H), 7.46 (d, <i>J</i> = 8 Hz, 1 H), 7.37 (d, <i>J</i> = 11.6 Hz, 1 H), 7.29 (s, 1 H), 7.18 (m, 3 H), 6.66 (d, <i>J</i> = 5.2 Hz, 1 H), 5.22 (m, 2 H), 4.22 (t, <i>J</i> = 8 Hz, 2 H), 4.09 (m, 2 H), 3.87 (m, 2 H), 3.65 (s, 6 H), 2.55 (m, 2 H), 2.01–2.34 (m, 9 H), 1.11 (m, 2 H), 0.88–0.98 (m, 12 H), 0.80 (m, 2 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>56</sub>FN<sub>9</sub>O<sub>7</sub>S, 946.40; found 946.4.</div></div><div id="sec5_2_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Dimethyl <i>N</i>,<i>N</i>′-({1-Fluoro-6-[5-(propan-2-yl)thiophen-2-yl]-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl}bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>16</b>)</h3><div class="NLM_p last">The title compound <b>16</b> was obtained by chiral SFC separation of the racemate (2.2 g) using the following conditions: column, Chiralpak AS-H, 250 mm × 4.6 mm, 5 μm; mobile phase B, 0.05% DEA in IPA, gradient, 40% B. Compound <b>16</b> (1.12 g, 51% yield). <sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.0–7.97 (m, 1 H), 7.83–7.74 (m, 3 H), 7.51–7.26 (m, 4 H), 7.16 (m, 1 H), 6.58 (m, 1 H), 6.52–6.50 (m, 1 H), 5.24–5.19 (m, 2 H), 4.24–4.22 (m, 2 H), 4.09 (s, 2 H), 3.87 (m, 2 H), 3.65 (s, 6 H), 3.01–2.99 (m, 1 H), 2.56–2.50 (m, 2 H), 2.56–2.50 (m, 8 H), 1.18–1.17 (d, <i>J</i> = 4 Hz, 6 H), 0.94–0.89 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>58</sub>FN<sub>9</sub>O<sub>7</sub>S, 948.42; found 948.60.</div></div><div id="sec5_2_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Dimethyl <i>N</i>,<i>N</i>′-([1-Fluoro-6-(5-propylthiophen-2-yl)-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>17</b>)</h3><div class="NLM_p last">The title compound <b>17</b> was obtained by chiral SFC separation of the corresponding racemate (21 g) using the following conditions: column, Chiralpak AS-H, 150 mm × 4.6 mm, 5 μm; mobile phase B, 0.05% DEA in IPA, gradient, 5–40% B. Compound <b>17</b> (6 g, 29% yield). <sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.01 (s, 1 H), 7.95 (s, 1 H), 7.81 (s, 1 H), 7.75 (s, 1 H), 7.51–7.57 (m, 1 H), 7.46–7.51 (m, 1 H), 7.39 (d, <i>J</i> = 10.8 Hz, 1 H), 7.30 (s, 1 H), 7.17 (d, <i>J</i> = 2.4 Hz, 1 H), 6.47–6.56 (m, 2 H), 5.22 (dt, <i>J</i> = 15.2, 7.2 Hz, 2 H), 4.21 (t, <i>J</i> = 7.2 Hz, 2 H), 4.08 (m, 2 H), 3.83–3.94 (m, 4 H), 3.64 (s, 6 H), 2.67 (q, <i>J</i> = 7.2 Hz, 2 H), 2.54 (d, <i>J</i> = 5.6 Hz, 2 H), 1.99–2.32 (m, 8 H), 1.13 (t, <i>J</i> = 7.2 Hz, 3 H), 0.85–1.00 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>58</sub>FN<sub>9</sub>O<sub>7</sub>S, 948.42; found 948.5.</div></div><div id="sec5_2_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Dimethyl <i>N</i>,<i>N</i>′-({1-Fluoro-6-[5-(trifluoromethyl)thiophen-2-yl]-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl}bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>18</b>)</h3><div class="NLM_p last">The title compound <b>18</b> was obtained by chiral SFC separation of the corresponding racemate (197 mg) using the following conditions: column, Chiralpak AS-H, 250 mm × 4.6 mm, 5 μm; mobile phase B, 0.05% DEA in IPA, gradient, 40% B. Compound <b>18</b> (60 mg, 30% yield). <sup>1</sup>H NMR (400 MHz, MeOH): δ 7.96–8.06 (m, 2 H), 7.89 (s, 1 H), 7.75 (s, 1 H), 7.57–7.65 (m, 2 H), 7.40 (d, <i>J</i> = 10.6 Hz, 1 H), 7.25–7.35 (m, 2 H), 7.19 (s, 1 H), 6.66 (d, <i>J</i> = 3.1 Hz, 1 H), 5.21 (dt, <i>J</i> = 19.4, 7.3 Hz, 2 H), 4.22 (t, <i>J</i> = 7.0 Hz, 2 H), 4.08 (br s, 2 H), 3.81–3.91 (m, 2 H), 3.64 (s, 6 H), 2.47–2.59 (m, 2 H), 2.12–2.29 (m, 6 H), 2.02–2.12 (m, 3 H), 0.83–0.95 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>48</sub>H<sub>51</sub>F<sub>4</sub>N<sub>9</sub>O<sub>7</sub>S, 974.03; found 974.4.</div></div><div id="sec5_2_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Dimethyl <i>N</i>,<i>N</i>′-({6-[5-(Difluoromethyl)thiophen-2-yl]-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl}bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>19</b>)</h3><div class="NLM_p last">The title compound <b>19</b> was obtained by chiral SFC separation of the corresponding racemate (156 mg) using the following conditions: column, Chiralpak AS-H, 250 mm × 4.6 mm, 5 μm; mobile phase B, 0.05% DEA in IPA, gradient, 40% B. Compound <b>19</b> (50 mg, 32% yield). <sup>1</sup>H NMR (MeOD): δ: 8.05 (s,1 H), 8.03 (s, 1 H), 7.92 (s, 1 H), 7.78 (s, 1 H), 7.70 (d, <i>J</i> = 8.0 Hz, 1 H), 7.62–7.56 (m, 2 H), 7.46–7.37 (m, 2 H), 7.24 (s, 1 H), 7.11 (s, 1 H), 6.85 (t, <i>J</i> = 55.4 Hz, 1 H), 6.66 (s, 1 H), 5.26–5.18 (m, 2 H), 4.23–4.19 (m, 2 H), 4.09 (m, 2 H), 3.87–3.85 (m, 2 H), 3.65 (s, 6 H), 2.59–2.00 (m, 10 H), 0.94–0.87 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>48</sub>H<sub>52</sub>F<sub>3</sub>N<sub>9</sub>O<sub>7</sub>S, 956.04; found 956.4.</div></div><div id="sec5_2_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Dimethyl <i>N</i>,<i>N</i>′-({1-Fluoro-6-[5-(2,2,2-trifluoroethyl)thiophen-2-yl]-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl}bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>20</b>)</h3><div class="NLM_p last">The title compound <b>20</b> was obtained by chiral SFC separation of the corresponding racemate (200 mg) using the following conditions: column, Chiralpak AS-H, 250 mm × 4.6 mm, 5 μm; mobile phase B, 0.05% DEA in IPA, gradient, 40% B. Compound <b>20</b> (60 mg, 60%). <sup>1</sup>H NMR (400 MHz, MeOD). δ: 8.02 (s, 1H), 7.90–7.90 (m, 2 H), 7.76 (m, 1 H), 7.53 (m, 1 H), 7.43–7.34 (m, 2 H), 7.21 (br s, 1 H), 6.82–6.81 (d, 1 H), 6.62–6.61 (d, 1 H), 5.25–5.17 (m, 2 H), 4.23–4.19 (m, 2 H), 4.09 (m, 2 H), 3.86 (m, 2 H), 3.66 (s, 6 H), 3.61–3.56 (m, 2 H), 2.57–2.51 (m, 2 H), 2.27- 2.03 (m, 8 H), 0.93–0.87 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>49</sub>H<sub>53</sub>F<sub>4</sub>N<sub>9</sub>O<sub>7</sub>S, 988.4; found 988.3.</div></div><div id="sec5_2_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Dimethyl <i>N</i>,<i>N</i>′-({6-[5-(Cyclopropylmethyl)thiophen-2-yl]-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl}bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>21</b>)</h3><div class="NLM_p last">The title compound <b>21</b> was obtained from chiral SFC separation of the corresponding racemate (220 mg) using the following conditions: column, Chiralpak AS-H, 250 mm × 4.6 mm, 5 μm; mobile phase B, 0.05% DEA in ethanol, gradient, 40% B. Compound <b>21</b> (100 mg, 45% yield). <sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.00(s, 1H), 7.87 (s, 1 H), 7.82 (s, 1 H), 7.75 (s, 1 H), 7.54–7.30 (m, 4 H), 7.18 (s, 1 H), 6.60,6.59 (d, 1 H, <i>J</i> = 3.6 Hz), 6.50,6.49(d, <i>J</i> = 3.6 Hz, 1 H), 5.26–5.16 (m, 2 H), 4.23–4.19 (m, 2 H), 4.08–4.06 (m, 2 H), 3.86–3.83 (m, 2 H), 3.64 (s, 6 H), 2.57–2.48 (m, 4 H), 2.26–2.02 (m, 8 H), 0.93–0.87 (m, 13H), 0.45–0.43 (m, 2 H), 0.11–0.10 (m, 2 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>51</sub>H<sub>58</sub>FN<sub>9</sub>O<sub>7</sub>S, 960.42; found 960.5.</div></div><div id="sec5_2_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Dimethyl <i>N</i>,<i>N</i>′-({6-[5-(2,2-Difluorocyclopropyl)thiophen-2-yl]-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl}bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>22</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.02 (s, 1 H), 7.93 (m, 2 H), 7.88 (s, 1 H), 7.52–7.59 (m, 2 H), 7.40 (d, <i>J</i> = 10.4 Hz, 1 H), 7.32 (s, 1 H), 7.20 (s, 1 H), 6.72 (s, 1 H), 6.57 (s, 1 H), 5.25 (m, 2 H), 4.26 (t, <i>J</i> = 6.8 Hz, 2 H), 4.11 (m, 2 H), 3.87–3.94 (m, 2 H), 3.68 (s, 6 H), 2.87 (m, 1 H), 2.58 (m, 2 H), 2.08–2.31 (m, 8 H), 1.89 (m, 1 H), 1.55 (m, 1 H), 0.92–0.98 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>54</sub>F<sub>3</sub>N<sub>9</sub>O<sub>7</sub>S, 982.39; found 982.3.</div></div><div id="sec5_2_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Dimethyl <i>N</i>,<i>N</i>′-([6-(5-Cyanothiophen-2-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>23</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH): δ 8.05–8.09 (m, 2 H), 7.93 (s, 1 H), 7.79 (s, 1 H), 7.59–7.67 (m, 2 H), 7.49 (d, <i>J</i> = 3.6 Hz, 1 H), 7.38–7.43 (m, 2 H), 7.24 (s, 1 H), 6.71 (d, <i>J</i> = 4.0 Hz, 1 H), 5.21 (m, 2 H), 4.21 (t, <i>J</i> = 7.2 Hz, 2 H), 4.09 (br s, 2 H), 3.81–3.91 (m, 2 H), 3.64 (s, 6 H), 2.40–2.60 (m, 2 H), 2.01–2.30 (m, 8 H), 0.88–0.93 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>48</sub>H<sub>51</sub>FN<sub>10</sub>O<sub>7</sub>S, 931.37; found 931.4.</div></div><div id="sec5_2_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Dimethyl <i>N</i>,<i>N</i>′-({6-[5-(Dimethylcarbamoyl)thiophen-2-yl]-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl}bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>24</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.02 (s, 1 H), 8.00 (s, 1 H), 7.87 (s, 1 H), 7.77 (s, 1H), 7.60 (m, 2 H), 7.35 (m, 2 H), 7.18 (m, 2 H), 6.67 (d, <i>J</i> = 3.6 Hz, 1 H), 5.23 (m, 2 H), 4.21 (m, 2 H), 4.08 (m, 2 H), 3.88 (m, 2 H) 3.65 (s, 6 H), 3.00–3.20 (m, 6 H), 2.50 (m, 2 H), 2.00 2.29 (m, 8 H), 0.88–0.94 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>57</sub>FN<sub>10</sub>O<sub>8</sub>S, 977.41; found 977.5.</div></div><div id="sec5_2_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Dimethyl <i>N</i>,<i>N</i>′-({1-Fluoro-6-[5-(methoxymethyl)thiophen-2-yl]-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl}bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>25</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl3) δ: 7.70–7.10 (m, 8H), 6.70 (m, 1H), 6.42 (m, 1H), 5.62–5.22 (m, 4H), 4.42 (s, 2H),4.38 (m, 2H), 3.80–3.60 (m, 6H), 3.75 (s, 6H), 3.37 (s, 3H), 2.40 (m, 2H), 2.22 (m, 2H), 2.15 (m, 2H), 2.00 (m, 4H), 1.10 (m, 1H), 0.95 (m, 12H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>49</sub>H<sub>56</sub>FN<sub>9</sub>O<sub>8</sub>S, 949.40, found 951.12.</div></div><div id="sec5_2_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Dimethyl <i>N</i>,<i>N</i>′-([6-(5-Cyclopropyl-4-methylthiophen-2-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>26</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.00 (s, 1 H), 7.95 (d, <i>J</i> = 6.0 Hz, 1 H), 7.74 (d, <i>J</i> = 1.6 Hz, 2 H), 7.48–7.54 (m, 2 H), 7.35–7.46 (m, 1 H), 7.27 (s, 1 H), 7.16 (d, <i>J</i> = 3.2 Hz, 1 H), 6.31 (s, 1 H), 5.21 (m, 2 H), 4.21 (t, <i>J</i> = 7.2 Hz, 2 H), 4.08 (m, 2 H), 3.83–3.87 (m, 2 H), 3.64 (s, 6 H), 2.55 (m, 2 H), 2.01–2.36 (m, 11 H), 1.82 (m, 1 H), 0.87–0.98 (m, 14 H), 0.43 (m, 2 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>51</sub>H<sub>58</sub>FN<sub>9</sub>O7S, 960.42; found 480.8 [M/2 + H]<sup>+</sup>.</div></div><div id="sec5_2_1_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Dimethyl <i>N</i>,<i>N</i>′-([6-(5-Cyclopropyl-4-fluorothiophen-2-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>27</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.94 (s, 1 H), 7.86 (s, 1 H), 7.71 (d, <i>J</i> = 2.4 Hz, 2 H), 7.51 (m, 2 H), 7.35 (d, <i>J</i> = 10.8 Hz, 1 H), 7.22 (s, 1 H), 7.10 (d, <i>J</i> = 2.4 Hz, 1 H), 6.35 (s, 1 H), 5.19 (m, 2 H), 4.20 (t, <i>J</i> = 6.8 Hz, 2 H), 4.06 (m, 2 H), 3.85 (m, 2 H), 3.62 (s, 6 H), 2.51 (m, 2 H), 2.03–2.25 (m, 8 H), 1.80 (m, 1 H), 0.85–0.91 (m, 14 H), 0.47 (d, <i>J</i> = 6.4 Hz, 2 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>55</sub>F<sub>2</sub>N<sub>9</sub>O<sub>7</sub>S, 964.39; found 964.5.</div></div><div id="sec5_2_1_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Dimethyl <i>N</i>,<i>N</i>′-([6-(5-Cyclopropyl-3-fluorothiophen-2-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>28</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.70 (m, 1 H), 7.60 (s, 1 H), 7.15–7.3 (m, 5 H), 6.95 (bm, 1 H), 6.85 (s, 1 H), 6.49 (s, 1 H), 5.15 (m, 2 H), 4.23 (m, 2 H), 4.00 (m, 2 H), 3.90 (m, 2 H), 3.65 (s, 6 H), 2.00–2.35 (m, 10 H), 1.83 (m, 1 H), 0.89–1.00 (m, 12 H), 0.84 (m, 2H), 0.48 (m, 2 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>55</sub>F<sub>2</sub>N<sub>9</sub>O<sub>7</sub>S, 964.39; found 964.4.</div></div><div id="sec5_2_1_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Methyl {(2<i>S</i>)-1-[(2<i>S</i>)-2-{5-[6-(1-Benzothiophen-2-yl)-3-{2-[(2<i>S</i>,4<i>R</i>)-4-fluoro-1-{(2<i>S</i>)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazin-10-yl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (<b>29</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.92–8.06 (m, 3 H), 7.71–7.78 (m, 2 H), 7.53–7.61 (m, 5 H), 7.24–7.28 (m, 3 H), 6.87 (s, 1 H), 5.52 (d, <i>J</i> = 44.0 Hz, 1 H), 5.30 (m, 2 H), 4.44 (dd, <i>J</i> = 12.0, 20.0 Hz, 1 H), 4.10–4.25 (m, 4 H), 3.90 (m, 1 H), 3.67 (s, 3 H), 3.66 (s, 3 H), 2.80–2.91 (m, 1 H), 2.73 (s, 1H), 2.38–2.64 (m, 2 H), 2.30 (m, 1 H), 2.13–2.24 (m, 3 H), 1.91–2.11 (m, 2 H), 1.27–1.44 (m, 3H), 0.80–1.05 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>51</sub>H<sub>54</sub>FN<sub>9</sub>O<sub>7</sub>S, 956.09; found 955.8.</div></div><div id="sec5_2_1_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Dimethyl <i>N</i>,<i>N</i>′-([6-(5,6-Dihydro-4<i>H</i>-cyclopenta[<i>b</i>]thiophen-2-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>30</b>)</h3><div class="NLM_p last">The title compound <b>30</b> was obtained by chiral SFC separation from the racemate (220 mg) using the following conditions: column, Chiralpak OD-3, 150 mm × 4.6 mm, mobile phase B, 0.05% DEA in methanol, gradient, 40% B. Compound <b>30</b> (91 mg, 41.3% yield). <sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.78–7.91 (m, 1 H), 7.17–7.46 (m, 7 H), 6.84–6.99 (m, 1 H), 6.24 (s, 1 H), 5.12–5.19 (m, 2 H), 4.19–4.31 (m, 2 H), 3.87–4.05 (m, 4 H), 3.59–3.64 (m, 6 H), 2.03–2.65 (m, 17 H), 0.90–0.95 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>56</sub>FN<sub>9</sub>O<sub>7</sub>S, 946.40; found 946.5.</div></div><div id="sec5_2_1_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Dimethyl <i>N</i>,<i>N</i>′-([1-Fluoro-6-(4,5,6,7-tetrahydrobenzo[<i>b</i>]thiophen-2-yl)-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>31</b>)</h3><div class="NLM_p last">The title compound <b>31</b> was obtained from chiral SFC separation of the corresponding racemate (1.5 g) by using the following conditions: column, Chiralpak AS-H, 250 mm × 4.6 mm, mobile phase B, 0.05% DEA in IPA, gradient, 50% B. Compound <b>31</b> (0.5 g, 33% yield). <sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.06 (s, 1H), 7.98–8.02 (m, 1H), 7.86 (s, 1 H), 7.80 (s, 1H), 7.58 (s, 2 H), 7.42 (d, <i>J</i> = 11.0 Hz, 1 H), 7.36 (s, 1H), 7.24 (br s, 1H), 6.31 (s, 1 H), 5.25 (dd, <i>J</i> = 15.1, 7.0 Hz, 2 H), 4.25 (t, <i>J</i> = 7.5 Hz, 2 H), 4.13 (br s, 2H), 3.86–3.93 (m, 2 H), 3.68 (s, 6 H), 3.45 (d, <i>J</i> = 12.0 Hz, 1 H), 2.60 (br s, 4 H), 2.41 (br s, 2 H), 2.01–2.34 (m, 8 H), 1.72 (d, <i>J</i> = 17.1 Hz, 4 H), 0.88–1.04 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>51</sub>H<sub>58</sub>FN<sub>9</sub>O<sub>7</sub>S, 960.42; found 960.5.</div></div><div id="sec5_2_1_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Dimethyl <i>N</i>,<i>N</i>′-([1-Fluoro-6-(1,3-oxazol-5-yl)-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>32</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.11 (s, 1 H), 7.96 (s, 1 H), 7.87 (s, 1 H), 7.83 (s, 1 H), 7.74 (s, 1H), 7.56 (s, 2 H), 7.38 (d, <i>J</i> = 10.8 Hz, 1 H), 7.25 (s, 1 H), 7.13 (d, <i>J</i> = 2.4 Hz, 1 H), 6.67 (s, 1 H), 5.21 (m, 2 H), 4.22 (t, <i>J</i> = 6.4 Hz, 2 H), 4.08 (m, 2 H), 3.88 (m, 2 H), 3.63 (s, 6 H), 2.51 (m, 2 H), 1.99–2.26 (m, 8 H), 0.92 (d, <i>J</i> = 6.8 Hz, 6 H), 0.88 (d, <i>J</i> = 5.6 Hz, 6 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>46</sub>H<sub>51</sub>FN<sub>10</sub>O<sub>8</sub>, 891.39; found 891.4.</div></div><div id="sec5_2_1_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Dimethyl <i>N</i>,<i>N</i>′-([6-(2-Cyclopropyl-1,3-oxazol-5-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>33</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.04 (s, 1 H), 7.99 (s, 1 H), 7.81 (s, 1 H), 7.78 (s, 1 H), 7.58 (s, 2 H), 7.46 (s, 1 H), 7.42 (s, 1H), 7.37 (s, 1 H), 6.50 (s, 1 H), 5.25 (m, 2 H), 4.20 (m, 2 H), 4.10 (bs, 2 H), 3.90 (m, 2 H), 3.64 (s, 6 H), 2.56 (bs, 2 H), 1.95–2.27 (m, 9 H), 0.99 (m, 4 H), 0.88 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>49</sub>H<sub>55</sub>FN<sub>10</sub>O<sub>8</sub>, 931.42; found 931.5.</div></div><div id="sec5_2_1_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Dimethyl <i>N</i>,<i>N</i>′-([6-(1,3-Benzoxazol-2-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>34</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.04 (s, 1 H), 7.97 (s, 1 H), 7.85 (d, <i>J</i> = 8 Hz, 1 H), 7.67–7.73 (m, 2 H), 7.46–7.58 (m, 3 H), 7.25–7.39 (m, 4 H), 7.17 (s, 1 H), 5.17 (m, 2 H), 4.18 (t, <i>J</i> = 7.6 Hz, 2 H), 4.06 (m, 2 H), 3.82 (m, 2 H), 3.60 (s, 6 H), 2.51 (m, 2 H), 2.01–2.25 (m, 8 H), 0.87 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>53</sub>FN<sub>10</sub>O<sub>8</sub>, 941.41; found 941.4.</div></div><div id="sec5_2_1_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Dimethyl <i>N</i>,<i>N</i>′-({1-Fluoro-6-[3-(propan-2-yl)-1,2-oxazol-5-yl]-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl}bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>35</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.00 (s, 1 H), 7.90 (m, 2 H), 7.76 (s, 1 H), 7.58–7.63 (m, 2 H), 7.40 (d, <i>J</i> = 10.8 Hz, 1 H), 7.34 (s, 1H), 7.18 (m, 1 H), 5.91 (s, 1 H), 5.17–5.25 (m, 2 H), 4.21 (t, <i>J</i> = 6.8 Hz, 2 H), 4.09 (br s, 2 H), 3.86 (m, 2 H), 3.64 (s, 6 H), 2.84 (m, 1 H), 2.49–2.55 (m, 2 H), 2.03–2.27 (m, 8 H), 1.08 (m, 6H), 0.92 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>49</sub>H<sub>57</sub>FN<sub>10</sub>O<sub>8</sub>, 933.44; found 933.4.</div></div><div id="sec5_2_1_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Dimethyl <i>N</i>,<i>N</i>′-([1-Fluoro-6-(5-ethyl-1,3,4-thiadiazol-2-yl)-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>36</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.24 (s, 1 H), 8.04 (d, <i>J</i> = 10.4 Hz, 2 H), 7.80 (s, 1 H), 7.72 (d, <i>J</i> = 8.8 Hz, 1 H), 7.62 (d, <i>J</i> = 8.8 Hz, 1 H), 7.47 (m, 2 H), 7.27 (s, 1 H), 5.24 (m, 2 H), 4.22 (t, <i>J</i> = 6.8 Hz, 2 H), 4.10 (br s, 2 H), 3.88 (m, 2 H), 3.65 (s, 6 H), 2.99 (m, 2 H), 2.58 (br s, 2 H), 2.04–2.28 (m, 8 H), 1.23 (m, 3 H), 0.91 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>47</sub>H<sub>54</sub>FN<sub>11</sub>O<sub>7</sub>S, 936.39; found 936.3.</div></div><div id="sec5_2_1_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Dimethyl <i>N</i>,<i>N</i>′-([1-Fluoro-6-(1,2,3-thiadiazol-5-yl)-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>37</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.49 (d, <i>J</i> = 12.0 Hz, 1 H), 8.38 (s, 1 H), 8.02 (d, <i>J</i> = 13.6 Hz, 1 H), 7.88 (d, <i>J</i> = 7.2 Hz, 1 H), 7.79 (s, 1 H), 7.72 (d, <i>J</i> = 8.8 Hz, 1H), 7.63 (d, <i>J</i> = 7.6 Hz, 1 H), 7.40–7.48 (m, 1 H), 7.35 (s, 1 H), 7.23 (d, <i>J</i> = 11.2 Hz, 1 H), 5.21 (m, 2 H), 4.21 (t, <i>J</i> = 6.4 Hz, 2 H), 4.08 (m, 2 H), 3.86 (m, 2 H), 3.64 (s, 6 H), 2.51 (m, 2 H), 2.04–2.27 (m, 8 H), 0.96 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>45</sub>H<sub>50</sub>FN<sub>11</sub>O<sub>7</sub>S, 908.36; found 908.4.</div></div><div id="sec5_2_1_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Dimethyl <i>N</i>,<i>N</i>′-([6-(4-Cyclopropyl-1,3-thiazol-2-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>38</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.92 (s, 1 H), 7.81 (m, 2 H), 7.74 (s, 1 H), 7.55 (s, 2 H), 7.37 (d, <i>J</i> = 11.2 Hz, 1 H), 7.22 (s, 1 H), 7.10 (s, 1 H), 6.96 (s, 1 H), 5.21 (m, 2 H), 4.22 (m, 2 H), 4.08 (br s, 2 H), 3.87 (m, 2 H), 3.64 (m, 6 H), 2.51 (m, 2 H), 2.05–2.26 (m, 8 H), 1.93 (m, 1 H), 0.93 (d, <i>J</i> = 6.8 Hz, 6 H), 0.88 (d, <i>J</i> = 6.8 Hz, 6 H), 0.79 (m, 2 H), 0.64 (br, 2H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>49</sub>H<sub>55</sub>FN<sub>10</sub>O<sub>7</sub>S, 947.40; found 947.4.</div></div><div id="sec5_2_1_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Dimethyl <i>N</i>,<i>N</i>′-([6-(5-Cyclopropyl-1,3-thiazol-2-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>39</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.0 (s, 1 H), 7.91 (s, 1 H), 7.87 (s, 1 H), 7.76 (s, 1 H), 7.55–7.61 (m, 2 H), 7.34–7.41 (m, 3 H), 7.20 (s, 1 H), 5.17–5.25 (m, 2 H), 4.21 (t, <i>J</i> = 6.8 Hz, 2 H), 4.08 (br, 2 H), 3.83–3.87 (m, 2 H), 3.64 (s, 6 H), 2.53–2.55 (m, 2 H), 2.26 (m, 2 H), 2.15 (m, 4 H), 1.94–2.06 (m, 3 H), 0.89–0.97 (m, 14 H), 0.50 (m, 2H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>49</sub>H<sub>55</sub>FN<sub>10</sub>O<sub>7</sub>S, 947.40; found 947.3.</div></div><div id="sec5_2_1_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Dimethyl <i>N</i>,<i>N</i>′-([(6<i>S</i>)-6-(2-Cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>40</b>)</h3><div class="NLM_p">To a suspension of 2-bromothiazole <b>83</b> (10 g, 61 mmol) in toluene/H<sub>2</sub>O (10:1, 200 mL) under N<sub>2</sub> were added cyclopropyl boronic acid (21 g, 243 mmol), Pd(OAc)<sub>2</sub> (683 mg, 3 mmol), Cs<sub>2</sub>CO<sub>3</sub> (79 g, 243 mmol), and cataCXium A (79 g, 243 mmol). The resulting mixture was heated at 100 °C overnight, cooled to room temperature, and diluted with EtOAc and water. The layers were separated and the organic layer was washed with brine and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The mixture was filtered and concentrated under vacuum to afford a residue which was purified by silica gel chromatography using a gradient of petroleum ether/ethyl acetate (100/1 to 40/1) as eluent to afford 2-cyclopropylthiazole <b>84</b> (2 g, 32%).</div><div class="NLM_p">To a solution of 2-cyclopropylthiazole <b>84</b> (1.8 g, 14.4 mmol) in THF (30 mL) under N<sub>2</sub> was added a 2.5 M solution of <i>n</i>-BuLi (6.3 mL, 15.8 mmol) dropwise at −78 °C. The mixture was stirred for 1 h at −78 °C whereupon DMF (1.7 mL, 1.6 g, 21.6 mmol) was added dropwise. The mixture was allowed to warm to room temperature and stirred for 3 h before it was quenched with saturated aqueous NH<sub>4</sub>Cl and extracted with EtOAc. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. The crude material was purified by silica gel chromatography using a gradient of petroleum ether/ethyl acetate (50/1 to 20/1) as eluent to afford 2-cyclopropylthiazole-4-carbaldehyde <b>85</b> (1.5 g, 49%).</div><div class="NLM_p">To a mixture of 2-cyclopropylthiazole-4-carbaldehyde <b>85</b> (0.52 g, 3.4 mmol) and 5-bromo-2-(5-bromoindolin-2-yl)-3-fluorophenol <b>69</b> (1.0 g, 2.6 mmol) in anhydrous CH<sub>3</sub>CN (20 mL) under N<sub>2</sub> was added TFA (0.059 mL, 0.089 g, 0.78 mmol) at room temperature. The mixture was stirred for 6 h whereupon a solid was formed. The solid was collected by filtration and was washed with CH<sub>3</sub>CN to afford 3,10-dibromo-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-12,12a-dihydro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine (<b>86</b>) (0.9 g, 68%).</div><div class="NLM_p">To a solution of <b>86</b> (0.86 g, 1.65 mmol) in dry toluene (20 mL) was added DDQ (0.560 g, 2.5 mmol). After refluxing for 2 h, the solvent was removed and diluted with EtOAc. The organic layer was washed with saturated aqueous Na<sub>2</sub>SO<sub>3</sub>, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The residue was washed with MeOH (10 mL), filtered, and the resulting solid was collected by filtration to afford <i>rac</i>-(6<i>R</i>)-3,10-dibromo-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine (<b>87)</b> (0.6 g, 82%).</div><div class="NLM_p">To a solution of <b>87</b> (0.6 g, 1.2 mmol) in 1,4-dioxane (30 mL) under N<sub>2</sub> were added bis(pinacolato)diboron (0.88 g, 3.5 mmol), Pd(dppf)Cl<sub>2</sub> (0.080 g, 0.12 mmol), and KOAc (0.47 g, 4.8 mmol). The reaction mixture was heated to 110 °C and stirred overnight. After cooling, the solvent was removed under vacuum and the crude residue was purified by silica gel chromatography using a gradient of petroleum ether/ethyl acetate (5/1–1/1) as eluent to afford <i>rac</i>-(6<i>R)</i>-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-3,10-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine (<b>88</b>) (0.6 g, 82%).</div><div class="NLM_p last">To a suspension of <b>88</b> (614 mg, 1 mmol) in THF/H<sub>2</sub>O (10:1, 27 mL) under N<sub>2</sub> were added methyl ((<i>S</i>)-1-((<i>S</i>)-2-(5-bromo-1<i>H</i>-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate <b>58</b><a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (0.93 g, 2.5 mmol), Pd(dppf)<sub>2</sub>Cl<sub>2</sub> (73 mg, 0.1 mmol), Na<sub>2</sub>CO<sub>3</sub> (0.42 g, 4 mmol). The mixture was refluxed at 95 °C overnight and was cooled to room temperature. The mixture was filtered and the resultant filtrate was extracted with H<sub>2</sub>O (50 mL) and the aqueous layer was further extracted with EtOAc (100 mL). The organic layers were combined, washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude residue was purified by reverse phase HPLC purification using Phenomenex Synergi C18 (150 mm × 30 mm, 5 μm) eluted with mobile phase composed of H<sub>2</sub>O (0.1% TFA) (A) and acetonitrile (B) with gradient 15–40% of B in 25 min (flow rate, 80 mL/min) to afford the desired compound <b>89</b> (200 mg, 21%) which was separated by chiral SFC using the following conditions: column, Chiralpak AS-H, 250 mm × 4.6 mm, mobile phase B, 0.05% DEA in IPA, gradient, 40% B. Compound <b>40</b> (90 mg, 45%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 8.30 (s, 1 H), 8.22 (bs, 1 H), 8.10 (bs, 1H), 8.00 (s, 1H), 7.78 (d, <i>J</i> = 8.7 Hz, 1 H), 7.65–7.67 (om, 2 H), 7.52 (br s, 1 H), 7.38 (s, 1 H), 7.28–7.31 (om, 2 H), 7.19 (d, <i>J</i> = 3.2 Hz, 1 H), 5.16 (t, <i>J</i> = 7.4 Hz, 1 H), 5.14 (t, <i>J</i> = 7.4 Hz, 1 H), 4.11–4.15 (om, 2 H), 3.81–3.91 (om, 4 H), 3.55 (s, 6 H), 2.36–2.45 (om, 2 H), 2.26 (m, 1 H), 2.13–2.20 (om, 2 H), 2.06–2.13 (om, 2 H), 2.00–2.06 (om, 4 H), 0.99 (m, 2 H), 0.77–0.85 (om, 14 H). <sup>13</sup>C NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 175.20, 171.21, 171.15, 158.61, 156.95, 156.94, 150.05, 149.54, 148.88, 141.37, 133.88, 133.00, 131.11, 130.68, 129.14, 128.78, 125.35, 121.40, 120.38, 118.15, 117.01, 114.18, 111.04, 110.75, 107.30, 106.67, 102.94, 78.48, 57.95, 57.93, 53.06, 52.91, 51.51, 47.16, 47.11, 31.02, 30.95, 29.08, 24.80, 24.75, 19.35, 19.32, 17.74, 13.88, 11.17, 11.05. HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>49</sub>H<sub>55</sub>FN<sub>10</sub>O<sub>7</sub>S, 947.4033; found 947.4047.</div></div><div id="sec5_2_1_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Dimethyl <i>N,N</i>′-([6-(1,3-Thiazol-5-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>41</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.90 (s, 1 H), 8.11 (s, 1H), 8.01 (s, 1 H), 7.90 (d, 1 H, <i>J</i> = 6 Hz), 7.76 (s, 1 H), 7.56–7.62 (m, 2 H), 7.39–7.42 (m, 2 H), 7.32 (bs, 1 H), 7.21 (bs, 1 H), 5.17–5.25 (m, 2 H), 4.21 (t, <i>J</i> = 7.2 Hz, 2 H), 4.08 (m, 2 H), 3.89 (m, 2 H), 3.64 (s, 6 H), 2.51 (m, 2 H), 2.25 (m, 2 H), 2.15 (m, 4 H), 2.00 (m, 2 H), 0.86–0.96 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>46</sub>H<sub>51</sub>FN<sub>10</sub>O<sub>7</sub>S, 906.36; found 907.4.</div></div><div id="sec5_2_1_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Dimethyl <i>N</i>,<i>N</i>′-({1-Fluoro-6-[2-(1-methylcyclopropyl)-1,3-thiazol-5-yl]-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl}bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>42</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.91 (s, 2 H), 7.94 (s, 1 H), 7.65 (s, 1 H), 7.55 (s, 2 H), 7.38 (m, 1 H), 7.07–7.18 (m, 2 H), 5.16–5.26 (m, 2 H), 4.24 (m, 2 H), 4.08 (m, 2 H), 3.90(m, 2 H), 3.65 (s, 6 H), 2.45–2.55 (m, 2 H), 2.08–2.28 (m, 8 H), 0.89–0.98 (m, 20 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>57</sub>FN<sub>10</sub>O<sub>7</sub>S, 961.41; found 961.4.</div></div><div id="sec5_2_1_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Dimethyl <i>N</i>,<i>N</i>′-([6-(2-Ethyl-1,3-thiazol-5-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>43</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.20 (s, 1 H), 8.08 (s, 1 H), 8.01 (s, 1 H), 7.82 (s, 1 H), 7.73 (d, <i>J</i> = 8.8 Hz, 1 H), 7.66 (d, <i>J</i> = 8 Hz, 1 H), 7.60 (s, 1 H), 7.50 (s, J = 11.2 Hz, 1 H), 7.44(s, 1 H), 7.25 (s, 1 H), 5.21–5.28 (m, 2 H), 4.22–4.25 (m, 2 H), 4.10 (m, 2 H), 3.96 (m, 2 H), 3.66 (s, 6 H), 3.05–3.09 (m, 2 H), 2.57 (m, 2 H), 2.09–2.14 (m, 8 H), 1.28 (m, 3 H), 0.88–0.96 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>48</sub>H<sub>55</sub>FN<sub>10</sub>O<sub>7</sub>S, 935.40; found 935.4.</div></div><div id="sec5_2_1_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Dimethyl <i>N</i>,<i>N</i>′-([1-Fluoro-6-(2-propyl-1,3-thiazol-5-yl)-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>44</b>)</h3><div class="NLM_p last">The title compound <b>44</b> was obtained by SFC chiral separation of the corresponding racemate (4.0 g) using the following conditions: column, Chiralpak AS-H, 150 mm × 4.6 mm, 5 μm, mobile phase B, 0.05% DEA in IPA, gradient, 40% B. Compound <b>44</b> (1.05 g, 32%). <sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.99 (s, 1 H), 7.87 (s, 1 H), 7.75 (s, 2 H), 7.58 (s, 1 H), 7.42–7.40 (d, <i>J</i> = 10.4 Hz, 1 H), 7.28 (s, 1 H), 7.22 (s, 1 H), 7.17 (s, 1 H), 7.16 (s, 1 H), 5.27–5.19 (m, 2 H), 4.25–4.22 (m, 2 H), 4.10–3.92 (m, 2 H), 3.90–3.88 (m, 2 H), 3.65 (s, 6 H), 3.31–3.29 (m, 3 H), 2.83–2.79 (m, 2 H), 2.56–2.50 (m, 2 H), 2.28–2.05 (m, 6 H), 1.66–1.60 (m, 2 H), 0.95–0.93 (m, 7 H), 0.90–0. 85 (m, 9 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>49</sub>H<sub>57</sub>FN<sub>10</sub>O<sub>7</sub>S, 949.10; found 949.4.</div></div><div id="sec5_2_1_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Dimethyl <i>N</i>,<i>N</i>′-({1-Fluoro-6-[2-(propan-2-yl)-1,3-thiazol-5-yl]-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl}bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>45</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.13 (s, 1 H), 8.09 (s, 1 H), 7.90 (s, 1 H), 7.96 (s, 1 H), 7.63 (m, 2 H), 7.45 (m, 2 H), 7.33 (s, 1 H), 7.15 (s, 1 H), 5.20–5.31 (m, 2 H), 4.23 (t, <i>J</i> = 6.4 Hz, 2 H), 4.08 (m, 2 H), 3.94 (m, 2 H), 3.64 (s, 6 H), 2.55 (m, 2 H), 2.08–2.26 (m, 8 H), 1.24 (m, 7 H), 0.87–0.95 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>49</sub>H<sub>57</sub>FN<sub>10</sub>O<sub>7</sub>S, 949.41; found 949.5.</div></div><div id="sec5_2_1_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Dimethyl <i>N</i>,<i>N</i>′-({1-Fluoro-6-[2-(2,2,2-trifluoroethyl)-1,3-thiazol-5-yl]-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl}bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>46</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.03 (s, 1 H), 8.01 (s, 1 H),), 8.00 (s, 1 H), 7.75 (s, 1 H), 7.6 (m, 2 H), 7.47 (d, <i>J</i> = 10.8 Hz, 1 H), 7.4 (s, 1 H), 7.31 (s, 1 H), 7.2 (s, 1 H), 5.23 (m, 2 H), 4.25 (t, <i>J</i> = 7.2 Hz, 2 H), 4.08 (m, 2 H), 3.79–3.92 (m, 4 H), 3.64 (s, 8 H), 3.50–3.75 (m, 2H), 2.55 (m, 2 H), 2.00–2.40 (m, 8 H), 0.75–1.01 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>48</sub>H<sub>52</sub>F<sub>4</sub>N<sub>10</sub>O<sub>7</sub>S, 990.06; found 990.02</div></div><div id="sec5_2_1_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Dimethyl <i>N</i>,<i>N</i>′-({6-[2-(Difluoromethyl)-1,3-thiazol-5-yl]-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl}bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>47</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.14 (s, 1 H), 8.00 (s, 1 H), 7.82 (bs, 1H), 7.77 (s, 1 H), 7.65 (d, <i>J</i> = 8.4 Hz, 1 H), 7.58 (dd, <i>J</i> = 1.6, 8.4 Hz, 1 H), 7.48 (bs, 2 H), 7.31 (m, 1 H), 7.20 (m, 1 H), 6.84 (t, <i>J</i> = 54.4, 1 H), 5.19 (m, 2 H), 4.21 (t, <i>J</i> = 6.4 Hz, 2 H), 4.08 (m, 2 H), 3.86 (m, 2 H), 3.64 (s, 6 H), 2.47–2.56 (m, 2 H), 2.04–2.26 (m, 8 H), 0.93 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>47</sub>H<sub>51</sub>F<sub>3</sub>N<sub>10</sub>O<sub>7</sub>S: 957.36; found 957.3.</div></div><div id="sec5_2_1_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Dimethyl <i>N</i>,<i>N</i>′-([1-Fluoro-6-(2-methoxy-1,3-thiazol-5-yl)-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl]bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>48</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.93 (m, 1H), 7.74–7.84 (m, 3 H), 7.55 (m, 2H), 7.36 (d, <i>J</i> = 10.8 Hz, 1 H), 7.22 (bs, 1H), 7.09 (bs, 1 H), 6.64 (s, 1 H), 5.22 (m, 2 H), 4.23 (s, 2 H), 4.08 (bs, 2 H), 3.91 (m, 5 H), 3.64 (s, 6 H), 2.51 (m, 2 H), 2.06–2.27 (m, 8 H), 0.93 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>47</sub>H<sub>53</sub>FN<sub>10</sub>O<sub>8</sub>S: 937.38; found 937.3.</div></div><div id="sec5_2_1_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Dimethyl <i>N</i>,<i>N</i>′-({1-Fluoro-6-[2-(methoxymethyl)-1,3-thiazol-5-yl]-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl}bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>49</b>)</h3><div class="NLM_p last">The title compound <b>49</b> was obtained by SFC chiral separation of the corresponding racemate (69 mg) using the following conditions: column, Chiralpak OJ-H, 250 mm × 4.6 mm, mobile phase B, 0.05% DEA in IPA, gradient, 40% B. Compound <b>49</b> (20 mg, 58% yield). <sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.96–8.11 (m, 2H), 7.73–7.87 (m, 2 H), 7.53–7.64 (m, 2H), 7.37–7.43 (m, 1 H), 7.28 (s, 1H), 7.14–7.21 (m, 1 H), 5.14–5.29 (m, 2 H), 4.53 (s, 2 H), 4.18–4.29 (d, 2 H), 3.97–4.15 (m, 2 H), 3.38 (s, 1 H), 3.65 (s, 5 H), 3.42 (d, <i>J</i> = 6.4 Hz1 H), 3.35 (s, 3 H), 2.44–2.63 (m, 2 H), 1.97–2.34 (m, 8 H), 0.84–1.03 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>48</sub>H<sub>55</sub>FN<sub>10</sub>O<sub>8</sub>S, 951.39; found 951.4.</div></div><div id="sec5_2_1_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Dimethyl <i>N</i>,<i>N</i>′-({1-Fluoro-6-[4-methyl-2-(propan-2-yl)-1,3-thiazol-5-yl]-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine-3,10-diyl}bis{1<i>H</i>-imidazole-5,2-diyl-(2<i>S</i>)-pyrrolidine-2,1-diyl[(2<i>S</i>)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate (<b>50</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.19 (s, 1 H), 8.10 (s, 1 H), 8.03 (s, 1 H), 7.82 (s, 1 H), 7.62 (m, 2 H), 7.51 (s, 1 H), 7.47 (s, 1H), 7.31 (d, <i>J</i> = 2.8 Hz, 1 H), 5.24 (m, 2 H), 4.22 (t, <i>J</i> = 7.6 Hz, 2 H), 4.09 (m, 2 H), 3.90 (m, 2 H), 3.65 (s, 6 H), 3.30 (m, 1 H), 2.67 (s, 3 H), 2.56 (m, 2 H), 2.05–2.29 (m, 8 H), 1.24 (m, 6 H), 0.87–0.95 (m, 12H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>59</sub>FN<sub>10</sub>O<sub>7</sub>S, 963.43; found 963.4.</div></div><div id="sec5_2_1_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Methyl {(2<i>S</i>)-1-[(1<i>R</i>,3<i>S</i>,5<i>R</i>)-3-{5-[6-(2-Cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-3-{2-[(2<i>S</i>)-1-{(2<i>S</i>)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazin-10-yl]-1<i>H</i>-imidazol-2-yl}-2-azabicyclo[3.1.0]hexan-2-yl]-3-methyl-1-oxobutan-2-yl}carbamate (<b>51</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.83 (m, 2 H), 7.43–7.77 (m, 3 H), 7.30 (s, 2 H), 7.08 (S, 1 H), 6.99 (s, 1H), 6.89 (s, 1 H), 5.12 (m, 2 H), 4.56 (s, 1 H), 4.25 (s, 1H), 4.02 (s, 1H), 3.91 (s, 1H), 3.77 (s, 1H), 3.65 (s, 6H), 2.61 (s, 1H), 2.33 (s, 1H), 2.05–2.33 (m, 9H), 1.28 (m, 2H), 0.91–1.14 (m, 19 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>55</sub>FN<sub>10</sub>O<sub>7</sub>S, 959.4; found 959.3.</div></div><div id="sec5_2_1_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Methyl {(2<i>S</i>)-1-[(2<i>S</i>)-2-(5-{1-Fluoro-10-{2-[(1<i>R</i>,3<i>S</i>,5<i>R</i>)-2-{(2<i>S</i>)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[3.1.0]hexan-3-yl]-1<i>H</i>-imidazol-5-yl}-6-[2-(propan-2-yl)-1,3-thiazol-5-yl]-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazin-3-yl}-1<i>H</i>-imidazol-2-yl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (<b>52</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.11 (s, 1 H), 8.04 (s, 1H), 7.99 (s, 1 H), 7.77 (s, 1 H), 7.59–7.67 (m, 2 H), 7.46 (d, <i>J</i> = 11.2 Hz, 1 H), 7.24 (s, 1 H), 7.23 (s, 1 H), 5.09–5.22 (m, 2 H), 4.53 (d, <i>J</i> = 6.4 Hz, 1 H), 4.20 (d, <i>J</i> = 7.2 Hz, 1 H), 4.08 (m, 1 H), 3.91 (m, 1 H), 3.80 (m, 1 H), 3.64 (s, 6 H), 3.23–3.42 (m, 3 H), 2.67 (m, 1 H), 2.54 (m, 1 H), 2.42 (m, 1 H), 2.08–2.21 (m, 6 H), 1.25 (d, <i>J</i> = 6.8 Hz, 6 H), 1.08 (m, 1 H), 0.86–0.99 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>57</sub>FN<sub>10</sub>O<sub>7</sub>S, 961.41; found 961.5.</div></div><div id="sec5_2_1_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Methyl {(2<i>S</i>)-1-[(2<i>S</i>)-2-{5-[6-(2-Ethyl-1,3-thiazol-5-yl)-1-fluoro-10-{2-[(1<i>R</i>,3<i>S</i>,5<i>R</i>)-2-{(2<i>S</i>)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[3.1.0]hexan-3-yl]-1<i>H</i>-imidazol-5-yl}-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazin-3-yl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (<b>53</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.94 (s, 2 H), 7.87 (s, 1 H), 7.71 (s, 1 H), 7.55 (s, 1 H), 7.37 (d, <i>J</i> = 10.8 Hz, 1 H), 7.23 (s, 1 H), 7.19 (s, 1 H), 7.11 (s, 1 H), 5.09–5.19 (m, 2 H), 4.53 (d, <i>J</i> = 6.8 Hz, 1 H), 4.21 (d, <i>J</i> = 6.8 Hz, 1 H), 4.10 (m, 1 H), 3.80–3.88 (m, 2 H), 3.64 (s, 6 H), 2.81–2.86 (m, 2 H), 2.65 (m, 1 H), 2.40–2.55 (m, 2 H), 2.06–2.25 (m, 7 H), 1.18 (m, 3 H), 0.87–0.99 (m, 14 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>49</sub>H<sub>55</sub>FN<sub>10</sub>O<sub>7</sub>S, 947.40; found 947.4.</div></div><div id="sec5_2_1_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Methyl {(2<i>S</i>)-1-[(2<i>S</i>)-2-{5-[1-Fluoro-10-{2-[(1<i>R</i>,3<i>S</i>,5<i>R</i>)-2-{(2<i>S</i>)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[3.1.0]hexan-3-yl]-1<i>H</i>-imidazol-5-yl}-6-(2-propyl-1,3-thiazol-5-yl)-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazin-3-yl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (<b>54</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.95 (m, 3 H), 7.70 (s, 1 H), 7.55 (s, 2 H), 7.37 (d, <i>J</i> = 10.8 Hz, 1 H), 7.26 (m, 2 H), 7.10 (s, 1 H), 5.09–5.21 (m, 2 H), 4.53 (d, <i>J</i> = 8.0 Hz, 1 H), 4.53 (d, <i>J</i> = 6.8 Hz, 1 H), 4.21 (d, <i>J</i> = 6.8 Hz, 1 H), 4.08 (m, 1 H), 3.75–3.90 (m, 2 H), 3.64 (s, 6 H), 2.78 (t, <i>J</i> = 7.6 Hz, 2 H), 2.65 (m, 1 H), 2.40–2.55 (m, 2 H), 2.05–2.18 (m, 7 H), 0.96 (m, 3 H), 0.84–0.93 (m, 14 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>57</sub>FN<sub>10</sub>O<sub>7</sub>S, 961.41; found 961.4.</div></div><div id="sec5_2_1_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Methyl {(2<i>S</i>)-1-[(2<i>S</i>)-2-(5-{1-Fluoro-10-{2-[(1<i>R</i>,3<i>S</i>,5<i>R</i>)-2-{(2<i>S</i>)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[3.1.0]hexan-3-yl]-1<i>H</i>-imidazol-5-yl}-6-[2-(1-methylcyclopropyl)-1,3-thiazol-5-yl]-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazin-3-yl}-1<i>H</i>-imidazol-2-yl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (<b>55</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 7.98 (m, 2 H), 7.86 (s, 1 H), 7.75 (s, 1 H), 7.57 (s, 2 H), 7.40 (d, <i>J</i> = 11.2 Hz, 1 H), 7.30 (s, 1 H), 7.18 (s, 1 H), 7.10, (s, 1 H), 5.12–5.22 (m, 2 H), 4.54 (d, <i>J</i> = 8.0 Hz, 1 H), 4.53 (d, <i>J</i> = 6.4 Hz, 1 H), 4.22 (d, <i>J</i> = 7.2 Hz, 1 H), 4.08 (m, 1 H), 3.80–3.88 (m, 2 H), 3.65 (s, 6 H), 2.67 (m, 1 H), 2.48 (m, 2 H), 2.05–2.19 (m, 5 H), 1.39 (s, 3 H), 1.11 (m, 3 H), 0.88–1.02 (m, 15 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>51</sub>H<sub>57</sub>FN<sub>10</sub>O<sub>7</sub>S, 973.41; found 973.4.</div></div><div id="sec5_2_1_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Methyl {(2<i>S</i>)-1-[(2<i>S</i>)-2-{5-[6-(5-Cyclopropylthiophen-2-yl)-1-fluoro-10-{2-[(1<i>R</i>,3<i>S</i>,5<i>R</i>)-2-{(2<i>S</i>)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[3.1.0]hexan-3-yl]-1<i>H</i>-imidazol-5-yl}-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazin-3-yl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (<b>56</b>)</h3><div class="NLM_p">To a solution of <b>90</b> (25 g, 130 mmol) in toluene/H<sub>2</sub>O (660 mL, 10:1) under N<sub>2</sub> were added cyclopropyl boronic acid (34 g, 390 mmol), Pd(OAc)<sub>2</sub> (1.7 g, 7.6 mmol), cataCXium A (4.6 g, 13 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (127 g, 390 mmol). The mixture was heated to 100 °C and was stirred for 16 h. The mixture was cooled to room temperature and the solution was extracted with EtOAc. The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography using a petroleum ether/ethyl acetate (50:1) as eluent to afford 5-cyclopropylthiophene-2-carbaldehyde <b>91</b> (18.5 g, 95% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 9.78 (s, 1 H), 7.58 (d, <i>J</i> = 3.9 Hz, 1 H), 6.86 (d, <i>J</i> = 3.5 Hz, 1 H), 2.12–2.22 (m, 1 H), 1.10–1.19 (m, 2 H), 0.78–0.90 (m, 2 H).</div><div class="NLM_p">To a mixture of <b>70</b> (20 g, 58 mmol) and compound <b>91</b> (15 g, 99 mmol) in anhydrous CH<sub>3</sub>CN (500 mL) was added TFA (1.98 g, 17.4 mmol) at 25 °C. The mixture was stirred for 6 h at 25 °C. The resulting solid was collected by filtration and washed with CH<sub>3</sub>CN to afford <i>rac</i>-(6<i>R)-</i>3-bromo-10-chloro-6-(5-cyclopropylthiophen-2-yl)-1-fluoro-12,12a-dihydro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine (<b>92</b>) (25 g, 87% yield). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>16</sub>BrClFNOS, 477.98; found 477. 8.</div><div class="NLM_p">To a solution of the compound <b>92</b> (25 g, 53 mmol) in dry toluene (250 mL) was added DDQ (18 g, 79.5 mmol). The mixture was refluxed for 2 h, cooled to room temperature, and the solvent was removed under vacuum. The mixture was diluted with EtOAc and was washed with saturated aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude material was washed with MeOH (10 mL) and the resulting solid was collected by filtration to afford <i>rac</i>-(6<i>R</i>)-3-bromo-10-chloro-6-(5-cyclopropylthiophen-2-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine (<b>93</b>) (20 g, 80% yield). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>14</sub>BrClFNOS, 475.96; found 476.0.</div><div class="NLM_p">To a suspension of the compound <b>93</b> (20 g, 0.042 mol) in dioxane (400 mL) under N<sub>2</sub> were added bis(pinacolato)diboron (11.8 g, 46 mmol), KOAc (12.3 g, 12.6 mmol), and Pd(dppf)Cl<sub>2</sub> (3.07 g, 42 mmol). The mixture was heated to 100 °C, stirred overnight, and cooled to room temperature. The reaction mixture was concentrated and the residue was purified by silica gel chromatography using a mixture of petroleum ether/ethyl acetate (10:1) to afford <i>rac</i>-(6<i>R</i>)-10-chloro-6-(5-cyclopropylthiophen-2-yl)-1-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazine (<b>94</b>) (14 g, 64% yield). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>28</sub>H<sub>26</sub>BClFNO<sub>3</sub>S, 522.14; found 522.2.</div><div class="NLM_p">To a sealed tube charged with a suspension of compound <b>94</b> (0.34 g, 0.65 mmol) in dioxane (7 mL) were added <b>58</b> (0.37 g, 0.98 mmol), Pd(dppf)Cl<sub>2</sub> (107 mg,0.13 mmol), and 1 M K<sub>2</sub>CO<sub>3</sub> (1.96 mL, 1.96 mmol). The sealed tube was degassed three times, flushed with N<sub>2</sub>, capped, and heated to 90 °C. The mixture was stirred at 90 °C overnight and was cooled to room temperature. The mixture was filtered, and the resulting filtrate was diluted with EtOAc (20 mL) and washed with brine (30 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude residue was purified by silica gel chromatography using EtOAc as eluent to afford methyl {(2<i>S</i>)-1-[(2<i>S</i>)-2-{5-[(6<i>RS</i>)-10-chloro-6-(5-cyclopropylthiophen-2-yl)-1-fluoro-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazin-3-yl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (<b>95</b>) (315 mg, 70% yield). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>36</sub>H<sub>35</sub>ClFN<sub>5</sub>O<sub>4</sub>S, 688.21; found 688.39.</div><div class="NLM_p">To a reaction tube charged with compound <b>95</b> (0.32 g, 0.46 mmol) in dioxane (3 mL) were added bis(pinacolato)diboron (0.17 g, 0.69 mmol), KOAc (0.14 g, 1.37 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (47 mg, 0.046 mmol), X-Phos (44 mg, 0.092 mmol). The mixture was degassed three times, purged with N<sub>2</sub>, and capped. The mixture was heated to 110 °C overnight. The crude residue was purified by silica gel chromatography using EtOAc as eluent to afford methyl {(2<i>S</i>)-1-[(2<i>S</i>)-2-{5-[(6<i>RS</i>)-6-(5-cyclopropylthiophen-2-yl)-1-fluoro-10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazin-3-yl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (<b>96</b>) (355 mg, 99% yield). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>42</sub>H<sub>47</sub>BFN<sub>5</sub>O<sub>6</sub>S, 780.33; found 780.46.</div><div class="NLM_p">To a pressure tube charged with a suspension of the compound <b>96</b> (0.36 g, 0.46 mmol) in dioxane (4 mL) were added cap <b>61</b> (179 mg, 0.55 mmol), Pd(dppf)Cl<sub>2</sub> (74.4 mg,0.091 mmol), and 1 M K<sub>2</sub>CO<sub>3</sub> (1.37 mL, 1.37 mmol). The mixture was degassed three times, purged with N<sub>2</sub>, and capped. The mixture was heated to 85 °C and stirred overnight. After cooling to room temperature, the mixture was filtered and the filtrate was diluted with EtOAc (20 mL). The resulting mixture was washed with brine (30 mL). The organic layer was separated, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude residue was purified by silica gel chromatography using a gradient of CH<sub>2</sub>Cl<sub>2</sub>/MeOH(10%) NH<sub>4</sub>OH (0–8%) to afford <i>tert</i>-butyl (1<i>R</i>,3<i>S</i>,5<i>R</i>)-3-(5-(6-(5-cyclopropylthiophen-2-yl)-1-fluoro-3-(2-((<i>S</i>)-1-((methoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-valyl)pyrrolidin-2-yl)-1<i>H</i>-imidazol-5-yl)-6<i>H</i>-benzo[5,6][1,3]oxazino[3,4-<i>a</i>]indol-10-yl)-1<i>H</i>-imidazol-2-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (<b>97</b>) (115 mg, 28% yield). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>49</sub>H<sub>53</sub>FN<sub>8</sub>O<sub>6</sub>S, 901.38; found 901.54.</div><div class="NLM_p">To a solution of compound <b>97</b> (115 mg, 0.13 mmol) in dioxane (1 mL) at room temperature was added 4 N HCl in dioxane (0.32 mL, 1.28 mmol) dropwise. The mixture was stirred at room temperature for 3 h, and the mixture was concentrated under vacuum to give crude <b>98</b> (116 mg, 100% yield).</div><div class="NLM_p">To a mixture of the crude <b>98</b> (86 mg, 0.094 mmol) in DMF (1.5 mL) at 0 °C were added Moc-<span class="smallcaps smallerCapital">l</span>-valine (17.4 mg, 0.1 mmol), HATU (39.5 mg, 0.1 mmol), and DIPEA (0.099 mL, 73.3 mg, 0.57 mmol). The resulting mixture was warmed to 25 °C and stirred for 2 h. A few drops of water were added and the crude material was purified by reverse phase HPLC chromatography to afford the desired product <b>99</b> (90 mg, 99% yield).</div><div class="NLM_p last">Compound <b>56</b> was obtained by SFC chiral separation of the corresponding racemate <b>99</b> (90 mg) using the following conditions: column Chiralpak AS, 21 mm × 250 mm, mobile phase B, 0.2% DEA in methanol, gradient, 40% B, flow rate 50 mL/min. Compound <b>56</b> (33 g, 34% yield). <sup>1</sup>H NMR (500 MHz, MeOD) δ: 7.90 (m, 1 H), 7.6 (m, 1 H), 7.5 (m, 1 H), 7.20–7.95 (m, 3 H), 7.30 (s, 2 H), 7.00 (m, 1 H), 6.89 (m, 2 H), 5.15 (m, 2 H), 4.56 (m, 1 H), 4.20 (s, 1 H), 3.95 (m, 1 H), 3.85 (m, 1H), 3.65 (m, 6 H), 2.45 (m, 1 H), 1.90–2.40 (m, 9 H), 1.30 (m, 7 H), 0.80–1.00 (m, 12 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>51</sub>H<sub>56</sub>FN<sub>9</sub>O<sub>7</sub>S, 958.4; found 958.67.</div></div><div id="sec5_2_1_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Methyl {(2<i>S</i>)-1-[(2<i>S</i>)-2-{5-[6-(5,6-Dihydro-4<i>H</i>-cyclopenta[<i>b</i>]thiophen-2-yl)-1-fluoro-10-{2-[(1<i>R</i>,3<i>S</i>,5<i>R</i>)-2-{(2<i>S</i>)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[3.1.0]hexan-3-yl]-1<i>H</i>-imidazol-5-yl}-6<i>H</i>-indolo[1,2-<i>c</i>][1,3]benzoxazin-3-yl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (<b>57</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOD) δ: 8.10 (s, 1 H), 7.92 (s, 1 H), 7.76 (s, 1 H), 7.72 (s, 1 H), 7.42 (m, 2 H), 7.29 (m, 2 H), 7.15 (s, 1 H), 6.35 (s, 1 H), 5.20 (m, 2 H), 4.60 (m, 2 H), 4.25 (m, 2H), 4.02 (s, 1H), 3.91 (s, 1H), 3.84 (s, 1H), 3.66 (s, 6H), 2.70 (m, 3 H), 2.53 (m, 4 H), 2.08–2.28 (m, 9 H), 0.89–1.09 (m, 15 H). LC/MS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>51</sub>H<sub>56</sub>FN<sub>9</sub>O<sub>7</sub>S, 958.4; found 958.3.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01310">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35027" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35027" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01310" class="ext-link">10.1021/acs.jmedchem.6b01310</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01310/suppl_file/jm6b01310_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline"><sup>1</sup>H NMR and LCMS spectra of final compounds and full characterization of compound <b>40</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01310/suppl_file/jm6b01310_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01310/suppl_file/jm6b01310_si_001.csv">jm6b01310_si_001.csv (8.26 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01310/suppl_file/jm6b01310_si_002.pdf">jm6b01310_si_002.pdf (8.05 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01310" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71624" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71624" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ling Tong</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3302-8184" title="Orcid link">http://orcid.org/0000-0003-3302-8184</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#35595c5b521b415a5b5275585047565e1b565a58"><span class="__cf_email__" data-cfemail="c2aeabaca5ecb6adaca582afa7b0a1a9eca1adaf">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wensheng Yu</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5978-9454" title="Orcid link">http://orcid.org/0000-0001-5978-9454</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Chen</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Oleg Selyutin</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael P. Dwyer</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anilkumar G. Nair</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Mazzola</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jae-Hun Kim</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deyou Sha</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jingjun Yin</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rebecca T. Ruck</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ian W. Davies</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bin Hu</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bin Zhong</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinglai Hao</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tao Ji</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuai Zan</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rong Liu</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sony Agrawal</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ellen Xia</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephanie Curry</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patricia McMonagle</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karin Bystol</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frederick Lahser</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donna Carr</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laura Rokosz</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Ingravallo</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shiying Chen</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kung-I Feng</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Cartwright</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ernest Asante-Appiah</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph A. Kozlowski</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Biology, §Department of Pharmacokinetics, and ∥Department of
Drug Safety, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Process and Analytical Chemistry, and #Department of Discovery Pharmaceutic Science, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, WuXi AppTec, Shanghai, 200131, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): The authors are employees of Merck & Co., Inc. except for J.-H.K, R.L., L.R., and M.C. who were employed at Merck & Co., Inc. during this work.<br /></br></div></li></ul></div><div class="ack" id="ACK-d171e6325-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50785" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50785" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Rong-Sheng Yang for obtaining HRES MS data. The authors also thank Margaret B. Hill, Sharon Brosemer, and Kristin Roman for generating IUPAC nomenclatures for final compounds.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i79" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i79"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i80" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i80"> Abbreviations Used</h2><tr><td class="NLM_term">GT</td><td class="NLM_def"><p class="first last">genotype</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">CLp</td><td class="NLM_def"><p class="first last">systemic clearance</p></td></tr><tr><td class="NLM_term">FDC</td><td class="NLM_def"><p class="first last">fixed-dose combination</p></td></tr><tr><td class="NLM_term">n.d.</td><td class="NLM_def"><p class="first last">not determined</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74833" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74833" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 25 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Liang, J. T.; Hoofnagle, J. H.</span> <span class="citation_source-book">Hepatitis C</span>; Biomedical Research Reports; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">London, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">2000</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">185</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=185-203&author=J.+T.+Liang&author=J.+H.+Hoofnagle&title=Hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%2BT.%26btitle%3DHepatitis%2520C%26pub%3DAcademic%2520Press%26date%3D2000%26spage%3D185%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Mohd Hanafiah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groeger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaxman, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiersma, S. T.</span><span> </span><span class="NLM_article-title">Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1333</span><span class="NLM_x">–</span> <span class="NLM_lpage">1342</span><span class="refDoi"> DOI: 10.1002/hep.26141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1002%2Fhep.26141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=1333-1342&author=K.+Mohd+Hanafiahauthor=J.+Groegerauthor=A.+D.+Flaxmanauthor=S.+T.+Wiersma&title=Global+epidemiology+of+hepatitis+C+virus+infection%3A+new+estimates+of+age-specific+antibody+to+HCV+seroprevalence&doi=10.1002%2Fhep.26141"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fhep.26141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26141%26sid%3Dliteratum%253Aachs%26aulast%3DMohd%2BHanafiah%26aufirst%3DK.%26aulast%3DGroeger%26aufirst%3DJ.%26aulast%3DFlaxman%26aufirst%3DA.%2BD.%26aulast%3DWiersma%26aufirst%3DS.%2BT.%26atitle%3DGlobal%2520epidemiology%2520of%2520hepatitis%2520C%2520virus%2520infection%253A%2520new%2520estimates%2520of%2520age-specific%2520antibody%2520to%2520HCV%2520seroprevalence%26jtitle%3DHepatology%26date%3D2013%26volume%3D57%26spage%3D1333%26epage%3D1342%26doi%3D10.1002%2Fhep.26141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><div class="note"><p class="first last">For a review on DAAs see the following:</p></div><span class="NLM_contrib-group">Holmes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A.</span><span> </span><span class="NLM_article-title">Interferon-Free combination therapies for the treatment of hepatitis C: current insights</span> <span class="citation_source-journal">Hepatic Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span><span class="refDoi"> DOI: 10.2147/HMER.S55864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.2147%2FHMER.S55864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A280%3ADC%252BC28rgsVSqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=51-70&author=J.+Holmesauthor=A.+Thompson&title=Interferon-Free+combination+therapies+for+the+treatment+of+hepatitis+C%3A+current+insights&doi=10.2147%2FHMER.S55864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon-free combination therapies for the treatment of hepatitis C: current insights</span></div><div class="casAuthors">Holmes Jacinta A; Thompson Alexander J</div><div class="citationInfo"><span class="NLM_cas:title">Hepatic medicine : evidence and research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-70</span>
        ISSN:<span class="NLM_cas:issn">1179-1535</span>.
    </div><div class="casAbstract">The hepatitis C virus (HCV) treatment landscape has rapidly changed over the past 5 years.  The development of direct-acting antiviral (DAA) agents that specifically target various steps in the HCV lifecycle has revolutionized therapeutic options for patients with HCV, with the development of highly effective and well-tolerated oral interferon-free regimens.  There are many DAAs that are currently in development or have recently been approved, which target different nonstructural HCV proteins and host targets that are essential for HCV replication.  This review will focus on the different classes of DAAs and the various combinations that are in advanced development for the treatment of chronic HCV infection and will focus on the different regimens in specific patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSaWQI_kNsvcFvAgqb2vdc5fW6udTcc2eaC_1MzV5Pro7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgsVSqtg%253D%253D&md5=132f4de5a7104defd164235b90711976</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2147%2FHMER.S55864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FHMER.S55864%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DA.%26atitle%3DInterferon-Free%2520combination%2520therapies%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%253A%2520current%2520insights%26jtitle%3DHepatic%2520Med.%26date%3D2015%26spage%3D51%26epage%3D70%26doi%3D10.2147%2FHMER.S55864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">van der Meer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veldt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feld, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedemeyer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufour, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lammert, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duarte-Rojo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heathcote, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manns, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuske, L.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">2584</span><span class="NLM_x">–</span> <span class="NLM_lpage">2593</span><span class="refDoi"> DOI: 10.1001/jama.2012.144878</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1001%2Fjama.2012.144878" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2012&pages=2584-2593&author=A.+van+der+Meerauthor=B.+Veldtauthor=J.+Feldauthor=H.+Wedemeyerauthor=J.+Dufourauthor=F.+Lammertauthor=A.+Duarte-Rojoauthor=E.+Heathcoteauthor=M.+Mannsauthor=L.+Kuske&title=Association+between+sustained+virological+response+and+all-cause+mortality+among+patients+with+chronic+hepatitis+C+and+advanced+hepatic+fibrosis&doi=10.1001%2Fjama.2012.144878"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1001%2Fjama.2012.144878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2012.144878%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BMeer%26aufirst%3DA.%26aulast%3DVeldt%26aufirst%3DB.%26aulast%3DFeld%26aufirst%3DJ.%26aulast%3DWedemeyer%26aufirst%3DH.%26aulast%3DDufour%26aufirst%3DJ.%26aulast%3DLammert%26aufirst%3DF.%26aulast%3DDuarte-Rojo%26aufirst%3DA.%26aulast%3DHeathcote%26aufirst%3DE.%26aulast%3DManns%26aufirst%3DM.%26aulast%3DKuske%26aufirst%3DL.%26atitle%3DAssociation%2520between%2520sustained%2520virological%2520response%2520and%2520all-cause%2520mortality%2520among%2520patients%2520with%2520chronic%2520hepatitis%2520C%2520and%2520advanced%2520hepatic%2520fibrosis%26jtitle%3DJAMA%26date%3D2012%26volume%3D308%26spage%3D2584%26epage%3D2593%26doi%3D10.1001%2Fjama.2012.144878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Smith, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BukH, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuiken, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muerhoff, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stapleton, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmonds, P.</span><span> </span><span class="NLM_article-title">Expanded classification of hepatitis C virus inti 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">318</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span><span class="refDoi"> DOI: 10.1002/hep.26744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1002%2Fhep.26744" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=318-327&issue=1&author=D.+B.+Smithauthor=J.+BukHauthor=C.+Kuikenauthor=A.+S.+Muerhoffauthor=C.+M.+Riceauthor=J.+T.+Stapletonauthor=P.+Simmonds&title=Expanded+classification+of+hepatitis+C+virus+inti+7+genotypes+and+67+subtypes%3A+updated+criteria+and+genotype+assignment+web+resource&doi=10.1002%2Fhep.26744"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fhep.26744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26744%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BB.%26aulast%3DBukH%26aufirst%3DJ.%26aulast%3DKuiken%26aufirst%3DC.%26aulast%3DMuerhoff%26aufirst%3DA.%2BS.%26aulast%3DRice%26aufirst%3DC.%2BM.%26aulast%3DStapleton%26aufirst%3DJ.%2BT.%26aulast%3DSimmonds%26aufirst%3DP.%26atitle%3DExpanded%2520classification%2520of%2520hepatitis%2520C%2520virus%2520inti%25207%2520genotypes%2520and%252067%2520subtypes%253A%2520updated%2520criteria%2520and%2520genotype%2520assignment%2520web%2520resource%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26issue%3D1%26spage%3D318%26epage%3D327%26doi%3D10.1002%2Fhep.26744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Coburn, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinke, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kargman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span> </span><span class="NLM_article-title">Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1930</span><span class="NLM_x">–</span> <span class="NLM_lpage">1940</span><span class="refDoi"> DOI: 10.1002/cmdc.201300343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1002%2Fcmdc.201300343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=24127258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1SkurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1930-1940&author=C.+A.+Coburnauthor=P.+T.+Meinkeauthor=W.+Changauthor=C.+M.+Fandozziauthor=D.+J.+Grahamauthor=B.+Huauthor=Q.+Huangauthor=S.+Kargmanauthor=J.+Kozlowskiauthor=R.+Liuauthor=J.+A.+McCauleyauthor=A.+A.+Nomeirauthor=R.+M.+Sollauthor=J.+P.+Vaccaauthor=D.+Wangauthor=H.+Wuauthor=B.+Zhongauthor=D.+B.+Olsenauthor=S.+W.+Ludmerer&title=Discovery+of+MK-8742%3A+an+HCV+NS5A+inhibitor+with+broad+genotype+activity&doi=10.1002%2Fcmdc.201300343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-8742: An HCV NS5A inhibitor with broad genotype activity</span></div><div class="casAuthors">Coburn, Craig A.; Meinke, Peter T.; Chang, Wei; Fandozzi, Christine M.; Graham, Donald J.; Hu, Bin; Huang, Qian; Kargman, Stacia; Kozlowski, Joseph; Liu, Rong; McCauley, John A.; Nomeir, Amin A.; Soll, Richard M.; Vacca, Joseph P.; Wang, Dahai; Wu, Hao; Zhong, Bin; Olsen, David B.; Ludmerer, Steven W.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1930-1940</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The NS5A protein plays a crit. role in the replication of HCV and has been the focus of numerous research efforts over the past few years.  NS5A inhibitors have shown impressive in vitro potency profiles in HCV replicon assays, making them attractive components for inclusion in all oral combination regimens.  Early work in the NS5A arena led to the discovery of our first clin. candidate, MK-4882 [2-((S)-pyrrolidin-2-yl)-5-(2-(4-(5-((S)-pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole].  While preclin. proof-of-concept studies in HCV-infected chimpanzees harboring chronic genotype 1 infections resulted in significant decreases in viral load after both single- and multiple-dose treatments, viral breakthrough proved to be a concern, thus necessitating the development of compds. with increased potency against a no. of genotypes and NS5A resistance mutations.  Modification of the MK-4882 core scaffold by introduction of a cyclic constraint afforded a series of tetracyclic inhibitors, which showed improved virol. profiles.  Herein we describe the research efforts that led to the discovery of MK-8742, a tetracyclic indole-based NS5A inhibitor, which is currently in phase 2b clin. trials as part of an all-oral, interferon-free regimen for the treatment of HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqknZKO01aZlLVg90H21EOLACvtfcHk0lg2-8rDk_VQvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1SkurzN&md5=2f2b3ed2281c43e39b24d4197b9f57ee</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300343%26sid%3Dliteratum%253Aachs%26aulast%3DCoburn%26aufirst%3DC.%2BA.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKargman%26aufirst%3DS.%26aulast%3DKozlowski%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DNomeir%26aufirst%3DA.%2BA.%26aulast%3DSoll%26aufirst%3DR.%2BM.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520MK-8742%253A%2520an%2520HCV%2520NS5A%2520inhibitor%2520with%2520broad%2520genotype%2520activity%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D1930%26epage%3D1940%26doi%3D10.1002%2Fcmdc.201300343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coburn, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selyutin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblum, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavey, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizvi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shankar, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rokosz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMonagle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahser, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asante-Appiah, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J. A.</span><span> </span><span class="NLM_article-title">Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3800</span><span class="NLM_x">–</span> <span class="NLM_lpage">3805</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.05.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.bmcl.2016.05.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3800-3805&author=W.+Yuauthor=C.+A.+Coburnauthor=A.+G.+Nairauthor=M.+Wongauthor=L.+Tongauthor=M.+P.+Dwyerauthor=B.+Huauthor=B.+Zhongauthor=J.+Haoauthor=D.-Y.+Yangauthor=O.+Selyutinauthor=Y.+Jiangauthor=S.+B.+Rosenblumauthor=S.+H.+Kimauthor=B.+J.+Laveyauthor=G.+Zhouauthor=R.+Rizviauthor=B.+B.+Shankarauthor=Q.+Zengauthor=L.+Chenauthor=S.+Agrawalauthor=D.+Carrauthor=L.+Rokoszauthor=R.+Liuauthor=S.+Curryauthor=P.+McMonagleauthor=P.+Ingravalloauthor=F.+Lahserauthor=E.+Asante-Appiahauthor=A.+Nomeirauthor=J.+A.+Kozlowski&title=Alkyl+substituted+aminal+derivatives+of+HCV+NS5A+inhibitor+MK-8742&doi=10.1016%2Fj.bmcl.2016.05.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.05.041%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCoburn%26aufirst%3DC.%2BA.%26aulast%3DNair%26aufirst%3DA.%2BG.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DD.-Y.%26aulast%3DSelyutin%26aufirst%3DO.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DRosenblum%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DLavey%26aufirst%3DB.%2BJ.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DRizvi%26aufirst%3DR.%26aulast%3DShankar%26aufirst%3DB.%2BB.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DRokosz%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DCurry%26aufirst%3DS.%26aulast%3DMcMonagle%26aufirst%3DP.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DLahser%26aufirst%3DF.%26aulast%3DAsante-Appiah%26aufirst%3DE.%26aulast%3DNomeir%26aufirst%3DA.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DAlkyl%2520substituted%2520aminal%2520derivatives%2520of%2520HCV%2520NS5A%2520inhibitor%2520MK-8742%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3800%26epage%3D3805%26doi%3D10.1016%2Fj.bmcl.2016.05.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coburn, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblum, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selyutin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masse, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMonagle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asante-Appiah, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J. A.</span><span> </span><span class="NLM_article-title">Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3414</span><span class="NLM_x">–</span> <span class="NLM_lpage">3420</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.06.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.bmcl.2016.06.056" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3414-3420&author=W.+Yuauthor=C.+A.+Coburnauthor=A.+G.+Nairauthor=M.+Wongauthor=S.+B.+Rosenblumauthor=G.+Zhouauthor=M.+P.+Dwyerauthor=L.+Tongauthor=B.+Huauthor=B.+Zhongauthor=J.+Haoauthor=T.+Jiauthor=S.+Zanauthor=S.+H.+Kimauthor=Q.+Zengauthor=O.+Selyutinauthor=L.+Chenauthor=F.+Masseauthor=S.+Agrawalauthor=R.+Liuauthor=E.+Xiaauthor=Y.+Zhaiauthor=S.+Curryauthor=P.+McMonagleauthor=P.+Ingravalloauthor=E.+Asante-Appiahauthor=M.+Linauthor=J.+A.+Kozlowski&title=Aryl+or+heteroaryl+substituted+aminal+derivatives+of+HCV+NS5A+inhibitor+MK-8742&doi=10.1016%2Fj.bmcl.2016.06.056"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.06.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.06.056%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCoburn%26aufirst%3DC.%2BA.%26aulast%3DNair%26aufirst%3DA.%2BG.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DRosenblum%26aufirst%3DS.%2BB.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DT.%26aulast%3DZan%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DSelyutin%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DMasse%26aufirst%3DF.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DE.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DCurry%26aufirst%3DS.%26aulast%3DMcMonagle%26aufirst%3DP.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DAsante-Appiah%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DAryl%2520or%2520heteroaryl%2520substituted%2520aminal%2520derivatives%2520of%2520HCV%2520NS5A%2520inhibitor%2520MK-8742%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3414%26epage%3D3420%26doi%3D10.1016%2Fj.bmcl.2016.06.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Yu, W.; Tong, L.; Hu, B.; Zhong, B.; Hao, J.; Ji, T.; Zan, S.; Coburn, C. A.; Selyutin, O.; Chen, L.; Masse, F.; Rokosz, L.; Liu, R.; Curry, S.; McMonagle, P.; Ingravallo, P.; Asante-Appiah, E.; Chen, S.; Kozlowski, J. A.</span><span> </span><span class="NLM_article-title">Discovery of chromane containing HCV NS5A inhibitors with improved potency against resistance associate variants</span>. J. Med. Chem.<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">, </span>ASAP. DOI: <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01234</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01234" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=W.+Yu&author=L.+Tong&author=B.+Hu&author=B.+Zhong&author=J.+Hao&author=T.+Ji&author=S.+Zan&author=C.+A.+Coburn&author=O.+Selyutin&author=L.+Chen&author=F.+Masse&author=L.+Rokosz&author=R.+Liu&author=S.+Curry&author=P.+McMonagle&author=P.+Ingravallo&author=E.+Asante-Appiah&author=S.+Chen&author=J.+A.+Kozlowski&title=Discovery+of+chromane+containing+HCV+NS5A+inhibitors+with+improved+potency+against+resistance+associate+variants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01234%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520chromane%2520containing%2520HCV%2520NS5A%2520inhibitors%2520with%2520improved%2520potency%2520against%2520resistance%2520associate%2520variants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26doi%3D10.1021%2Facs.jmedchem.6b01234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coburn, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzola, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sha, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selyutin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblum, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavey, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keertikar, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masse, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMonagle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asante-Appiah, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J. A.</span><span> </span><span class="NLM_article-title">Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">4851</span><span class="NLM_x">–</span> <span class="NLM_lpage">4856</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.bmcl.2016.08.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=4851-4856&author=W.+Yuauthor=G.+Zhouauthor=C.+A.+Coburnauthor=Q.+Zengauthor=L.+Tongauthor=M.+P.+Dwyerauthor=L.+Chenauthor=R.+Mazzolaauthor=J.-H.+Kimauthor=D.+Shaauthor=O.+Selyutinauthor=S.+B.+Rosenblumauthor=B.+Laveyauthor=A.+G.+Nairauthor=S.+H.+Kimauthor=K.+M.+Keertikarauthor=F.+Masseauthor=S.+Agrawalauthor=R.+Liuauthor=E.+Xiaauthor=Y.+Zhaiauthor=S.+Curryauthor=P.+McMonagleauthor=P.+Ingravalloauthor=E.+Asante-Appiahauthor=S.+Chenauthor=J.+A.+Kozlowski&title=Substituted+tetracyclic+indole+core+derivatives+of+HCV+NS5A+inhibitor+MK-8742&doi=10.1016%2Fj.bmcl.2016.08.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DCoburn%26aufirst%3DC.%2BA.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DMazzola%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DSha%26aufirst%3DD.%26aulast%3DSelyutin%26aufirst%3DO.%26aulast%3DRosenblum%26aufirst%3DS.%2BB.%26aulast%3DLavey%26aufirst%3DB.%26aulast%3DNair%26aufirst%3DA.%2BG.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DKeertikar%26aufirst%3DK.%2BM.%26aulast%3DMasse%26aufirst%3DF.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DE.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DCurry%26aufirst%3DS.%26aulast%3DMcMonagle%26aufirst%3DP.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DAsante-Appiah%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DSubstituted%2520tetracyclic%2520indole%2520core%2520derivatives%2520of%2520HCV%2520NS5A%2520inhibitor%2520MK-8742%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D4851%26epage%3D4856%26doi%3D10.1016%2Fj.bmcl.2016.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coburn, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinke, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selyutin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblum, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fells, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asante-Appiah, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J. A.</span><span> </span><span class="NLM_article-title">Alternative Core Development Around the HCV NS5A Inhibitor MK-8742 Scaffold</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">5132</span><span class="NLM_x">–</span> <span class="NLM_lpage">5137</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.07.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.bmcl.2016.07.057" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5132-5137&author=L.+Tongauthor=W.+Yuauthor=C.+A.+Coburnauthor=P.+T.+Meinkeauthor=A.+G.+Nairauthor=M.+P.+Dwyerauthor=L.+Chenauthor=O.+Selyutinauthor=S.+B.+Rosenblumauthor=Y.+Jiangauthor=J.+Fellsauthor=B.+Huauthor=B.+Zhongauthor=R.+M.+Sollauthor=R.+Liuauthor=S.+Agrawalauthor=E.+Xiaauthor=Y.+Zhaiauthor=R.+Kongauthor=P.+Ingravalloauthor=A.+Nomeirauthor=E.+Asante-Appiahauthor=J.+A.+Kozlowski&title=Alternative+Core+Development+Around+the+HCV+NS5A+Inhibitor+MK-8742+Scaffold&doi=10.1016%2Fj.bmcl.2016.07.057"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.07.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.07.057%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCoburn%26aufirst%3DC.%2BA.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26aulast%3DNair%26aufirst%3DA.%2BG.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSelyutin%26aufirst%3DO.%26aulast%3DRosenblum%26aufirst%3DS.%2BB.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DFells%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DSoll%26aufirst%3DR.%2BM.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DXia%26aufirst%3DE.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DR.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DNomeir%26aufirst%3DA.%26aulast%3DAsante-Appiah%26aufirst%3DE.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DAlternative%2520Core%2520Development%2520Around%2520the%2520HCV%2520NS5A%2520Inhibitor%2520MK-8742%2520Scaffold%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5132%26epage%3D5137%26doi%3D10.1016%2Fj.bmcl.2016.07.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coburn, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selyutin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shankar, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblum, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruck, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMonagle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bystol, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahser, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asante-Appiah, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J. A.</span><span> </span><span class="NLM_article-title">Structure-Activity Relationships of Proline Modifications Around the Tetracyclic-indole Class of NS5A Inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">5354</span><span class="NLM_x">–</span> <span class="NLM_lpage">5360</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.08.097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.bmcl.2016.08.097" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5354-5360&author=L.+Tongauthor=W.+Yuauthor=C.+A.+Coburnauthor=L.+Chenauthor=O.+Selyutinauthor=Q.+Zengauthor=M.+P.+Dwyerauthor=A.+G.+Nairauthor=B.+B.+Shankarauthor=S.+H.+Kimauthor=D.-Y.+Yangauthor=S.+B.+Rosenblumauthor=R.+T.+Ruckauthor=I.+W.+Daviesauthor=B.+Huauthor=B.+Zhongauthor=J.+Haoauthor=T.+Jiauthor=S.+Zanauthor=R.+Liuauthor=S.+Agrawalauthor=D.+Carrauthor=S.+Curryauthor=P.+McMonagleauthor=K.+Bystolauthor=F.+Lahserauthor=P.+Ingravalloauthor=S.+Chenauthor=E.+Asante-Appiahauthor=J.+A.+Kozlowski&title=Structure-Activity+Relationships+of+Proline+Modifications+Around+the+Tetracyclic-indole+Class+of+NS5A+Inhibitors&doi=10.1016%2Fj.bmcl.2016.08.097"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.08.097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.08.097%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCoburn%26aufirst%3DC.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSelyutin%26aufirst%3DO.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DNair%26aufirst%3DA.%2BG.%26aulast%3DShankar%26aufirst%3DB.%2BB.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DYang%26aufirst%3DD.-Y.%26aulast%3DRosenblum%26aufirst%3DS.%2BB.%26aulast%3DRuck%26aufirst%3DR.%2BT.%26aulast%3DDavies%26aufirst%3DI.%2BW.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DT.%26aulast%3DZan%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DCurry%26aufirst%3DS.%26aulast%3DMcMonagle%26aufirst%3DP.%26aulast%3DBystol%26aufirst%3DK.%26aulast%3DLahser%26aufirst%3DF.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DAsante-Appiah%26aufirst%3DE.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DStructure-Activity%2520Relationships%2520of%2520Proline%2520Modifications%2520Around%2520the%2520Tetracyclic-indole%2520Class%2520of%2520NS5A%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5354%26epage%3D5360%26doi%3D10.1016%2Fj.bmcl.2016.08.097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Scheel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C.</span><span> </span><span class="NLM_article-title">Understanding the hepatitis C virus life cycle paves the way for highly effective therapies</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">837</span><span class="NLM_x">–</span> <span class="NLM_lpage">849</span><span class="refDoi"> DOI: 10.1038/nm.3248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1038%2Fnm.3248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=23836234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKru7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=837-849&author=T.+Scheelauthor=C.+Rice&title=Understanding+the+hepatitis+C+virus+life+cycle+paves+the+way+for+highly+effective+therapies&doi=10.1038%2Fnm.3248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the hepatitis C virus life cycle paves the way for highly effective therapies</span></div><div class="casAuthors">Scheel, Troels K. H.; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">837-849</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  More than two decades of intense research has provided a detailed understanding of hepatitis C virus (HCV), which chronically infects 2% of the world's population.  This effort has paved the way for the development of antiviral compds. to spare patients from life-threatening liver disease.  An exciting new era in HCV therapy dawned with the recent approval of two viral protease inhibitors, used in combination with pegylated interferon-α and ribavirin; however, this is just the beginning.  Multiple classes of antivirals with distinct targets promise highly efficient combinations, and interferon-free regimens with short treatment duration and fewer side effects are the future of HCV therapy.  Ongoing and future trials will det. the best antiviral combinations and whether the current seemingly rich pipeline is sufficient for successful treatment of all patients in the face of major challenges, such as HCV diversity, viral resistance, the influence of host genetics, advanced liver disease and other co-morbidities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpde8altGxkeLVg90H21EOLACvtfcHk0lhR0S_PeyGq3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKru7rI&md5=dabc9fbc7dc0bc56115d5ede0d8ae072</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnm.3248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3248%26sid%3Dliteratum%253Aachs%26aulast%3DScheel%26aufirst%3DT.%26aulast%3DRice%26aufirst%3DC.%26atitle%3DUnderstanding%2520the%2520hepatitis%2520C%2520virus%2520life%2520cycle%2520paves%2520the%2520way%2520for%2520highly%2520effective%2520therapies%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D837%26epage%3D849%26doi%3D10.1038%2Fnm.3248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D.,  II</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">465</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span><span class="refDoi"> DOI: 10.1038/nature08960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1038%2Fnature08960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=20410884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=96-100&author=M.+Gaoauthor=R.+Nettlesauthor=M.+Belemaauthor=L.+Snyderauthor=V.+Nguyenauthor=R.+Fridellauthor=M.+Serrano-Wuauthor=D.+Langleyauthor=J.+Sunauthor=D.+O%E2%80%99Boyle&title=Chemical+genetics+strategy+identifies+an+HCV+NS5A+inhibitor+with+a+potent+clinical+effect&doi=10.1038%2Fnature08960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span></div><div class="casAuthors">Gao, Min; Nettles, Richard E.; Belema, Makonen; Snyder, Lawrence B.; Nguyen, Van N.; Fridell, Robert A.; Serrano-Wu, Michael H.; Langley, David R.; Sun, Jin-Hua; O'Boyle, Donald R., II; Lemm, Julie A.; Wang, Chunfu; Knipe, Jay O.; Chien, Caly; Colonno, Richard J.; Grasela, Dennis M.; Meanwell, Nicholas A.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7294</span>),
    <span class="NLM_cas:pages">96-100</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estd. to be approaching 200 million people.  Current therapy relies upon a combination of pegylated interferon-α and ribavirin, a poorly tolerated regimen typically assocd. with less than 50% sustained virol. response rate in those infected with genotype 1 virus.  The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B.  Here we describe the profile of BMS-790052, a small mol. inhibitor of the HCV NS5A protein that exhibits picomolar half-max. effective concns. (EC50) towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture.  In a phase I clin. trial in patients chronically infected with HCV, administration of a single 100-mg dose of BMS-790052 was assocd. with a 3.3 log10 redn. in mean viral load measured 24 h post-dose that was sustained for an addnl. 120 h in two patients infected with genotype 1b virus.  Genotypic anal. of samples taken at baseline, 24 and 144 h post-dose revealed that the major HCV variants obsd. had substitutions at amino-acid positions identified using the in vitro replicon system.  These results provide the first clin. validation of an inhibitor of HCV NS5A, a protein with no known enzymic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations of HCV inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAY7Lig0xT9LVg90H21EOLACvtfcHk0lhR0S_PeyGq3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D&md5=620427e987f2bccd153270cde2ef5027</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1038%2Fnature08960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08960%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DNettles%26aufirst%3DR.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DSnyder%26aufirst%3DL.%26aulast%3DNguyen%26aufirst%3DV.%26aulast%3DFridell%26aufirst%3DR.%26aulast%3DSerrano-Wu%26aufirst%3DM.%26aulast%3DLangley%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%26atitle%3DChemical%2520genetics%2520strategy%2520identifies%2520an%2520HCV%2520NS5A%2520inhibitor%2520with%2520a%2520potent%2520clinical%2520effect%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D96%26epage%3D100%26doi%3D10.1038%2Fnature08960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nettles, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marbury, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldwater, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMicco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vutikullird, A.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1956</span><span class="NLM_x">–</span> <span class="NLM_lpage">1965</span><span class="refDoi"> DOI: 10.1002/hep.24609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1002%2Fhep.24609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=21837752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1956-1965&author=R.+Nettlesauthor=M.+Gaoauthor=M.+Bifanoauthor=E.+Chungauthor=A.+Perssonauthor=T.+Marburyauthor=R.+Goldwaterauthor=M.+DeMiccoauthor=M.+Rodriguez-Torresauthor=A.+Vutikullird&title=Multiple+ascending+dose+study+of+BMS-790052%2C+a+nonstructural+protein+5A+replication+complex+inhibitor%2C+in+patients+infected+with+hepatitis+C+virus+genotype+1&doi=10.1002%2Fhep.24609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1</span></div><div class="casAuthors">Nettles, Richard E.; Gao, Min; Bifano, Marc; Chung, Ellen; Persson, Anna; Marbury, Thomas C.; Goldwater, Ronald; DeMicco, Michael P.; Rodriguez-Torres, Maribel; Vutikullird, Apinya; Fuentes, Ernesto; Lawitz, Eric; Lopez-Talavera, Juan Carlos; Grasela, Dennis M.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1956-1965</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The antiviral activity, resistance profile, pharmacokinetics (PK), safety, and tolerability of BMS-790052, a nonstructural protein 5A (NS5A) replication complex inhibitor, were evaluated in a double-blind, placebo-controlled, sequential panel, multiple ascending dose study.  Thirty patients with chronic hepatitis C virus (HCV) genotype 1 infection were randomized to receive a 14-day course of BMS-790052 (1, 10, 30, 60, or 100 mg once daily or 30 mg twice daily) or placebo in a ratio of 4:1.  The mean max. decline from baseline in HCV RNA ranged from 2.8 to 4.1 log10 IU/mL; the placebo group showed no evidence of antiviral activity.  Most patients experienced viral rebound on or before day 7 of treatment with BMS-790052 monotherapy; viral rebound was assocd. with viral variants that had been previously implicated in resistance development in the in vitro replicon system.  The PK profile was supportive of once-daily dosing with median peak plasma concns. at 1-2 h postdose and mean terminal half-life of 12-15 h.  Steady state was achieved following 3-4 days of daily dosing.  BMS-790052 was well tolerated in all dose groups, with adverse events occurring with a similar frequency in BMS-790052- and placebo-treated groups.  There were no clin. relevant changes in vital signs, lab., or ECG parameters.  Conclusion: BMS-7590052 is the first NS5A replication complex inhibitor with multiple dose proof-of-concept in clinic.  At doses of 1-100 mg daily, BMS-790052 was well tolerated, had a PK profile supportive of once-daily dosing, and produced a rapid and substantial decrease in HCV-RNA levels in patients chronically infected with HCV genotype 1. (HEPATOl.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjY1mjsJbg-LVg90H21EOLACvtfcHk0lhmn8QK0KIpBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsLrJ&md5=080f30aec3629e68b832fe6491c54d16</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1002%2Fhep.24609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24609%26sid%3Dliteratum%253Aachs%26aulast%3DNettles%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DBifano%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DMarbury%26aufirst%3DT.%26aulast%3DGoldwater%26aufirst%3DR.%26aulast%3DDeMicco%26aufirst%3DM.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DVutikullird%26aufirst%3DA.%26atitle%3DMultiple%2520ascending%2520dose%2520study%2520of%2520BMS-790052%252C%2520a%2520nonstructural%2520protein%25205A%2520replication%2520complex%2520inhibitor%252C%2520in%2520patients%2520infected%2520with%2520hepatitis%2520C%2520virus%2520genotype%25201%26jtitle%3DHepatology%26date%3D2011%26volume%3D54%26spage%3D1956%26epage%3D1965%26doi%3D10.1002%2Fhep.24609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachand, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavoie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2013</span><span class="NLM_x">–</span> <span class="NLM_lpage">2032</span><span class="refDoi"> DOI: 10.1021/jm401836p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401836p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVWhsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2013-2032&author=M.+Belemaauthor=V.+Nguyenauthor=C.+Bachandauthor=D.+Deonauthor=J.+Goodrichauthor=C.+Jamesauthor=R.+Lavoieauthor=O.+Lopezauthor=A.+Martelauthor=J.+Romine&title=Hepatitis+C+virus+NS5A+replication+complex+inhibitors%3A+the+discovery+of+daclatasvir&doi=10.1021%2Fjm401836p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir</span></div><div class="casAuthors">Belema, Makonen; Nguyen, Van N.; Bachand, Carol; Deon, Dan H.; Goodrich, Jason T.; James, Clint A.; Lavoie, Rico; Lopez, Omar D.; Martel, Alain; Romine, Jeffrey L.; Ruediger, Edward H.; Snyder, Lawrence B.; St. Laurent, Denis R.; Yang, Fukang; Zhu, Juliang; Wong, Henry S.; Langley, David R.; Adams, Stephen P.; Cantor, Glenn H.; Chimalakonda, Anjaneya; Fura, Aberra; Johnson, Benjamin M.; Knipe, Jay O.; Parker, Dawn D.; Santone, Kenneth S.; Fridell, Robert A.; Lemm, Julie A.; O'Boyle, Donald R., II; Colonno, Richard J.; Gao, Min; Meanwell, Nicholas A.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2013-2032</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The biphenyl derivs. I (R = NHCO2Me, NMe2) are prototypes of a novel class of NS5A replication complex inhibitors that demonstrate high inhibitory potency toward a panel of clin. relevant HCV strains encompassing genotypes 1-6.  However, these compds. exhibit poor systemic exposure in rat pharmacokinetic studies after oral dosing.  The structure-activity relationship investigations that improved the exposure properties of the parent bis-phenylimidazole chemotype, culminating in the identification of the highly potent NS5A replication complex inhibitor daclatasvir (II, X = 4,4'-biphenylene) are described.  An element crit. to success was the realization that the arylglycine cap of I (R = NHCO2Me) could be replaced with an alkylglycine deriv. and still maintain the high inhibitory potency of the series if accompanied with a stereoinversion, a finding that enabled a rapid optimization of exposure properties.  Compd. II had EC50 values of 50 and 9 pM toward genotype-1a and -1b replicons, resp., and oral bioavailabilities of 38-108% in preclin. species.  Compd. II provided clin. proof-of-concept for the NS5A replication complex inhibitor class, and regulatory approval to market it with the NS3/4A protease inhibitor asunaprevir for the treatment of HCV genotype-1b infection has recently been sought in Japan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYnJILm4L3mbVg90H21EOLACvtfcHk0lhmn8QK0KIpBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVWhsr8%253D&md5=ca5c44e9b15fda7cb4632066ef2a673a</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1021%2Fjm401836p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401836p%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%26aulast%3DBachand%26aufirst%3DC.%26aulast%3DDeon%26aufirst%3DD.%26aulast%3DGoodrich%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DC.%26aulast%3DLavoie%26aufirst%3DR.%26aulast%3DLopez%26aufirst%3DO.%26aulast%3DMartel%26aufirst%3DA.%26aulast%3DRomine%26aufirst%3DJ.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitors%253A%2520the%2520discovery%2520of%2520daclatasvir%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2013%26epage%3D2032%26doi%3D10.1021%2Fjm401836p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lok, A.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A inhibitors and drug resistance mutations</span> <span class="citation_source-journal">Clin. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span><span class="refDoi"> DOI: 10.1016/j.cld.2012.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.cld.2012.09.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=111-121&author=A.+Lok&title=Hepatitis+C+virus+NS5A+inhibitors+and+drug+resistance+mutations&doi=10.1016%2Fj.cld.2012.09.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1016%2Fj.cld.2012.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cld.2012.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DLok%26aufirst%3DA.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520inhibitors%2520and%2520drug%2520resistance%2520mutations%26jtitle%3DClin.%2520Liver%2520Dis.%26date%3D2013%26volume%3D17%26spage%3D111%26epage%3D121%26doi%3D10.1016%2Fj.cld.2012.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pawlotsky, J.-M.</span><span> </span><span class="NLM_article-title">NS5A inhibitors in the treatment of hepatitis C</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">382</span><span class="refDoi"> DOI: 10.1016/j.jhep.2013.03.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.jhep.2013.03.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=23567084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVSltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2013&pages=375-382&author=J.-M.+Pawlotsky&title=NS5A+inhibitors+in+the+treatment+of+hepatitis+C&doi=10.1016%2Fj.jhep.2013.03.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">NS5A inhibitors in the treatment of hepatitis C</span></div><div class="casAuthors">Pawlotsky, Jean-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">375-382</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus infection is a major health problem worldwide and no vaccine has yet been developed against this virus.  In addn., currently approved pharmacotherapies achieve suboptimal cure rates and have side effects that result in non-compliance and premature treatment discontinuation.  Significant research has been devoted to developing direct-acting antiviral agents that inhibit key viral functions.  In particular, several novel drug candidates that inhibit the viral non-structural protein 5A (NS5A) have been demonstrated to possess high potency, pan-genotypic activity, and a high barrier to resistance.  Clin. trials using combination therapies contg. NS5A inhibitors have reported results that promise high cure rates and raise the possibility of developing interferon-free, all-oral regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjUOPI9xaUQ7Vg90H21EOLACvtfcHk0lhmn8QK0KIpBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVSltrk%253D&md5=6692cd6e6c9d6b392ee977f9f9155913</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2013.03.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2013.03.030%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.-M.%26atitle%3DNS5A%2520inhibitors%2520in%2520the%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DJ.%2520Hepatol.%26date%3D2013%26volume%3D59%26spage%3D375%26epage%3D382%26doi%3D10.1016%2Fj.jhep.2013.03.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Belda, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Targett-Adams, P.</span><span> </span><span class="NLM_article-title">Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein</span> <span class="citation_source-journal">Virus Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">170</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1016/j.virusres.2012.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.virusres.2012.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=23009750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKru7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2012&pages=1-14&author=O.+Beldaauthor=P.+Targett-Adams&title=Small+molecule+inhibitors+of+the+hepatitis+C+virus-encoded+NS5A+protein&doi=10.1016%2Fj.virusres.2012.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein</span></div><div class="casAuthors">Belda, Oscar; Targett-Adams, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-14</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) is a modern-day pandemic; 2-3% of the world's population are thought to be infected with the virus and are subsequently at risk of developing end-stage liver diseases.  The traditional std. of care (SOC) for HCV-infected patients has been limited to a regimen of pegylated-interferon alpha (pegIFN) and ribavirin; displaying low cure rates in a majority of patients and severe side effects.  However, in 2011 the first direct-acting antivirals (DAA) were licensed to treat HCV-infected patients in combination with SOC, which served to elevate treatment response rates.  The HCV drug development pipeline is currently populated with many addnl. and improved DAAs; primarily mols. that target the virus-encoded protease or polymerase enzymes.  These mols. are being evaluated both in combination with the traditional SOC and together with other DAAs as all-oral pegIFN-free regimens with the ultimate goal of developing multiple DAA-contg. HCV therapies that do not rely on an pegIFN backbone.  A recent addn. to the arsenal of HCV inhibitors in development is represented by an entirely new DAA class; mols. that target the HCV-encoded non-enzymic NS5A protein.  NS5A is essential for HCV propagation and, although its actual functions are largely unknown, it is likely a key regulator of viral genome replication and virion assembly.  The protein is exquisitely sensitive to small mol.-mediated inhibition; NS5A-targeting mols. are probably the most potent antiviral mols. ever discovered and exhibit a no. of other attractive drug-like properties, including activity against many HCV genotypes/subtypes and once-daily dosing potential.  Although their mechanism of action is unclear, NS5A-targeting mols. are already proving their utility in clin. evaluation; particularly as components of pegIFN-sparring DAA combination regimens.  This review will aim to amalgamate our current understanding and knowledge of NS5A-targeting mols.; their discovery, properties, applications, and insight into their future impact as components of all-oral pegIFN-free DAA combination therapies to combat HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG1WoP20i-q7Vg90H21EOLACvtfcHk0ljuLu6_Ybd7ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKru7zO&md5=f2137b9130775af1b45bc72bd205dbfc</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2012.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2012.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DBelda%26aufirst%3DO.%26aulast%3DTargett-Adams%26aufirst%3DP.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus-encoded%2520NS5A%2520protein%26jtitle%3DVirus%2520Res.%26date%3D2012%26volume%3D170%26spage%3D1%26epage%3D14%26doi%3D10.1016%2Fj.virusres.2012.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cordek, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bechtel, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maynard, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmierski, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span> </span><span class="NLM_article-title">Targeting the NS5A protein of HCV: an emerging option</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">711</span><span class="refDoi"> DOI: 10.1358/dof.2011.036.09.1641618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1358%2Fdof.2011.036.09.1641618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=23378700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1eis7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=691-711&author=D.+G.+Cordekauthor=J.+T.+Bechtelauthor=A.+T.+Maynardauthor=W.+M.+Kazmierskiauthor=C.+E.+Cameron&title=Targeting+the+NS5A+protein+of+HCV%3A+an+emerging+option&doi=10.1358%2Fdof.2011.036.09.1641618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14dR"><div class="casContent"><span class="casTitleNuber">14d</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the protein NS5A protein of HCV: an emerging option</span></div><div class="casAuthors">Cordek, D. G.; Bechtel, J. T.; Maynard, A. T.; Kazmierski, W. M.; Cameron, C. E.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">691-711</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) infects more than 3% of the world's population, leading to an increased risk of cirrhosis and hepatocellular carcinoma.  The current std. of care, a combination of pegylated interferon alfa and ribavirin, is poorly tolerated and often ineffective against the most prevalent genotype of the virus, genotype 7.  The very recent approval of boceprevir and telaprevir, two HCV protease inhibitors, promises to significantly improve treatment options and outcomes.  In addn. to the viral protease NS3 and the viral polymerase NS5B, direct-acting antivirals are now in development against NS5A.  A multifunctional phosphoprotein, NS5A is essential to HCV genome replication, but has no known enzymic function.  Here we report how the design of small-mol. inhibitors against NS5A has evolved from promising monomers to highly potent dimeric compds. effective against many HCV genotypes.  We also highlight recent clin. data and how the inhibitors may bind to NS5A, itself capable of forming dimers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2lefIUXhmK7Vg90H21EOLACvtfcHk0ljuLu6_Ybd7ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1eis7nE&md5=7e779d99491df4f8631c7848cb9e56dc</span></div><a href="/servlet/linkout?suffix=cit14d&amp;dbid=16384&amp;doi=10.1358%2Fdof.2011.036.09.1641618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2011.036.09.1641618%26sid%3Dliteratum%253Aachs%26aulast%3DCordek%26aufirst%3DD.%2BG.%26aulast%3DBechtel%26aufirst%3DJ.%2BT.%26aulast%3DMaynard%26aufirst%3DA.%2BT.%26aulast%3DKazmierski%26aufirst%3DW.%2BM.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26atitle%3DTargeting%2520the%2520NS5A%2520protein%2520of%2520HCV%253A%2520an%2520emerging%2520option%26jtitle%3DDrugs%2520Future%26date%3D2011%26volume%3D36%26spage%3D691%26epage%3D711%26doi%3D10.1358%2Fdof.2011.036.09.1641618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Schmitz, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, S.-L.</span><span> </span><span class="NLM_article-title">NS5A-From obscurity to new target for HCV therapy</span> <span class="citation_source-journal">Recent Pat. Anti-Infect. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span><span class="refDoi"> DOI: 10.2174/157489108784746597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.2174%2F157489108784746597" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=77-92&author=U.+Schmitzauthor=S.-L.+Tan&title=NS5A-From+obscurity+to+new+target+for+HCV+therapy&doi=10.2174%2F157489108784746597"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14e&amp;dbid=16384&amp;doi=10.2174%2F157489108784746597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157489108784746597%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitz%26aufirst%3DU.%26aulast%3DTan%26aufirst%3DS.-L.%26atitle%3DNS5A-From%2520obscurity%2520to%2520new%2520target%2520for%2520HCV%2520therapy%26jtitle%3DRecent%2520Pat.%2520Anti-Infect.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D77%26epage%3D92%26doi%3D10.2174%2F157489108784746597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Schinazi, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavegnano, C.</span><span> </span><span class="NLM_article-title">HCV drug discovery aimed at viral eradication</span> <span class="citation_source-journal">J. Viral Hepat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span><span class="refDoi"> DOI: 10.1111/j.1365-2893.2009.01246.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1111%2Fj.1365-2893.2009.01246.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=20040045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FnsFygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=77-90&author=R.+F.+Schinaziauthor=L.+Bassitauthor=C.+Gavegnano&title=HCV+drug+discovery+aimed+at+viral+eradication&doi=10.1111%2Fj.1365-2893.2009.01246.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">HCV drug discovery aimed at viral eradication</span></div><div class="casAuthors">Schinazi R F; Bassit L; Gavegnano C</div><div class="citationInfo"><span class="NLM_cas:title">Journal of viral hepatitis</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">77-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hepatitis C virus (HCV) causes significant morbidity and mortality worldwide with nearly 3% of the world population infected by this virus.  Fortunately, this virus does not establish latency, and hence it may be possible to eradicate it.  HCV is strongly associated with liver cirrhosis and hepatocellular carcinoma and is currently treated with pegylated interferon-alpha (peg-IFN-alpha) and ribavirin.  Unfortunately, these limited treatment options often produce significant side effects, and currently, complete eradication of virus with combined drug modalities has not yet been achieved for the majority of chronically HCV-infected individuals.  Restricted treatment options, lack of a universal cure for HCV and the link between chronic infection, liver cirrhosis and hepatocellular carcinoma necessitate design of novel drugs and treatment options.  Understanding the relationship between the immune response, viral clearance and inhibition of viral replication with pharmacology-based design can ultimately allow for complete eradication of HCV.  This review focuses upon significant novel preclinical and clinical specifically targeted antiviral therapy (STAT-C) drugs under development, highlights their mechanism of action, and discusses their impact on systemic viral loads and permanent clearance of infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxPMbaFdWlO4YPsCkJIw00fW6udTcc2eag7RZ34vhrzrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FnsFygtg%253D%253D&md5=27a90c264b557eb92e7c266a9ae5b613</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2893.2009.01246.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2893.2009.01246.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DBassit%26aufirst%3DL.%26aulast%3DGavegnano%26aufirst%3DC.%26atitle%3DHCV%2520drug%2520discovery%2520aimed%2520at%2520viral%2520eradication%26jtitle%3DJ.%2520Viral%2520Hepat.%26date%3D2010%26volume%3D17%26spage%3D77%26epage%3D90%26doi%3D10.1111%2Fj.1365-2893.2009.01246.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Link, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squires, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrish, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matles, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mogalian, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mondou, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornpropst, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, M. C.</span><span> </span><span class="NLM_article-title">Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">2033</span><span class="NLM_x">–</span> <span class="NLM_lpage">2046</span><span class="refDoi"> DOI: 10.1021/jm401499g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401499g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2033-2046&issue=5&author=J.+O.+Linkauthor=J.+G.+Taylorauthor=L.+Xuauthor=M.+Mitchellauthor=H.+Guoauthor=H.+Liuauthor=D.+Katoauthor=T.+Kirschbergauthor=J.+Sunauthor=N.+Squiresauthor=J.+Parrishauthor=T.+Kellerauthor=Z.+Yangauthor=C.+Yangauthor=M.+Matlesauthor=Y.+Wangauthor=K.+Wangauthor=G.+Chengauthor=Y.+Tianauthor=E.+Mogalianauthor=E.+Mondouauthor=M.+Cornpropstauthor=J.+Perryauthor=M.+C.+Desai&title=Discovery+of+ledipasvir+%28GS-5885%29%3A+a+potent%2C+once-daily+oral+NS5A+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Fjm401499g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Link, John O.; Taylor, James G.; Xu, Lianhong; Mitchell, Michael; Guo, Hongyan; Liu, Hongtao; Kato, Darryl; Kirschberg, Thorsten; Sun, Jianyu; Squires, Neil; Parrish, Jay; Kellar, Terry; Yang, Zheng-Yu; Yang, Chris; Matles, Mike; Wang, Yujin; Wang, Kelly; Cheng, Guofeng; Tian, Yang; Mogalian, Erik; Mondou, Elsa; Cornpropst, Melanie; Perry, Jason; Desai, Manoj C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2033-2046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of highly potent NS5A inhibitors with an unsym. benzimidazole-difluorofluorene-imidazole core and distal [2.2.1]-azabicyclic ring system was discovered.  Optimization of antiviral potency and pharmacokinetics led to the identification of ledipasvir (GS-5885).  Ledipasvir (GT1a replicon EC50 = 31 pM) has an extended plasma half-life of 37-45 h in healthy volunteers and produces a rapid >3 log viral load redn. in monotherapy at oral doses of 3 mg or greater with once-daily dosing in genotype 1a HCV-infected patients. ledipasvir has been shown to be safe and efficacious, with SVR12 rates up to 100% when used in combination with direct-acting antivirals having complementary mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiLazFwyH5rrVg90H21EOLACvtfcHk0linqwhMTu4z_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltb3I&md5=30cec1d10b7b7dd02faae4fba4b88bd8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm401499g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401499g%26sid%3Dliteratum%253Aachs%26aulast%3DLink%26aufirst%3DJ.%2BO.%26aulast%3DTaylor%26aufirst%3DJ.%2BG.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DMitchell%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DKato%26aufirst%3DD.%26aulast%3DKirschberg%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DSquires%26aufirst%3DN.%26aulast%3DParrish%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DMatles%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DMogalian%26aufirst%3DE.%26aulast%3DMondou%26aufirst%3DE.%26aulast%3DCornpropst%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DJ.%26aulast%3DDesai%26aufirst%3DM.%2BC.%26atitle%3DDiscovery%2520of%2520ledipasvir%2520%2528GS-5885%2529%253A%2520a%2520potent%252C%2520once-daily%2520oral%2520NS5A%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D5%26spage%3D2033%26epage%3D2046%26doi%3D10.1021%2Fjm401499g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">DeGoey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randolph, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulenko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motter, C.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Discovery of ABT-267, A Pan-genotypic inhibitor of HCV NS5A</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2047</span><span class="NLM_x">–</span> <span class="NLM_lpage">205</span><span class="refDoi"> DOI: 10.1021/jm401398x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401398x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2047-205&author=D.+DeGoeyauthor=J.+Randolphauthor=D.+Liuauthor=J.+Prattauthor=C.+Hutchinsauthor=P.+Donnerauthor=A.+Kruegerauthor=M.+Matulenkoauthor=S.+Patelauthor=C.+Motter&title=Discovery+of+ABT-267%2C+A+Pan-genotypic+inhibitor+of+HCV+NS5A&doi=10.1021%2Fjm401398x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A</span></div><div class="casAuthors">DeGoey, David A.; Randolph, John T.; Liu, Dachun; Pratt, John; Hutchins, Charles; Donner, Pamela; Krueger, A. Chris; Matulenko, Mark; Patel, Sachin; Motter, Christopher E.; Nelson, Lissa; Keddy, Ryan; Tufano, Michael; Caspi, Daniel D.; Krishnan, Preethi; Mistry, Neeta; Koev, Gennadiy; Reisch, Thomas J.; Mondal, Rubina; Pilot-Matias, Tami; Gao, Yi; Beno, David W. A.; Maring, Clarence J.; Molla, Akhter; Dumas, Emily; Campbell, Andrew; Williams, Laura; Collins, Christine; Wagner, Rolf; Kati, Warren M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2047-2057</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe here N-phenylpyrrolidine-based inhibitors of HCV NS5A with excellent potency, metabolic stability, and pharmacokinetics.  Compds. with 2S,5S stereochem. at the pyrrolidine ring provided improved genotype 1 (GT1) potency compared to the 2R,5R analogs.  Furthermore, the attachment of substituents at the 4-position of the central N-Ph group resulted in compds. with improved potency.  Substitution with tert-Bu, as in compd. 38 (ABT-267)(I), provided compds. with low-picomolar EC50 values and superior pharmacokinetics.  It was discovered that compd. 38 was a pan-genotypic HCV inhibitor, with an EC50 range of 1.7-19.3 pM against GT1a, -1b, -2a, -2b, -3a, -4a, and -5a and 366 pM against GT6a.  Compd. 38 decreased HCV RNA up to 3.10 log10 IU/mL during 3-day monotherapy in treatment-naive HCV GT1-infected subjects and is currently in phase 3 clin. trials in combination with an NS3 protease inhibitor with ritonavir (r) (ABT-450/r) and an NS5B non-nucleoside polymerase inhibitor (ABT-333), with and without ribavirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQLXZPjB144rVg90H21EOLACvtfcHk0linqwhMTu4z_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKhsQ%253D%253D&md5=70f0d0f8e9751b533617fecc1b4a8016</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm401398x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401398x%26sid%3Dliteratum%253Aachs%26aulast%3DDeGoey%26aufirst%3DD.%26aulast%3DRandolph%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DPratt%26aufirst%3DJ.%26aulast%3DHutchins%26aufirst%3DC.%26aulast%3DDonner%26aufirst%3DP.%26aulast%3DKrueger%26aufirst%3DA.%26aulast%3DMatulenko%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DMotter%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520ABT-267%252C%2520A%2520Pan-genotypic%2520inhibitor%2520of%2520HCV%2520NS5A%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2047%26epage%3D205%26doi%3D10.1021%2Fjm401398x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Younossi, Z. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stepanova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feld, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hezode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nader, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, S.</span><span> </span><span class="NLM_article-title">Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1016/j.jhep.2016.02.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.jhep.2016.02.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=26956698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtValuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=33-39&author=Z.+M.+Younossiauthor=M.+Stepanovaauthor=J.+Feldauthor=S.+Zeuzemauthor=I.+Jacobsonauthor=K.+Agarwalauthor=C.+Hezodeauthor=F.+Naderauthor=L.+Henryauthor=S.+Hunt&title=Sofosbuvir%2Fvelpatasvir+improves+patient-reported+outcomes+in+HCV+patients%3A+results+from+ASTRAL-1+placebo-controlled+trial&doi=10.1016%2Fj.jhep.2016.02.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial</span></div><div class="casAuthors">Younossi, Zobair M.; Stepanova, Maria; Feld, Jordan; Zeuzem, Stefan; Jacobson, Ira; Agarwal, Kosh; Hezode, Christophe; Nader, Fatema; Henry, Linda; Hunt, Sharon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-39</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The new pan-genotypic regimen [sofosbuvir (SOF) and velpatasvir (VEL)] for hepatitis C virus (HCV) has been assocd. with high efficacy.  The aim of this study was to assess patient-reported outcomes (PROs) of this regimen.The PRO data (CLDQ-HCV, SF-36, FACIT-F, WPAI) came from the ASTRAL-1 study, a multicenter multinational blinded placebo-controlled phase 3 clin. trial of a fixed dose combination of SOF 400 mg and VEL 100 mg for patients with genotype 1, 2, 4, 5, and 6 compared to placebo for 12 wk.624 patients received active treatment [618 achieved sustained virol. response (SVR)], and 116 received placebo.  The baseline PRO scores were similar.  By treatment week 4, patients receiving SOF/VEL experienced improvements in general health (on av., +2.3 points), emotional well-being (+3.4), FACIT-F (+1.3), and all domains of CLDQ-HCV (+2.1 to +7.3) (all p <0.005).  On the other hand, the only PRO that improved in patients receiving placebo was the worry domain of CLDQ-HCV: +4.6 (p = 0.002).  By the end of treatment, improvement in PRO scores with SOF/VEL continued, and no improvement was noted in the placebo.  Improvement in PROs were also noted 12 and 24 wk post-treatment: +3.7, on av., in patients with SVR-12 after SOF/VEL vs. -2.6, on av., in the placebo arm (p <0.005).  Multivariate anal. showed that treatment-emergent changes in PROs were predicted by receiving SOF/VEL for some summary PRO score (p <0.005).This placebo-controlled trial shows that patients treated with SOF/VEL experience significant improvement of their PROs during treatment and after achieving SVR.In patients with chronic hepatitis C infection, health-related quality of life and work productivity are often impaired due to HCV-related fatigue.  Treatment of hepatitis C with interferon-based regimens, which was the std. of care for all HCV patients until recently, had substantial and potentially debilitating side effects.  These regimens caused addnl. impairment in health-related quality of life and work productivity during treatment and shortly after treatment cessation.  The newly developed interferon-free combination of sofosbuvir and velpatasvir has been shown to improve health-related quality of life during treatment, and lead to an improvement in a no. of indicators of patient-reported outcomes after successful clearance of HCV and achieving sustained virol. response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ-LX9rrAJ0bVg90H21EOLACvtfcHk0lhJVBRUCKFWEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtValuro%253D&md5=b2260e84f37dcaef1d4bd3a0860518aa</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2016.02.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2016.02.042%26sid%3Dliteratum%253Aachs%26aulast%3DYounossi%26aufirst%3DZ.%2BM.%26aulast%3DStepanova%26aufirst%3DM.%26aulast%3DFeld%26aufirst%3DJ.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DJacobson%26aufirst%3DI.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DHezode%26aufirst%3DC.%26aulast%3DNader%26aufirst%3DF.%26aulast%3DHenry%26aufirst%3DL.%26aulast%3DHunt%26aufirst%3DS.%26atitle%3DSofosbuvir%252Fvelpatasvir%2520improves%2520patient-reported%2520outcomes%2520in%2520HCV%2520patients%253A%2520results%2520from%2520ASTRAL-1%2520placebo-controlled%2520trial%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D65%26spage%3D33%26epage%3D39%26doi%3D10.1016%2Fj.jhep.2016.02.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Yu, W.; Tong, L.; Kozlowski, J. A.; Selyutin, O.; Chen, L.; Kim, J.-H.; Sha, D.; Rizvi, R.; Shankar, B.; Hu, B.; Zhong, B.; Wai, D.; Hao, J.; Wei, W.; Ji, T.; Zan, S.</span><span> </span><span class="NLM_article-title">Preparation of thiazolyl-substituted tetracyclic compounds end-capped with peptide derivatives as antiviral agents for treating hepatitis C virus infection</span>. Patent WO 2014110687 A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=W.+Yu&author=L.+Tong&author=J.+A.+Kozlowski&author=O.+Selyutin&author=L.+Chen&author=J.-H.+Kim&author=D.+Sha&author=R.+Rizvi&author=B.+Shankar&author=B.+Hu&author=B.+Zhong&author=D.+Wai&author=J.+Hao&author=W.+Wei&author=T.+Ji&author=S.+Zan&title=Preparation+of+thiazolyl-substituted+tetracyclic+compounds+end-capped+with+peptide+derivatives+as+antiviral+agents+for+treating+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26atitle%3DPreparation%2520of%2520thiazolyl-substituted%2520tetracyclic%2520compounds%2520end-capped%2520with%2520peptide%2520derivatives%2520as%2520antiviral%2520agents%2520for%2520treating%2520hepatitis%2520C%2520virus%2520infection%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Neau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansette, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andronik, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">hydroxylation of the thiophene ring by hepatic monooxygenases</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1101</span><span class="NLM_x">–</span> <span class="NLM_lpage">1107</span><span class="refDoi"> DOI: 10.1016/0006-2952(90)90290-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2F0006-2952%2890%2990290-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1990&pages=1101-1107&author=E.+Neauauthor=P.+Dansetteauthor=V.+Andronikauthor=D.+Mansuy&title=hydroxylation+of+the+thiophene+ring+by+hepatic+monooxygenases&doi=10.1016%2F0006-2952%2890%2990290-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2890%2990290-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252890%252990290-2%26sid%3Dliteratum%253Aachs%26aulast%3DNeau%26aufirst%3DE.%26aulast%3DDansette%26aufirst%3DP.%26aulast%3DAndronik%26aufirst%3DV.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3Dhydroxylation%2520of%2520the%2520thiophene%2520ring%2520by%2520hepatic%2520monooxygenases%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1990%26volume%3D39%26spage%3D1101%26epage%3D1107%26doi%3D10.1016%2F0006-2952%2890%2990290-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">McMurtry, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, J.</span><span> </span><span class="NLM_article-title">renal and hepatic necrosis after metabolic activation of 2-substituted furans and thiophenes, including furosemide and cephaloridine</span> <span class="citation_source-journal">Toxicol. Appl. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span><span class="refDoi"> DOI: 10.1016/0041-008X(77)90005-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2F0041-008X%2877%2990005-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=595008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADyaE1cXpvFSntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1977&pages=285-300&author=R.+McMurtryauthor=J.+Mitchell&title=renal+and+hepatic+necrosis+after+metabolic+activation+of+2-substituted+furans+and+thiophenes%2C+including+furosemide+and+cephaloridine&doi=10.1016%2F0041-008X%2877%2990005-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Renal and hepatic necrosis after metabolic activation of 2-substituted furans and thiophenes, including furosemide and cephaloridine</span></div><div class="casAuthors">McMurtry, Randolph J.; Mitchell, Jerry R.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">285-300</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    </div><div class="casAbstract">Single i.p. or i.v. injections of several 2-substituted furans and thiophenes, including furosemide (I)  [54-31-9] and cephaloridine (II)  [50-59-9], produced renal tubular necrosis or hepatic necrosis in mice and rats.  Pretreatment of animals with substances that altered drug-metabolizing enzymes usually altered the severity of the renal and hepatic necrosis produced by the furans and thiophenes and occasionally changed the target organ susceptibility to injury from 1 tissue to the other or the intraorgan zone of the lesion.  Studies with a tritiated nephrotoxic and hepatotoxic furan, 2-furamide  [609-38-1], showed direct correlations between the covalent binding of a chem. reactive metabolite of 2-furamide and the severity of renal and hepatic necrosis after pretreatment of mice with compds. that altered drug-metabolizing enzymes.  A comparison of the covalent binding of the toxic metabolite of 2-furamide to tissues in vivo vs. the covalent binding to hepatic and renal microsomal enzymes in vitro indicated that the renal necrosis was caused by the metabolic activation of 2-furamide in situ in the kidney.  The covalent binding to renal and hepatic microsomal enzymes in vitro was dependent on NADPH, O, and temp. and was inhibited by a CO-O atm.  Collectively, the data provide strong support for the hypothesis that the spectrum of tissue lesions produced in animals by many furans and thiophenes results from organ-specific metabolic transformation of parent drug to chem. reactive intermediates by cytochrome P-450 monooxygenases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5SVh1qYYpGLVg90H21EOLACvtfcHk0lhJVBRUCKFWEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXpvFSntA%253D%253D&md5=2d2082a218bc0e2c738bc06131e6d9be</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2F0041-008X%2877%2990005-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0041-008X%252877%252990005-9%26sid%3Dliteratum%253Aachs%26aulast%3DMcMurtry%26aufirst%3DR.%26aulast%3DMitchell%26aufirst%3DJ.%26atitle%3Drenal%2520and%2520hepatic%2520necrosis%2520after%2520metabolic%2520activation%2520of%25202-substituted%2520furans%2520and%2520thiophenes%252C%2520including%2520furosemide%2520and%2520cephaloridine%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D1977%26volume%3D42%26spage%3D285%26epage%3D300%26doi%3D10.1016%2F0041-008X%2877%2990005-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Dansette, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pons, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">Oxidative activation of the thiophene ring by hepatic enzymes</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">911</span><span class="NLM_x">–</span> <span class="NLM_lpage">918</span><span class="refDoi"> DOI: 10.1016/0006-2952(90)90207-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2F0006-2952%2890%2990207-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1990&pages=911-918&author=P.+Dansetteauthor=C.+Amarauthor=C.+Smithauthor=C.+Ponsauthor=D.+Mansuy&title=Oxidative+activation+of+the+thiophene+ring+by+hepatic+enzymes&doi=10.1016%2F0006-2952%2890%2990207-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2890%2990207-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252890%252990207-2%26sid%3Dliteratum%253Aachs%26aulast%3DDansette%26aufirst%3DP.%26aulast%3DAmar%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DPons%26aufirst%3DC.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DOxidative%2520activation%2520of%2520the%2520thiophene%2520ring%2520by%2520hepatic%2520enzymes%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1990%26volume%3D39%26spage%3D911%26epage%3D918%26doi%3D10.1016%2F0006-2952%2890%2990207-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Kozlowski, J. A.; Rosenblum, S. B.; Coburn, C. A.; Shankar, B. B.; Nair, A. G.; Chen, L.; Dwyer, M. P.; Jiang, Y.; Keertikar, K. M.; Lavey, B. J.; Selyutin, O. B.; Tong, L.; Wong, M.; Yang, D.-Y.; Yu, W.; Zhou, G.; Wu, H.; Hu, B.; Zhong, B.; Sun, F.; Ji, T.; Shen, C.</span><span> </span><span class="NLM_article-title">Preparation of tetracyclic indole derivatives for treatment of HCV infection</span>. Patent WO 2012040923 A1,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+A.+Kozlowski&author=S.+B.+Rosenblum&author=C.+A.+Coburn&author=B.+B.+Shankar&author=A.+G.+Nair&author=L.+Chen&author=M.+P.+Dwyer&author=Y.+Jiang&author=K.+M.+Keertikar&author=B.+J.+Lavey&author=O.+B.+Selyutin&author=L.+Tong&author=M.+Wong&author=D.-Y.+Yang&author=W.+Yu&author=G.+Zhou&author=H.+Wu&author=B.+Hu&author=B.+Zhong&author=F.+Sun&author=T.+Ji&author=C.+Shen&title=Preparation+of+tetracyclic+indole+derivatives+for+treatment+of+HCV+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DPreparation%2520of%2520tetracyclic%2520indole%2520derivatives%2520for%2520treatment%2520of%2520HCV%2520infection%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Tong, L.; Yu, W.; Kozlowski, J. A.; Chen, L.; Selyutin, O.; Kim, S. H.; Dwyer, M.; Hu, B.; Zhong, B.; Wai, D.; Hao, J.; Shen, C.; Lei, Z.; Wang, W.</span><span> </span><span class="NLM_article-title">Preparation of thiophene-substituted tetracyclic compounds end-capped with peptide derivatives as antiviral agents for treating hepatitis C virus infection</span>. Patent WO 2014110706 A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=L.+Tong&author=W.+Yu&author=J.+A.+Kozlowski&author=L.+Chen&author=O.+Selyutin&author=S.+H.+Kim&author=M.+Dwyer&author=B.+Hu&author=B.+Zhong&author=D.+Wai&author=J.+Hao&author=C.+Shen&author=Z.+Lei&author=W.+Wang&title=Preparation+of+thiophene-substituted+tetracyclic+compounds+end-capped+with+peptide+derivatives+as+antiviral+agents+for+treating+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DL.%26atitle%3DPreparation%2520of%2520thiophene-substituted%2520tetracyclic%2520compounds%2520end-capped%2520with%2520peptide%2520derivatives%2520as%2520antiviral%2520agents%2520for%2520treating%2520hepatitis%2520C%2520virus%2520infection%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="note"><p class="first last">Single crystal X-ray analysis for compound <b>40</b> is described in a patent entitled “Process for preparing substituted tetracyclic heterocycle compounds”. It was filed on June 4, 2015. This patent is expected to be published in December 2016.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Tong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girijavallabhan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prongay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saksena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralston, R.</span><span> </span><span class="NLM_article-title">Characterization of resistance mutations against HCV ketoamide protease inhibitors</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2007.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.antiviral.2007.11.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=177-185&issue=3&author=X.+Tongauthor=S.+Bogenauthor=R.+Chaseauthor=V.+Girijavallabhanauthor=Z.+Guoauthor=F.+G.+Njorogeauthor=A.+Prongayauthor=A.+Saksenaauthor=A.+Skeltonauthor=E.+Xiaauthor=R.+Ralston&title=Characterization+of+resistance+mutations+against+HCV+ketoamide+protease+inhibitors&doi=10.1016%2Fj.antiviral.2007.11.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2007.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2007.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DX.%26aulast%3DBogen%26aufirst%3DS.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26aulast%3DProngay%26aufirst%3DA.%26aulast%3DSaksena%26aufirst%3DA.%26aulast%3DSkelton%26aufirst%3DA.%26aulast%3DXia%26aufirst%3DE.%26aulast%3DRalston%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520resistance%2520mutations%2520against%2520HCV%2520ketoamide%2520protease%2520inhibitors%26jtitle%3DAntiviral%2520Res.%26date%3D2008%26volume%3D77%26issue%3D3%26spage%3D177%26epage%3D185%26doi%3D10.1016%2Fj.antiviral.2007.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Lahser, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bystol, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMonagle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazuda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howe, A. Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asante-Appiah, E.</span><span> </span><span class="NLM_article-title">The combination of grazoprevir, a HCV NS3 protease inhibitor, and elbasvir, a HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2954</span><span class="NLM_x">–</span> <span class="NLM_lpage">2964</span><span class="refDoi"> DOI: 10.1128/AAC.00051-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1128%2FAAC.00051-16" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=2954-2964&author=F.+C.+Lahserauthor=K.+Bystolauthor=S.+Curryauthor=P.+McMonagleauthor=E.+Xiaauthor=P.+Ingravalloauthor=R.+Chaseauthor=R.+Liuauthor=T.+Blackauthor=D.+Hazudaauthor=A.+Y.+M.+Howeauthor=E.+Asante-Appiah&title=The+combination+of+grazoprevir%2C+a+HCV+NS3+protease+inhibitor%2C+and+elbasvir%2C+a+HCV+NS5A+inhibitor%2C+demonstrates+a+high+genetic+barrier+to+resistance+in+HCV+genotype+1a+replicons&doi=10.1128%2FAAC.00051-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1128%2FAAC.00051-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00051-16%26sid%3Dliteratum%253Aachs%26aulast%3DLahser%26aufirst%3DF.%2BC.%26aulast%3DBystol%26aufirst%3DK.%26aulast%3DCurry%26aufirst%3DS.%26aulast%3DMcMonagle%26aufirst%3DP.%26aulast%3DXia%26aufirst%3DE.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DBlack%26aufirst%3DT.%26aulast%3DHazuda%26aufirst%3DD.%26aulast%3DHowe%26aufirst%3DA.%2BY.%2BM.%26aulast%3DAsante-Appiah%26aufirst%3DE.%26atitle%3DThe%2520combination%2520of%2520grazoprevir%252C%2520a%2520HCV%2520NS3%2520protease%2520inhibitor%252C%2520and%2520elbasvir%252C%2520a%2520HCV%2520NS5A%2520inhibitor%252C%2520demonstrates%2520a%2520high%2520genetic%2520barrier%2520to%2520resistance%2520in%2520HCV%2520genotype%25201a%2520replicons%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D2954%26epage%3D2964%26doi%3D10.1128%2FAAC.00051-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8a','cit8b'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b','cit13c'],'ref14':['cit14a','cit14b','cit14c','cit14d','cit14e'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20a','cit20b','cit20c'],'ref21':['cit21'],'ref22':['cit22'],'ref23':[],'ref24':['cit24'],'ref25':['cit25']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 33 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yong-Jin Wu, <span class="NLM_string-name hlFld-ContribAuthor">Nicholas A. Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (14)
                                     , 9786-9874. <a href="https://doi.org/10.1021/acs.jmedchem.1c00790" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00790</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00790%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DGeminal%252BDiheteroatomic%252BMotifs%25253A%252BSome%252BApplications%252Bof%252BAcetals%25252C%252BKetals%25252C%252Band%252BTheir%252BSulfur%252Band%252BNitrogen%252BHomologues%252Bin%252BMedicinal%252BChemistry%252Band%252BDrug%252BDesign%26aulast%3DWu%26aufirst%3DYong-Jin%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D30042021%26date%3D02072021%26volume%3D64%26issue%3D14%26spage%3D9786%26epage%3D9874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Vidya Ramdas, Rashmi Talwar, Moloy Banerjee, Advait Arun Joshi, Amit Kumar Das, Deepak Sahebrao Walke, Prashant Borhade, Usha Dhayagude, Rajesh Loriya, Ganesh Gote, Apparao Bommakanti, Aruna Sivaram, Gautam Agarwal, Arnab Goswami, Prashant Nigade, Maneesh Mehta, Vinod Patil, Dipak Modi, Hemant Kumar, Sadanand Mallurwar, Amruta Dash, Falguni Modi, Sandip Kuldharan, Pratima Srivastava, Minakshi Singh, Lakshmi Narasimham, Jayasagar Gundu, Sharad Sharma, Rajender Kumar Kamboj, <span class="NLM_string-name hlFld-ContribAuthor">Venkata P. Palle</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (23)
                                     , 10563-10582. <a href="https://doi.org/10.1021/acs.jmedchem.9b01562" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01562</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01562%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BCharacterization%252Bof%252BPotent%252BPan-Genotypic%252BHCV%252BNS5A%252BInhibitors%252BContaining%252BNovel%252BTricyclic%252BCentral%252BCore%252BLeading%252Bto%252BClinical%252BCandidate%26aulast%3DRamdas%26aufirst%3DVidya%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D19092019%26date%3D22112019%26date%3D11112019%26volume%3D62%26issue%3D23%26spage%3D10563%26epage%3D10582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wensheng Yu, Ling Tong, Oleg Selyutin, Lei Chen, Bin Hu, Bin Zhong, Jinglai Hao, Tao Ji, Shuai Zan, Jingjun Yin, Rebecca T. Ruck, Stephanie Curry, Patricia McMonagle, Sony Agrawal, Laura Rokosz, Donna Carr, Paul Ingravallo, Karin Bystol, Frederick Lahser, Rong Liu, Shiying Chen, Kung-I Feng, Mark Cartwright, Ernest Asante-Appiah, <span class="NLM_string-name hlFld-ContribAuthor">Joseph A. Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (9)
                                     , 3984-4003. <a href="https://doi.org/10.1021/acs.jmedchem.7b01927" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01927</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01927%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BMK-6169%25252C%252Ba%252BPotent%252BPan-Genotype%252BHepatitis%252BC%252BVirus%252BNS5A%252BInhibitor%252Bwith%252BOptimized%252BActivity%252Bagainst%252BCommon%252BResistance-Associated%252BSubstitutions%26aulast%3DYu%26aufirst%3DWensheng%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D30122017%26date%3D01052018%26date%3D21042018%26volume%3D61%26issue%3D9%26spage%3D3984%26epage%3D4003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Ling    Tong </span><span class="hlFld-ContribAuthor "> Joseph A.    Kozlowski </span><span class="hlFld-ContribAuthor "> Louis-Charles    Campeau </span><span class="hlFld-ContribAuthor "> Jingjun    Yin </span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of Ruzasvir: An Investigational Next Generation Pan-Genotype HCV Nonstructural Protein 5A (NS5A) Inhibitor for the Cure of Hepatitis C Virus Infections. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 115-149. <a href="https://doi.org/10.1021/bk-2018-1307.ch005" title="DOI URL">https://doi.org/10.1021/bk-2018-1307.ch005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2018-1307.ch005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2018-1307.ch005%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252BRuzasvir%25253A%252BAn%252BInvestigational%252BNext%252BGeneration%252BPan-Genotype%252BHCV%252BNonstructural%252BProtein%252B5A%252B%252528NS5A%252529%252BInhibitor%252Bfor%252Bthe%252BCure%252Bof%252BHepatitis%252BC%252BVirus%252BInfections%26aulast%3DTong%26aufirst%3DLing%26date%3D2018%26date%3D2018%26spage%3D115%26epage%3D149%26atitle%3DComplete%252BAccounts%252Bof%252BIntegrated%252BDrug%252BDiscovery%252Band%252BDevelopment%25253A%252BRecent%252BExamples%252Bfrom%252Bthe%252BPharmaceutical%252BIndustry%252BVolume%252B1%26aulast%3DAbdel-Magid%26aufirst%3DAhmed%2BF.%26date%3D2018%26date%3D2018%26volume%3D1307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huai-Long  Teng</span>, <span class="hlFld-ContribAuthor ">Yong  Luo</span>, <span class="hlFld-ContribAuthor ">Masayoshi  Nishiura</span>, and <span class="hlFld-ContribAuthor ">Zhaomin  Hou</span>  . </span><span class="cited-content_cbyCitation_article-title">Diastereodivergent Asymmetric Carboamination/Annulation of Cyclopropenes with Aminoalkenes by Chiral Lanthanum Catalysts. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2017,</strong> <em>139 </em>
                                    (46)
                                     , 16506-16509. <a href="https://doi.org/10.1021/jacs.7b10786" title="DOI URL">https://doi.org/10.1021/jacs.7b10786</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.7b10786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.7b10786%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DDiastereodivergent%252BAsymmetric%252BCarboamination%25252FAnnulation%252Bof%252BCyclopropenes%252Bwith%252BAminoalkenes%252Bby%252BChiral%252BLanthanum%252BCatalysts%26aulast%3DTeng%26aufirst%3DHuai-Long%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D10102017%26date%3D13112017%26date%3D22112017%26date%3D08112017%26volume%3D139%26issue%3D46%26spage%3D16506%26epage%3D16509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.  Sotthivirat</span>, <span class="hlFld-ContribAuthor ">J.  Ren</span>, <span class="hlFld-ContribAuthor ">W.  Wasylaschuk</span>, <span class="hlFld-ContribAuthor ">N.  Afanador</span>, <span class="hlFld-ContribAuthor ">K.  Rosenberg</span>, <span class="hlFld-ContribAuthor ">R.V.  Taggart</span>, <span class="hlFld-ContribAuthor ">D.  Skomski</span>, <span class="hlFld-ContribAuthor ">C.  Brown</span>. </span><span class="cited-content_cbyCitation_article-title">An Integrated Approach for High-Shear Wet Granulation (HSWG) Processing of TPGS-Based Formulations: Demonstration of Process Robustness through Experimental Design Conditions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical Sciences</span><span> <strong>2021,</strong> <em>110 </em>
                                    (8)
                                     , 2934-2945. <a href="https://doi.org/10.1016/j.xphs.2021.03.015" title="DOI URL">https://doi.org/10.1016/j.xphs.2021.03.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.xphs.2021.03.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.xphs.2021.03.015%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DAn%252BIntegrated%252BApproach%252Bfor%252BHigh-Shear%252BWet%252BGranulation%252B%252528HSWG%252529%252BProcessing%252Bof%252BTPGS-Based%252BFormulations%25253A%252BDemonstration%252Bof%252BProcess%252BRobustness%252Bthrough%252BExperimental%252BDesign%252BConditions%26aulast%3DSotthivirat%26aufirst%3DS.%26date%3D2021%26volume%3D110%26issue%3D8%26spage%3D2934%26epage%3D2945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Byeong Wook  Kim</span>, <span class="hlFld-ContribAuthor ">Hwa  Lee</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>, <span class="hlFld-ContribAuthor ">B. Moon  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-activity relationship (SAR) studies on the mutagenic properties of 2,7-diaminofluorene and 2,7-diaminocarbazole derivatives. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>31 </em>, 127662. <a href="https://doi.org/10.1016/j.bmcl.2020.127662" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127662</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127662%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure-activity%252Brelationship%252B%252528SAR%252529%252Bstudies%252Bon%252Bthe%252Bmutagenic%252Bproperties%252Bof%252B2%25252C7-diaminofluorene%252Band%252B2%25252C7-diaminocarbazole%252Bderivatives%26aulast%3DKim%26aufirst%3DByeong%2BWook%26date%3D2021%26volume%3D31%26spage%3D127662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrey A.  Ivashchenko</span>, <span class="hlFld-ContribAuthor ">Yan A.  Ivanenkov</span>, <span class="hlFld-ContribAuthor ">Vladimir A.  Aladinskiy</span>, <span class="hlFld-ContribAuthor ">Ruben N.  Karapetian</span>, <span class="hlFld-ContribAuthor ">Angela G.  Koryakova</span>, <span class="hlFld-ContribAuthor ">Alexey A.  Ryakhovskiy</span>, <span class="hlFld-ContribAuthor ">Oleg D.  Mitkin</span>, <span class="hlFld-ContribAuthor ">Dmitry V.  Kravchenko</span>, <span class="hlFld-ContribAuthor ">Nikolai P.  Savchuk</span>, <span class="hlFld-ContribAuthor ">Bogdan A.  Zagribelnyy</span>, <span class="hlFld-ContribAuthor ">Alexander V.  Ivashchenko</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (20)
                                     , 115716. <a href="https://doi.org/10.1016/j.bmc.2020.115716" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115716</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115716%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bin%252Bsilico%252Bmodeling%252Bof%252Bnovel%252Bpan-genotypic%252BNS5A%252Binhibitors%26aulast%3DIvashchenko%26aufirst%3DAndrey%2BA.%26date%3D2020%26volume%3D28%26issue%3D20%26spage%3D115716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaheen  Khan</span>, <span class="hlFld-ContribAuthor ">Shalini  Soni</span>, <span class="hlFld-ContribAuthor ">Naga Suresh  Veerapu</span>. </span><span class="cited-content_cbyCitation_article-title">HCV Replicon Systems: Workhorses of Drug Discovery and Resistance. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cellular and Infection Microbiology</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.3389/fcimb.2020.00325" title="DOI URL">https://doi.org/10.3389/fcimb.2020.00325</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcimb.2020.00325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcimb.2020.00325%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cellular%2520and%2520Infection%2520Microbiology%26atitle%3DHCV%252BReplicon%252BSystems%25253A%252BWorkhorses%252Bof%252BDrug%252BDiscovery%252Band%252BResistance%26aulast%3DKhan%26aufirst%3DShaheen%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Z.  Qin</span>, <span class="hlFld-ContribAuthor ">A.  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">QSAR studies on hepatitis C virus NS5A protein tetracyclic inhibitors in wild type and mutants by CoMFA and CoMSIA. </span><span class="cited-content_cbyCitation_journal-name">SAR and QSAR in Environmental Research</span><span> <strong>2020,</strong> <em>31 </em>
                                    (4)
                                     , 281-311. <a href="https://doi.org/10.1080/1062936X.2020.1740889" title="DOI URL">https://doi.org/10.1080/1062936X.2020.1740889</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1062936X.2020.1740889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1062936X.2020.1740889%26sid%3Dliteratum%253Aachs%26jtitle%3DSAR%2520and%2520QSAR%2520in%2520Environmental%2520Research%26atitle%3DQSAR%252Bstudies%252Bon%252Bhepatitis%252BC%252Bvirus%252BNS5A%252Bprotein%252Btetracyclic%252Binhibitors%252Bin%252Bwild%252Btype%252Band%252Bmutants%252Bby%252BCoMFA%252Band%252BCoMSIA%26aulast%3DQin%26aufirst%3DZ.%26date%3D2020%26date%3D2020%26volume%3D31%26issue%3D4%26spage%3D281%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammad Idham Darussalam  Mardjan</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 5–6 Systems With One Bridgehead (Ring Junction) Nitrogen Atom: One Extra Heteroatom 0:1. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00032-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00032-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00032-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00032-9%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B5%2525E2%252580%2525936%252BSystems%252BWith%252BOne%252BBridgehead%252B%252528Ring%252BJunction%252529%252BNitrogen%252BAtom%25253A%252BOne%252BExtra%252BHeteroatom%252B0%25253A1%26aulast%3DMardjan%26aufirst%3DMuhammad%2BIdham%2BDarussalam%26date%3D2020%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2020%26volume%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul Alain  Tagnouokam-Ngoupo</span>, <span class="hlFld-ContribAuthor ">Marie Nicole  Ngoufack</span>, <span class="hlFld-ContribAuthor ">Sebastien  Kenmoe</span>, <span class="hlFld-ContribAuthor ">Simon Frédéric  Lissock</span>, <span class="hlFld-ContribAuthor ">Marie  Amougou-Atsama</span>, <span class="hlFld-ContribAuthor ">Robert  Banai</span>, <span class="hlFld-ContribAuthor ">Laure  Ngono</span>, <span class="hlFld-ContribAuthor ">Richard  Njouom</span>. </span><span class="cited-content_cbyCitation_article-title">Hepatitis C virus genotyping based on Core and NS5B regions in Cameroonian patients. </span><span class="cited-content_cbyCitation_journal-name">Virology Journal</span><span> <strong>2019,</strong> <em>16 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12985-019-1214-9" title="DOI URL">https://doi.org/10.1186/s12985-019-1214-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12985-019-1214-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12985-019-1214-9%26sid%3Dliteratum%253Aachs%26jtitle%3DVirology%2520Journal%26atitle%3DHepatitis%252BC%252Bvirus%252Bgenotyping%252Bbased%252Bon%252BCore%252Band%252BNS5B%252Bregions%252Bin%252BCameroonian%252Bpatients%26aulast%3DTagnouokam-Ngoupo%26aufirst%3DPaul%2BAlain%26date%3D2019%26date%3D2019%26volume%3D16%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ernest  Asante-Appiah</span>, <span class="hlFld-ContribAuthor ">Paul  Ingravallo</span>, <span class="hlFld-ContribAuthor ">Patricia  McMonagle</span>, <span class="hlFld-ContribAuthor ">Karin  Bystol</span>, <span class="hlFld-ContribAuthor ">Ellen  Xia</span>, <span class="hlFld-ContribAuthor ">Stephanie  Curry</span>, <span class="hlFld-ContribAuthor ">Ping  Qiu</span>, <span class="hlFld-ContribAuthor ">Stuart  Black</span>, <span class="hlFld-ContribAuthor ">Robert  Chase</span>, <span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Fred  Lahser</span>. </span><span class="cited-content_cbyCitation_article-title">Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in Hepatitis C Virus Genotype 2. </span><span class="cited-content_cbyCitation_journal-name">Antimicrobial Agents and Chemotherapy</span><span> <strong>2019,</strong> <em>63 </em>
                                    (12)
                                     <a href="https://doi.org/10.1128/AAC.01269-19" title="DOI URL">https://doi.org/10.1128/AAC.01269-19</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/AAC.01269-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FAAC.01269-19%26sid%3Dliteratum%253Aachs%26jtitle%3DAntimicrobial%2520Agents%2520and%2520Chemotherapy%26atitle%3DInterplay%252Bof%252BAmino%252BAcid%252BResidues%252Bat%252BPositions%252B28%252Band%252B31%252Bin%252BNS5A%252BDefines%252BResistance%252BPathways%252Bin%252BHepatitis%252BC%252BVirus%252BGenotype%252B2%26aulast%3DAsante-Appiah%26aufirst%3DErnest%26date%3D2019%26volume%3D63%26issue%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eric  Lawitz</span>, <span class="hlFld-ContribAuthor ">Edward  Gane</span>, <span class="hlFld-ContribAuthor ">Jordan J.  Feld</span>, <span class="hlFld-ContribAuthor ">Maria  Buti</span>, <span class="hlFld-ContribAuthor ">Graham R.  Foster</span>, <span class="hlFld-ContribAuthor ">Mordechai  Rabinovitz</span>, <span class="hlFld-ContribAuthor ">Eduard  Burnevich</span>, <span class="hlFld-ContribAuthor ">Helena  Katchman</span>, <span class="hlFld-ContribAuthor ">Krzysztof  Tomasiewicz</span>, <span class="hlFld-ContribAuthor ">Fred  Lahser</span>, <span class="hlFld-ContribAuthor ">Beth  Jackson</span>, <span class="hlFld-ContribAuthor ">Melissa  Shaughnessy</span>, <span class="hlFld-ContribAuthor ">Stephanie  Klopfer</span>, <span class="hlFld-ContribAuthor ">Wendy W.  Yeh</span>, <span class="hlFld-ContribAuthor ">Michael N.  Robertson</span>, <span class="hlFld-ContribAuthor ">George J.  Hanna</span>, <span class="hlFld-ContribAuthor ">Eliav  Barr</span>, <span class="hlFld-ContribAuthor ">Heather L.  Platt</span>, , <span class="hlFld-ContribAuthor ">Stuart C.  Gordon</span>, <span class="hlFld-ContribAuthor ">Eric J.  Lawitz</span>, <span class="hlFld-ContribAuthor ">Peter Jerome  Ruane</span>, <span class="hlFld-ContribAuthor ">Amandeep  Sahota</span>, <span class="hlFld-ContribAuthor ">Norah A.  Terrault</span>, <span class="hlFld-ContribAuthor ">Naoky  Tsai</span>, <span class="hlFld-ContribAuthor ">Sumodh C.  Kalathil</span>, <span class="hlFld-ContribAuthor ">Gautham  Reddy</span>, <span class="hlFld-ContribAuthor ">Wayne  Ghesquiere</span>, <span class="hlFld-ContribAuthor ">Sergio  Borgia</span>, <span class="hlFld-ContribAuthor ">Brian  Conway</span>, <span class="hlFld-ContribAuthor ">Jordan  Feld</span>, <span class="hlFld-ContribAuthor ">Keith  Tsoi</span>, <span class="hlFld-ContribAuthor ">Curtis L.  Cooper</span>, <span class="hlFld-ContribAuthor ">Peter Maged  Ghali</span>, <span class="hlFld-ContribAuthor ">Alexander James Venn  Thompson</span>, <span class="hlFld-ContribAuthor ">Jose Luis Calleja  Panero</span>, <span class="hlFld-ContribAuthor ">Sabela Lens Maria Buti  Ferret</span>, <span class="hlFld-ContribAuthor ">Luis Margusino  Franinan</span>, <span class="hlFld-ContribAuthor ">Maria  Angeles Castro Iglesias</span>, <span class="hlFld-ContribAuthor ">Ashley  Brown</span>, <span class="hlFld-ContribAuthor ">Kaushik  Agarwal</span>, <span class="hlFld-ContribAuthor ">Graham  Foster</span>, <span class="hlFld-ContribAuthor ">Matthew  Cramp</span>, <span class="hlFld-ContribAuthor ">Eli  Zuckerman</span>, <span class="hlFld-ContribAuthor ">Ella  Veitsman</span>, <span class="hlFld-ContribAuthor ">Michal  Cohen</span>, <span class="hlFld-ContribAuthor ">Yoav  Lurie</span>, <span class="hlFld-ContribAuthor ">Ziv Ben  Ari</span>, <span class="hlFld-ContribAuthor ">Ewa  Janczewska</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Szymczak</span>, <span class="hlFld-ContribAuthor ">Waldemar  Halota</span>, <span class="hlFld-ContribAuthor ">Robert  Flisiak</span>, <span class="hlFld-ContribAuthor ">Adam  Mahomed</span>, <span class="hlFld-ContribAuthor ">Mark Wayne  Sonderup</span>, <span class="hlFld-ContribAuthor ">Zelda Erika  Punt</span>, <span class="hlFld-ContribAuthor ">Mpho Klaas  Kgomo</span>, <span class="hlFld-ContribAuthor ">David C  Bernhardi</span>, <span class="hlFld-ContribAuthor ">Eduard Z.  Burnevich</span>, <span class="hlFld-ContribAuthor ">Svetlana  Kizhlo</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. </span><span class="cited-content_cbyCitation_journal-name">Journal of Viral Hepatitis</span><span> <strong>2019,</strong> <em>12 </em><a href="https://doi.org/10.1111/jvh.13132" title="DOI URL">https://doi.org/10.1111/jvh.13132</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jvh.13132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjvh.13132%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Viral%2520Hepatitis%26atitle%3DEfficacy%252Band%252Bsafety%252Bof%252Ba%252Btwo%2525E2%252580%252590drug%252Bdirect%2525E2%252580%252590acting%252Bantiviral%252Bagent%252Bregimen%252Bruzasvir%252B180%2525C2%2525A0mg%252Band%252Buprifosbuvir%252B450%2525C2%2525A0mg%252Bfor%252B12%2525C2%2525A0weeks%252Bin%252Badults%252Bwith%252Bchronic%252Bhepatitis%252BC%252Bvirus%252Bgenotype%252B1%25252C%252B2%25252C%252B3%25252C%252B4%25252C%252B5%252Bor%252B6%26aulast%3DLawitz%26aufirst%3DEric%26date%3D2019%26date%3D2019%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yung-Chi  Lee</span>, <span class="hlFld-ContribAuthor ">Michael  McNevin</span>, <span class="hlFld-ContribAuthor ">Craig  Ikeda</span>, <span class="hlFld-ContribAuthor ">Georgia  Chouzouri</span>, <span class="hlFld-ContribAuthor ">Justin  Moser</span>, <span class="hlFld-ContribAuthor ">David  Harris</span>, <span class="hlFld-ContribAuthor ">Logan  Howell</span>. </span><span class="cited-content_cbyCitation_article-title">Combination of Colloidal Silicon Dioxide with Spray-Dried Solid Dispersion to Facilitate Discharge from an Agitated Dryer. </span><span class="cited-content_cbyCitation_journal-name">AAPS PharmSciTech</span><span> <strong>2019,</strong> <em>20 </em>
                                    (5)
                                     <a href="https://doi.org/10.1208/s12249-019-1392-1" title="DOI URL">https://doi.org/10.1208/s12249-019-1392-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1208/s12249-019-1392-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1208%2Fs12249-019-1392-1%26sid%3Dliteratum%253Aachs%26jtitle%3DAAPS%2520PharmSciTech%26atitle%3DCombination%252Bof%252BColloidal%252BSilicon%252BDioxide%252Bwith%252BSpray-Dried%252BSolid%252BDispersion%252Bto%252BFacilitate%252BDischarge%252Bfrom%252Ban%252BAgitated%252BDryer%26aulast%3DLee%26aufirst%3DYung-Chi%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eric  Lawitz</span>, <span class="hlFld-ContribAuthor ">Fred  Poordad</span>, <span class="hlFld-ContribAuthor ">Leah J.  Anderson</span>, <span class="hlFld-ContribAuthor ">Michelle  Vesay</span>, <span class="hlFld-ContribAuthor ">Michelle M.  Kelly</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Wei  Gao</span>, <span class="hlFld-ContribAuthor ">Doreen  Fernsler</span>, <span class="hlFld-ContribAuthor ">Ernest  Asante‐Appiah</span>, <span class="hlFld-ContribAuthor ">Michael N.  Robertson</span>, <span class="hlFld-ContribAuthor ">George J.  Hanna</span>, <span class="hlFld-ContribAuthor ">Eliav  Barr</span>, <span class="hlFld-ContribAuthor ">Joan  Butterton</span>, <span class="hlFld-ContribAuthor ">Kris V.  Kowdley</span>, <span class="hlFld-ContribAuthor ">Tarek  Hassanein</span>, <span class="hlFld-ContribAuthor ">Amandeep  Sahota</span>, <span class="hlFld-ContribAuthor ">Stuart C.  Gordon</span>, <span class="hlFld-ContribAuthor ">Wendy W.  Yeh</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. </span><span class="cited-content_cbyCitation_journal-name">Journal of Viral Hepatitis</span><span> <strong>2019,</strong> <em>26 </em>
                                    (6)
                                     , 675-684. <a href="https://doi.org/10.1111/jvh.13079" title="DOI URL">https://doi.org/10.1111/jvh.13079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jvh.13079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjvh.13079%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Viral%2520Hepatitis%26atitle%3DEfficacy%252Band%252Bsafety%252Bof%252Bruzasvir%252B60%2525C2%2525A0mg%252Band%252Buprifosbuvir%252B450%2525C2%2525A0mg%252Bfor%252B12%2525C2%2525A0weeks%252Bin%252Badults%252Bwith%252Bchronic%252Bhepatitis%252BC%252Bvirus%252Bgenotype%252B1%25252C%252B2%25252C%252B3%25252C%252B4%252Bor%252B6%252Binfection%26aulast%3DLawitz%26aufirst%3DEric%26date%3D2019%26date%3D2019%26volume%3D26%26issue%3D6%26spage%3D675%26epage%3D684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ernest  Asante-Appiah</span>, <span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Stephanie  Curry</span>, <span class="hlFld-ContribAuthor ">Patricia  McMonagle</span>, <span class="hlFld-ContribAuthor ">Sony  Agrawal</span>, <span class="hlFld-ContribAuthor ">Donna  Carr</span>, <span class="hlFld-ContribAuthor ">Laura  Rokosz</span>, <span class="hlFld-ContribAuthor ">Frederick  Lahser</span>, <span class="hlFld-ContribAuthor ">Karin  Bystol</span>, <span class="hlFld-ContribAuthor ">Robert  Chase</span>, <span class="hlFld-ContribAuthor ">Stuart  Black</span>, <span class="hlFld-ContribAuthor ">Eric  Ferrari</span>, <span class="hlFld-ContribAuthor ">Paul  Ingravallo</span>, <span class="hlFld-ContribAuthor ">Ling  Tong</span>, <span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Joseph  Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">In Vitro
              Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A. </span><span class="cited-content_cbyCitation_journal-name">Antimicrobial Agents and Chemotherapy</span><span> <strong>2018,</strong> <em>62 </em>
                                    (11)
                                     <a href="https://doi.org/10.1128/AAC.01280-18" title="DOI URL">https://doi.org/10.1128/AAC.01280-18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/AAC.01280-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FAAC.01280-18%26sid%3Dliteratum%253Aachs%26jtitle%3DAntimicrobial%2520Agents%2520and%2520Chemotherapy%26atitle%3DIn%252BVitro%252BAntiviral%252BProfile%252Bof%252BRuzasvir%25252C%252Ba%252BPotent%252Band%252BPangenotype%252BInhibitor%252Bof%252BHepatitis%252BC%252BVirus%252BNS5A%26aulast%3DAsante-Appiah%26aufirst%3DErnest%26date%3D2018%26volume%3D62%26issue%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Geoffrey  Dusheiko</span>. </span><span class="cited-content_cbyCitation_article-title">Hepatitis C. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 436-467. <a href="https://doi.org/10.1002/9781119237662.ch23" title="DOI URL">https://doi.org/10.1002/9781119237662.ch23</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119237662.ch23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119237662.ch23%26sid%3Dliteratum%253Aachs%26atitle%3DHepatitis%252BC%26aulast%3DDusheiko%26aufirst%3DGeoffrey%26date%3D2018%26date%3D2018%26spage%3D436%26epage%3D467%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Ltd%26atitle%3DSherlock%252527s%252BDiseases%252Bof%252Bthe%252BLiver%252Band%252BBiliary%252BSystem%26aulast%3DDooley%26aufirst%3DJames%2BS.%26date%3D2018%26volume%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anilkumar G.  Nair</span>, <span class="hlFld-ContribAuthor ">Qingbei  Zeng</span>, <span class="hlFld-ContribAuthor ">Oleg  Selyutin</span>, <span class="hlFld-ContribAuthor ">Stuart B.  Rosenblum</span>, <span class="hlFld-ContribAuthor ">Yueheng  Jiang</span>, <span class="hlFld-ContribAuthor ">De-Yi  Yang</span>, <span class="hlFld-ContribAuthor ">Kerry  Keertikar</span>, <span class="hlFld-ContribAuthor ">Guowei  Zhou</span>, <span class="hlFld-ContribAuthor ">Michael  Dwyer</span>, <span class="hlFld-ContribAuthor ">Seong Heon  Kim</span>, <span class="hlFld-ContribAuthor ">Bandarpalle  Shankar</span>, <span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Ling  Tong</span>, <span class="hlFld-ContribAuthor ">Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Robert  Mazzola</span>, <span class="hlFld-ContribAuthor ">John  Caldwell</span>, <span class="hlFld-ContribAuthor ">Haiqun  Tang</span>, <span class="hlFld-ContribAuthor ">Sony  Agrawal</span>, <span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Rong  Kong</span>, <span class="hlFld-ContribAuthor ">Paul  Ingravallo</span>, <span class="hlFld-ContribAuthor ">Ellen  Xia</span>, <span class="hlFld-ContribAuthor ">Ying  Zhai</span>, <span class="hlFld-ContribAuthor ">Amin  Nomeir</span>, <span class="hlFld-ContribAuthor ">Ernest  Asante-Appiah</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (10)
                                     , 1954-1957. <a href="https://doi.org/10.1016/j.bmcl.2018.03.049" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.03.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.03.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.03.049%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DMK-8325%25253A%252BA%252Bsilyl%252Bproline-containing%252BNS5A%252Binhibitor%252Bwith%252Bpan-genotype%252Bactivity%252Bfor%252Btreatment%252Bof%252BHCV%26aulast%3DNair%26aufirst%3DAnilkumar%2BG.%26date%3D2018%26volume%3D28%26issue%3D10%26spage%3D1954%26epage%3D1957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fedora  Grande</span>, <span class="hlFld-ContribAuthor ">Maria A.  Occhiuzzi</span>, <span class="hlFld-ContribAuthor ">Giuseppina  Ioele</span>, <span class="hlFld-ContribAuthor ">Gaetano  Ragno</span>, <span class="hlFld-ContribAuthor ">Antonio  Garofalo</span>. </span><span class="cited-content_cbyCitation_article-title">Benzopyrroloxazines containing a bridgehead nitrogen atom as promising scaffolds for the achievement of biologically active agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>151 </em>, 121-144. <a href="https://doi.org/10.1016/j.ejmech.2018.03.061" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.03.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.03.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.03.061%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBenzopyrroloxazines%252Bcontaining%252Ba%252Bbridgehead%252Bnitrogen%252Batom%252Bas%252Bpromising%252Bscaffolds%252Bfor%252Bthe%252Bachievement%252Bof%252Bbiologically%252Bactive%252Bagents%26aulast%3DGrande%26aufirst%3DFedora%26date%3D2018%26volume%3D151%26spage%3D121%26epage%3D144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ulrich  Spengler</span>. </span><span class="cited-content_cbyCitation_article-title">Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2018,</strong> <em>183 </em>, 118-126. <a href="https://doi.org/10.1016/j.pharmthera.2017.10.009" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2017.10.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2017.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2017.10.009%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DDirect%252Bantiviral%252Bagents%252B%252528DAAs%252529%252B-%252BA%252Bnew%252Bage%252Bin%252Bthe%252Btreatment%252Bof%252Bhepatitis%252BC%252Bvirus%252Binfection%26aulast%3DSpengler%26aufirst%3DUlrich%26date%3D2018%26volume%3D183%26spage%3D118%26epage%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong-Jin  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Five-Membered Ring Systems. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 243-262. <a href="https://doi.org/10.1016/B978-0-08-102788-2.00009-X" title="DOI URL">https://doi.org/10.1016/B978-0-08-102788-2.00009-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102788-2.00009-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102788-2.00009-X%26sid%3Dliteratum%253Aachs%26atitle%3DFive-Membered%252BRing%252BSystems%26aulast%3DWu%26aufirst%3DYong-Jin%26date%3D2018%26spage%3D243%26epage%3D262%26pub%3DElsevier%26date%3D2018%26volume%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satya P.  Gupta</span>. </span><span class="cited-content_cbyCitation_article-title">The Medicinal Chemistry of Antihepatitis Agents III. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 133-210. <a href="https://doi.org/10.1016/B978-0-12-813330-9.00007-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-813330-9.00007-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-813330-9.00007-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-813330-9.00007-7%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BMedicinal%252BChemistry%252Bof%252BAntihepatitis%252BAgents%252BIII%26aulast%3DGupta%26aufirst%3DSatya%2BP.%26date%3D2018%26spage%3D133%26epage%3D210%26pub%3DElsevier%26atitle%3DStudies%252Bon%252BHepatitis%252BViruses%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Youngsu  You</span>, <span class="hlFld-ContribAuthor ">Hee Sun  Kim</span>, <span class="hlFld-ContribAuthor ">Jung Woo  Park</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>, <span class="hlFld-ContribAuthor ">Sung Key  Jang</span>, <span class="hlFld-ContribAuthor ">B. Moon  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Sulfur(
              vi
              ) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure–activity relationship studies. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2018,</strong> <em>8 </em>
                                    (55)
                                     , 31803-31821. <a href="https://doi.org/10.1039/C8RA05471A" title="DOI URL">https://doi.org/10.1039/C8RA05471A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8RA05471A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8RA05471A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DSulfur%252528%252Bvi%252B%252529%252Bfluoride%252Bexchange%252Bas%252Ba%252Bkey%252Breaction%252Bfor%252Bsynthesizing%252Bbiaryl%252Bsulfate%252Bcore%252Bderivatives%252Bas%252Bpotent%252Bhepatitis%252BC%252Bvirus%252BNS5A%252Binhibitors%252Band%252Btheir%252Bstructure%2525E2%252580%252593activity%252Brelationship%252Bstudies%26aulast%3DYou%26aufirst%3DYoungsu%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D55%26spage%3D31803%26epage%3D31821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David  Wyles</span>, <span class="hlFld-ContribAuthor ">Heiner  Wedemeyer</span>, <span class="hlFld-ContribAuthor ">Ziv  Ben-Ari</span>, <span class="hlFld-ContribAuthor ">Edward J.  Gane</span>, <span class="hlFld-ContribAuthor ">Jesper Bach  Hansen</span>, <span class="hlFld-ContribAuthor ">Ira M.  Jacobson</span>, <span class="hlFld-ContribAuthor ">Alex L.  Laursen</span>, <span class="hlFld-ContribAuthor ">Annie  Luetkemeyer</span>, <span class="hlFld-ContribAuthor ">Ronald  Nahass</span>, <span class="hlFld-ContribAuthor ">Stephen  Pianko</span>, <span class="hlFld-ContribAuthor ">Stefan  Zeuzem</span>, <span class="hlFld-ContribAuthor ">Patricia  Jumes</span>, <span class="hlFld-ContribAuthor ">Hsueh-Cheng  Huang</span>, <span class="hlFld-ContribAuthor ">Joan  Butterton</span>, <span class="hlFld-ContribAuthor ">Michael  Robertson</span>, <span class="hlFld-ContribAuthor ">Janice  Wahl</span>, <span class="hlFld-ContribAuthor ">Eliav  Barr</span>, <span class="hlFld-ContribAuthor ">Hee-Koung  Joeng</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Martin</span>, <span class="hlFld-ContribAuthor ">Lawrence  Serfaty</span>, . </span><span class="cited-content_cbyCitation_article-title">Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure. </span><span class="cited-content_cbyCitation_journal-name">Hepatology</span><span> <strong>2017,</strong> <em>66 </em>
                                    (6)
                                     , 1794-1804. <a href="https://doi.org/10.1002/hep.29358" title="DOI URL">https://doi.org/10.1002/hep.29358</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/hep.29358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fhep.29358%26sid%3Dliteratum%253Aachs%26jtitle%3DHepatology%26atitle%3DGrazoprevir%25252C%252Bruzasvir%25252C%252Band%252Buprifosbuvir%252Bfor%252Bhepatitis%252BC%252Bvirus%252Bafter%252BNS5A%252Btreatment%252Bfailure%26aulast%3DWyles%26aufirst%3DDavid%26date%3D2017%26date%3D2017%26volume%3D66%26issue%3D6%26spage%3D1794%26epage%3D1804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hosnieh  Fathi</span>, <span class="hlFld-ContribAuthor ">Andrew  Clark</span>, <span class="hlFld-ContribAuthor ">Nathan R.  Hill</span>, <span class="hlFld-ContribAuthor ">Geoffrey  Dusheiko</span>. </span><span class="cited-content_cbyCitation_article-title">Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review. </span><span class="cited-content_cbyCitation_journal-name">BMC Infectious Diseases</span><span> <strong>2017,</strong> <em>17 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12879-017-2820-z" title="DOI URL">https://doi.org/10.1186/s12879-017-2820-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12879-017-2820-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12879-017-2820-z%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Infectious%2520Diseases%26atitle%3DEffectiveness%252Bof%252Bcurrent%252Band%252Bfuture%252Bregimens%252Bfor%252Btreating%252Bgenotype%252B3%252Bhepatitis%252BC%252Bvirus%252Binfection%25253A%252Ba%252Blarge-scale%252Bsystematic%252Breview%26aulast%3DFathi%26aufirst%3DHosnieh%26date%3D2017%26date%3D2017%26volume%3D17%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reza  Taherkhani</span>, <span class="hlFld-ContribAuthor ">Fatemeh  Farshadpour</span>. </span><span class="cited-content_cbyCitation_article-title">Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. </span><span class="cited-content_cbyCitation_journal-name">World Journal of Hepatology</span><span> <strong>2017,</strong> <em>9 </em>
                                    (33)
                                     , 1239-1252. <a href="https://doi.org/10.4254/wjh.v9.i33.1239" title="DOI URL">https://doi.org/10.4254/wjh.v9.i33.1239</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4254/wjh.v9.i33.1239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4254%2Fwjh.v9.i33.1239%26sid%3Dliteratum%253Aachs%26jtitle%3DWorld%2520Journal%2520of%2520Hepatology%26atitle%3DGlobal%252Belimination%252Bof%252Bhepatitis%252BC%252Bvirus%252Binfection%25253A%252BProgresses%252Band%252Bthe%252Bremaining%252Bchallenges%26aulast%3DTaherkhani%26aufirst%3DReza%26date%3D2017%26volume%3D9%26issue%3D33%26spage%3D1239%26epage%3D1252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Edward J  Gane</span>, <span class="hlFld-ContribAuthor ">Stephen  Pianko</span>, <span class="hlFld-ContribAuthor ">Stuart K  Roberts</span>, <span class="hlFld-ContribAuthor ">Alexander J  Thompson</span>, <span class="hlFld-ContribAuthor ">Stefan  Zeuzem</span>, <span class="hlFld-ContribAuthor ">Eli  Zuckerman</span>, <span class="hlFld-ContribAuthor ">Ziv  Ben-Ari</span>, <span class="hlFld-ContribAuthor ">Graham R  Foster</span>, <span class="hlFld-ContribAuthor ">Kosh  Agarwal</span>, <span class="hlFld-ContribAuthor ">Alex L  Laursen</span>, <span class="hlFld-ContribAuthor ">Jan  Gerstoft</span>, <span class="hlFld-ContribAuthor ">Wei  Gao</span>, <span class="hlFld-ContribAuthor ">Hsueh-Cheng  Huang</span>, <span class="hlFld-ContribAuthor ">Brian  Fitzgerald</span>, <span class="hlFld-ContribAuthor ">Doreen  Fernsler</span>, <span class="hlFld-ContribAuthor ">Jerry J  Li</span>, <span class="hlFld-ContribAuthor ">Anjana  Grandhi</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Feng-Hsiu  Su</span>, <span class="hlFld-ContribAuthor ">Shuyan  Wan</span>, <span class="hlFld-ContribAuthor ">Zhen  Zeng</span>, <span class="hlFld-ContribAuthor ">Huei-Ling  Chen</span>, <span class="hlFld-ContribAuthor ">Frank J  Dutko</span>, <span class="hlFld-ContribAuthor ">Bach-Yen T  Nguyen</span>, <span class="hlFld-ContribAuthor ">Janice  Wahl</span>, <span class="hlFld-ContribAuthor ">Michael N  Robertson</span>, <span class="hlFld-ContribAuthor ">Eliav  Barr</span>, <span class="hlFld-ContribAuthor ">Wendy W  Yeh</span>, <span class="hlFld-ContribAuthor ">Rebeca M  Plank</span>, <span class="hlFld-ContribAuthor ">Joan R  Butterton</span>, <span class="hlFld-ContribAuthor ">Rafael  Esteban</span>. </span><span class="cited-content_cbyCitation_article-title">Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. </span><span class="cited-content_cbyCitation_journal-name">The Lancet Gastroenterology & Hepatology</span><span> <strong>2017,</strong> <em>2 </em>
                                    (11)
                                     , 805-813. <a href="https://doi.org/10.1016/S2468-1253(17)30159-0" title="DOI URL">https://doi.org/10.1016/S2468-1253(17)30159-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S2468-1253(17)30159-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS2468-1253%2817%2930159-0%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Lancet%2520Gastroenterology%2520%2526%2520Hepatology%26atitle%3DSafety%252Band%252Befficacy%252Bof%252Ban%252B8-week%252Bregimen%252Bof%252Bgrazoprevir%252Bplus%252Bruzasvir%252Bplus%252Buprifosbuvir%252Bcompared%252Bwith%252Bgrazoprevir%252Bplus%252Belbasvir%252Bplus%252Buprifosbuvir%252Bin%252Bparticipants%252Bwithout%252Bcirrhosis%252Binfected%252Bwith%252Bhepatitis%252BC%252Bvirus%252Bgenotypes%252B1%25252C%252B2%25252C%252Bor%252B3%252B%252528C-CREST-1%252Band%252BC-CREST-2%25252C%252Bpart%252BA%252529%25253A%252Btwo%252Brandomised%25252C%252Bphase%252B2%25252C%252Bopen-label%252Btrials%26aulast%3DGane%26aufirst%3DEdward%2BJ%26date%3D2017%26volume%3D2%26issue%3D11%26spage%3D805%26epage%3D813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eric  Lawitz</span>, <span class="hlFld-ContribAuthor ">Maria  Buti</span>, <span class="hlFld-ContribAuthor ">John M  Vierling</span>, <span class="hlFld-ContribAuthor ">Piero L  Almasio</span>, <span class="hlFld-ContribAuthor ">Savino  Bruno</span>, <span class="hlFld-ContribAuthor ">Peter J  Ruane</span>, <span class="hlFld-ContribAuthor ">Tarek I  Hassanein</span>, <span class="hlFld-ContribAuthor ">Beat  Muellhaupt</span>, <span class="hlFld-ContribAuthor ">Brian  Pearlman</span>, <span class="hlFld-ContribAuthor ">Ligita  Jancoriene</span>, <span class="hlFld-ContribAuthor ">Wei  Gao</span>, <span class="hlFld-ContribAuthor ">Hsueh-Cheng  Huang</span>, <span class="hlFld-ContribAuthor ">Aimee  Shepherd</span>, <span class="hlFld-ContribAuthor ">Brynne  Tannenbaum</span>, <span class="hlFld-ContribAuthor ">Doreen  Fernsler</span>, <span class="hlFld-ContribAuthor ">Jerry J  Li</span>, <span class="hlFld-ContribAuthor ">Anjana  Grandhi</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Feng-Hsiu  Su</span>, <span class="hlFld-ContribAuthor ">Shuyan  Wan</span>, <span class="hlFld-ContribAuthor ">Frank J  Dutko</span>, <span class="hlFld-ContribAuthor ">Bach-Yen T  Nguyen</span>, <span class="hlFld-ContribAuthor ">Janice  Wahl</span>, <span class="hlFld-ContribAuthor ">Michael N  Robertson</span>, <span class="hlFld-ContribAuthor ">Eliav  Barr</span>, <span class="hlFld-ContribAuthor ">Wendy W  Yeh</span>, <span class="hlFld-ContribAuthor ">Rebeca M  Plank</span>, <span class="hlFld-ContribAuthor ">Joan R  Butterton</span>, <span class="hlFld-ContribAuthor ">Eric M  Yoshida</span>. </span><span class="cited-content_cbyCitation_article-title">Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. </span><span class="cited-content_cbyCitation_journal-name">The Lancet Gastroenterology & Hepatology</span><span> <strong>2017,</strong> <em>2 </em>
                                    (11)
                                     , 814-823. <a href="https://doi.org/10.1016/S2468-1253(17)30163-2" title="DOI URL">https://doi.org/10.1016/S2468-1253(17)30163-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S2468-1253(17)30163-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS2468-1253%2817%2930163-2%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Lancet%2520Gastroenterology%2520%2526%2520Hepatology%26atitle%3DSafety%252Band%252Befficacy%252Bof%252Ba%252Bfixed-dose%252Bcombination%252Bregimen%252Bof%252Bgrazoprevir%25252C%252Bruzasvir%25252C%252Band%252Buprifosbuvir%252Bwith%252Bor%252Bwithout%252Bribavirin%252Bin%252Bparticipants%252Bwith%252Band%252Bwithout%252Bcirrhosis%252Bwith%252Bchronic%252Bhepatitis%252BC%252Bvirus%252Bgenotype%252B1%25252C%252B2%25252C%252Bor%252B3%252Binfection%252B%252528C-CREST-1%252Band%252BC-CREST-2%25252C%252Bpart%252BB%252529%25253A%252Btwo%252Brandomised%25252C%252Bphase%252B2%25252C%252Bopen-label%252Btrials%26aulast%3DLawitz%26aufirst%3DEric%26date%3D2017%26volume%3D2%26issue%3D11%26spage%3D814%26epage%3D823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vincent  Soriano</span>, <span class="hlFld-ContribAuthor ">José V.  Fernandez-Montero</span>, <span class="hlFld-ContribAuthor ">Carmen  de Mendoza</span>, <span class="hlFld-ContribAuthor ">Laura  Benitez-Gutierrez</span>, <span class="hlFld-ContribAuthor ">José M.  Peña</span>, <span class="hlFld-ContribAuthor ">Ana  Arias</span>, <span class="hlFld-ContribAuthor ">Pablo  Barreiro</span>. </span><span class="cited-content_cbyCitation_article-title">Treatment of hepatitis C with new fixed dose combinations. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2017,</strong> <em>18 </em>
                                    (12)
                                     , 1235-1242. <a href="https://doi.org/10.1080/14656566.2017.1346609" title="DOI URL">https://doi.org/10.1080/14656566.2017.1346609</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2017.1346609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2017.1346609%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DTreatment%252Bof%252Bhepatitis%252BC%252Bwith%252Bnew%252Bfixed%252Bdose%252Bcombinations%26aulast%3DSoriano%26aufirst%3DVincent%26date%3D2017%26date%3D2017%26volume%3D18%26issue%3D12%26spage%3D1235%26epage%3D1242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vicente  Soriano</span>, <span class="hlFld-ContribAuthor ">Pablo  Labarga</span>, <span class="hlFld-ContribAuthor ">José V.  Fernandez-Montero</span>, <span class="hlFld-ContribAuthor ">Carmen de  Mendoza</span>, <span class="hlFld-ContribAuthor ">Laura  Benítez-Gutiérrez</span>, <span class="hlFld-ContribAuthor ">José M.  Peña</span>, <span class="hlFld-ContribAuthor ">Pablo  Barreiro</span>. </span><span class="cited-content_cbyCitation_article-title">Drug interactions in HIV-infected patients treated for hepatitis C. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Metabolism & Toxicology</span><span> <strong>2017,</strong> <em>13 </em>
                                    (8)
                                     , 807-816. <a href="https://doi.org/10.1080/17425255.2017.1351942" title="DOI URL">https://doi.org/10.1080/17425255.2017.1351942</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17425255.2017.1351942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17425255.2017.1351942%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Metabolism%2520%2526%2520Toxicology%26atitle%3DDrug%252Binteractions%252Bin%252BHIV-infected%252Bpatients%252Btreated%252Bfor%252Bhepatitis%252BC%26aulast%3DSoriano%26aufirst%3DVicente%26date%3D2017%26date%3D2017%26volume%3D13%26issue%3D8%26spage%3D807%26epage%3D816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yining  Ji</span>, <span class="hlFld-ContribAuthor ">Hongming  Li</span>, <span class="hlFld-ContribAuthor ">Alan M.  Hyde</span>, <span class="hlFld-ContribAuthor ">Qinghao  Chen</span>, <span class="hlFld-ContribAuthor ">Kevin M.  Belyk</span>, <span class="hlFld-ContribAuthor ">Katrina W.  Lexa</span>, <span class="hlFld-ContribAuthor ">Jingjun  Yin</span>, <span class="hlFld-ContribAuthor ">Edward C.  Sherer</span>, <span class="hlFld-ContribAuthor ">R. Thomas  Williamson</span>, <span class="hlFld-ContribAuthor ">Andrew  Brunskill</span>, <span class="hlFld-ContribAuthor ">Sumei  Ren</span>, <span class="hlFld-ContribAuthor ">Louis-Charles  Campeau</span>, <span class="hlFld-ContribAuthor ">Ian W.  Davies</span>, <span class="hlFld-ContribAuthor ">Rebecca T.  Ruck</span>. </span><span class="cited-content_cbyCitation_article-title">A rational pre-catalyst design for bis-phosphine mono-oxide palladium catalyzed reactions. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2017,</strong> <em>8 </em>
                                    (4)
                                     , 2841-2851. <a href="https://doi.org/10.1039/C6SC05472B" title="DOI URL">https://doi.org/10.1039/C6SC05472B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6SC05472B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6SC05472B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DA%252Brational%252Bpre-catalyst%252Bdesign%252Bfor%252Bbis-phosphine%252Bmono-oxide%252Bpalladium%252Bcatalyzed%252Breactions%26aulast%3DJi%26aufirst%3DYining%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D4%26spage%3D2841%26epage%3D2851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01310&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Compound <b>40</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01310&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Common Intermediates <b>69</b> and <b>70</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01310&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) AcOH/EtOH/40 °C to reflux, 6 h; (b) PPA/xylene, 100 °C, 2 h; (c) Zn/TFA, 70–76 °C, 17 h.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthetic Approach to Thiophene/Thiazole Analogs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01310&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TFA/CH<sub>3</sub>CN, 25 °C, 6 h; (b) DDQ, toluene, reflux, 2 h; (c) bis(pinacolato)diboron, KOAc, Pd(dppf)Cl<sub>2</sub>, dioxane, 100 °C, overnight; (d) <b>58</b>, Na<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, THF/H<sub>2</sub>O, 80 °C, overnight; (e) <b>59</b>, K<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, THF/H<sub>2</sub>O, 80 °C, overnight; (f) HCl in dioxane/CH<sub>2</sub>Cl<sub>2</sub>, 20 °C, 1 h; (g) HATU, Moc-<span class="smallcaps smallerCapital">l</span>-valine, DIPEA, DMF, 0 °C, 40 min; (h) pyridine/PCl<sub>5</sub>/CH<sub>2</sub>Cl<sub>2</sub>, −10 °C, 0.5 h; (i) Cs<sub>2</sub>CO<sub>3</sub>/DMSO, 100 °C, 1 h; (j) chiral SFC separation.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>6</b> and <b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01310&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) cyclopropyl boronic acid, Pd<sub>2</sub>(dba)<sub>3</sub>, X-Phos, K<sub>2</sub>CO<sub>3</sub>/dioxane, 110 °C, 16 h, 46% for <b>82</b> and 18% for <b>6</b>; (b) chiral SFC separation.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01310&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd(OAc)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, <i>n</i>-BuPdCl<sub>2</sub>, toluene/H<sub>2</sub>O, 100 °C, overnight, 32%; (b) <i>n</i>-BuLi, DMF, −78 °C, 3 h, 49% (c) TFA/CH<sub>3</sub>CN, 25 °C, 6 h, 68%; (d) DDQ, toluene, reflux, 2 h, 82%; (e) bis(pinacolato)diboron, KOAc, Pd(dppf)Cl<sub>2</sub>, dioxane, 110 °C, overnight, 82%; (f) <b>58</b>, Na<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, THF/H<sub>2</sub>O, 95 °C, overnight; (g) SFC chiral separation, 10% over two steps.</p></p></figure><figure data-id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Common intermediates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01310&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/medium/jm-2016-01310j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>56</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-1/acs.jmedchem.6b01310/20170106/images/large/jm-2016-01310j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01310&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd(OAc)<sub>2</sub>, cataCXiumA, Cs<sub>2</sub>CO<sub>3</sub>, toluene/H<sub>2</sub>O, 100 °C, 16 h, 95%; (b) TFA, rt, CH<sub>3</sub>CN, 6 h, 78%; (c) DDQ, toluene, reflux, 2 h, 82%; (d) bis(pinacolato)diboron, KOAc, Pd(dppf)Cl<sub>2</sub>, dioxane, 100 °C, 82%; (e) <b>58</b>, K<sub>2</sub>CO<sub>3</sub> aq, Pd(dppf)Cl<sub>2</sub>, dioxane, 90 °C, overnight, 70%; (f) Pd<sub>2</sub>(dba)<sub>3</sub>, X-Phos, KOAc/dioxane, 110 °C, overnight, 99%; (g) <b>61</b>, 1 M K<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, dioxane/H<sub>2</sub>O, 85 °C, overnight, 28%; (h) 4 N HCl in dioxane, 25 °C, 3 h, 100%; (i) HATU, Moc-<span class="smallcaps smallerCapital">l</span>-valine, DIPEA, DMF, rt, 3 h 99%; (j) chiral SFC separation, 34%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i81">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44620" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44620" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 25 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Liang, J. T.; Hoofnagle, J. H.</span> <span class="citation_source-book">Hepatitis C</span>; Biomedical Research Reports; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">London, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">2000</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">185</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=185-203&author=J.+T.+Liang&author=J.+H.+Hoofnagle&title=Hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%2BT.%26btitle%3DHepatitis%2520C%26pub%3DAcademic%2520Press%26date%3D2000%26spage%3D185%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Mohd Hanafiah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groeger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaxman, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiersma, S. T.</span><span> </span><span class="NLM_article-title">Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1333</span><span class="NLM_x">–</span> <span class="NLM_lpage">1342</span><span class="refDoi"> DOI: 10.1002/hep.26141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1002%2Fhep.26141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=1333-1342&author=K.+Mohd+Hanafiahauthor=J.+Groegerauthor=A.+D.+Flaxmanauthor=S.+T.+Wiersma&title=Global+epidemiology+of+hepatitis+C+virus+infection%3A+new+estimates+of+age-specific+antibody+to+HCV+seroprevalence&doi=10.1002%2Fhep.26141"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fhep.26141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26141%26sid%3Dliteratum%253Aachs%26aulast%3DMohd%2BHanafiah%26aufirst%3DK.%26aulast%3DGroeger%26aufirst%3DJ.%26aulast%3DFlaxman%26aufirst%3DA.%2BD.%26aulast%3DWiersma%26aufirst%3DS.%2BT.%26atitle%3DGlobal%2520epidemiology%2520of%2520hepatitis%2520C%2520virus%2520infection%253A%2520new%2520estimates%2520of%2520age-specific%2520antibody%2520to%2520HCV%2520seroprevalence%26jtitle%3DHepatology%26date%3D2013%26volume%3D57%26spage%3D1333%26epage%3D1342%26doi%3D10.1002%2Fhep.26141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><div class="note"><p class="first last">For a review on DAAs see the following:</p></div><span class="NLM_contrib-group">Holmes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A.</span><span> </span><span class="NLM_article-title">Interferon-Free combination therapies for the treatment of hepatitis C: current insights</span> <span class="citation_source-journal">Hepatic Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span><span class="refDoi"> DOI: 10.2147/HMER.S55864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.2147%2FHMER.S55864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A280%3ADC%252BC28rgsVSqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=51-70&author=J.+Holmesauthor=A.+Thompson&title=Interferon-Free+combination+therapies+for+the+treatment+of+hepatitis+C%3A+current+insights&doi=10.2147%2FHMER.S55864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon-free combination therapies for the treatment of hepatitis C: current insights</span></div><div class="casAuthors">Holmes Jacinta A; Thompson Alexander J</div><div class="citationInfo"><span class="NLM_cas:title">Hepatic medicine : evidence and research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-70</span>
        ISSN:<span class="NLM_cas:issn">1179-1535</span>.
    </div><div class="casAbstract">The hepatitis C virus (HCV) treatment landscape has rapidly changed over the past 5 years.  The development of direct-acting antiviral (DAA) agents that specifically target various steps in the HCV lifecycle has revolutionized therapeutic options for patients with HCV, with the development of highly effective and well-tolerated oral interferon-free regimens.  There are many DAAs that are currently in development or have recently been approved, which target different nonstructural HCV proteins and host targets that are essential for HCV replication.  This review will focus on the different classes of DAAs and the various combinations that are in advanced development for the treatment of chronic HCV infection and will focus on the different regimens in specific patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSaWQI_kNsvcFvAgqb2vdc5fW6udTcc2ebNkrO8CTo_o7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgsVSqtg%253D%253D&md5=132f4de5a7104defd164235b90711976</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2147%2FHMER.S55864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FHMER.S55864%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DA.%26atitle%3DInterferon-Free%2520combination%2520therapies%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%253A%2520current%2520insights%26jtitle%3DHepatic%2520Med.%26date%3D2015%26spage%3D51%26epage%3D70%26doi%3D10.2147%2FHMER.S55864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">van der Meer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veldt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feld, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedemeyer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufour, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lammert, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duarte-Rojo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heathcote, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manns, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuske, L.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">2584</span><span class="NLM_x">–</span> <span class="NLM_lpage">2593</span><span class="refDoi"> DOI: 10.1001/jama.2012.144878</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1001%2Fjama.2012.144878" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2012&pages=2584-2593&author=A.+van+der+Meerauthor=B.+Veldtauthor=J.+Feldauthor=H.+Wedemeyerauthor=J.+Dufourauthor=F.+Lammertauthor=A.+Duarte-Rojoauthor=E.+Heathcoteauthor=M.+Mannsauthor=L.+Kuske&title=Association+between+sustained+virological+response+and+all-cause+mortality+among+patients+with+chronic+hepatitis+C+and+advanced+hepatic+fibrosis&doi=10.1001%2Fjama.2012.144878"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1001%2Fjama.2012.144878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2012.144878%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BMeer%26aufirst%3DA.%26aulast%3DVeldt%26aufirst%3DB.%26aulast%3DFeld%26aufirst%3DJ.%26aulast%3DWedemeyer%26aufirst%3DH.%26aulast%3DDufour%26aufirst%3DJ.%26aulast%3DLammert%26aufirst%3DF.%26aulast%3DDuarte-Rojo%26aufirst%3DA.%26aulast%3DHeathcote%26aufirst%3DE.%26aulast%3DManns%26aufirst%3DM.%26aulast%3DKuske%26aufirst%3DL.%26atitle%3DAssociation%2520between%2520sustained%2520virological%2520response%2520and%2520all-cause%2520mortality%2520among%2520patients%2520with%2520chronic%2520hepatitis%2520C%2520and%2520advanced%2520hepatic%2520fibrosis%26jtitle%3DJAMA%26date%3D2012%26volume%3D308%26spage%3D2584%26epage%3D2593%26doi%3D10.1001%2Fjama.2012.144878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Smith, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BukH, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuiken, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muerhoff, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stapleton, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmonds, P.</span><span> </span><span class="NLM_article-title">Expanded classification of hepatitis C virus inti 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">318</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span><span class="refDoi"> DOI: 10.1002/hep.26744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1002%2Fhep.26744" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=318-327&issue=1&author=D.+B.+Smithauthor=J.+BukHauthor=C.+Kuikenauthor=A.+S.+Muerhoffauthor=C.+M.+Riceauthor=J.+T.+Stapletonauthor=P.+Simmonds&title=Expanded+classification+of+hepatitis+C+virus+inti+7+genotypes+and+67+subtypes%3A+updated+criteria+and+genotype+assignment+web+resource&doi=10.1002%2Fhep.26744"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fhep.26744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26744%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BB.%26aulast%3DBukH%26aufirst%3DJ.%26aulast%3DKuiken%26aufirst%3DC.%26aulast%3DMuerhoff%26aufirst%3DA.%2BS.%26aulast%3DRice%26aufirst%3DC.%2BM.%26aulast%3DStapleton%26aufirst%3DJ.%2BT.%26aulast%3DSimmonds%26aufirst%3DP.%26atitle%3DExpanded%2520classification%2520of%2520hepatitis%2520C%2520virus%2520inti%25207%2520genotypes%2520and%252067%2520subtypes%253A%2520updated%2520criteria%2520and%2520genotype%2520assignment%2520web%2520resource%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26issue%3D1%26spage%3D318%26epage%3D327%26doi%3D10.1002%2Fhep.26744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Coburn, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinke, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kargman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span> </span><span class="NLM_article-title">Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1930</span><span class="NLM_x">–</span> <span class="NLM_lpage">1940</span><span class="refDoi"> DOI: 10.1002/cmdc.201300343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1002%2Fcmdc.201300343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=24127258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1SkurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1930-1940&author=C.+A.+Coburnauthor=P.+T.+Meinkeauthor=W.+Changauthor=C.+M.+Fandozziauthor=D.+J.+Grahamauthor=B.+Huauthor=Q.+Huangauthor=S.+Kargmanauthor=J.+Kozlowskiauthor=R.+Liuauthor=J.+A.+McCauleyauthor=A.+A.+Nomeirauthor=R.+M.+Sollauthor=J.+P.+Vaccaauthor=D.+Wangauthor=H.+Wuauthor=B.+Zhongauthor=D.+B.+Olsenauthor=S.+W.+Ludmerer&title=Discovery+of+MK-8742%3A+an+HCV+NS5A+inhibitor+with+broad+genotype+activity&doi=10.1002%2Fcmdc.201300343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-8742: An HCV NS5A inhibitor with broad genotype activity</span></div><div class="casAuthors">Coburn, Craig A.; Meinke, Peter T.; Chang, Wei; Fandozzi, Christine M.; Graham, Donald J.; Hu, Bin; Huang, Qian; Kargman, Stacia; Kozlowski, Joseph; Liu, Rong; McCauley, John A.; Nomeir, Amin A.; Soll, Richard M.; Vacca, Joseph P.; Wang, Dahai; Wu, Hao; Zhong, Bin; Olsen, David B.; Ludmerer, Steven W.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1930-1940</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The NS5A protein plays a crit. role in the replication of HCV and has been the focus of numerous research efforts over the past few years.  NS5A inhibitors have shown impressive in vitro potency profiles in HCV replicon assays, making them attractive components for inclusion in all oral combination regimens.  Early work in the NS5A arena led to the discovery of our first clin. candidate, MK-4882 [2-((S)-pyrrolidin-2-yl)-5-(2-(4-(5-((S)-pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole].  While preclin. proof-of-concept studies in HCV-infected chimpanzees harboring chronic genotype 1 infections resulted in significant decreases in viral load after both single- and multiple-dose treatments, viral breakthrough proved to be a concern, thus necessitating the development of compds. with increased potency against a no. of genotypes and NS5A resistance mutations.  Modification of the MK-4882 core scaffold by introduction of a cyclic constraint afforded a series of tetracyclic inhibitors, which showed improved virol. profiles.  Herein we describe the research efforts that led to the discovery of MK-8742, a tetracyclic indole-based NS5A inhibitor, which is currently in phase 2b clin. trials as part of an all-oral, interferon-free regimen for the treatment of HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqknZKO01aZlLVg90H21EOLACvtfcHk0lgkSzskOW_VEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1SkurzN&md5=2f2b3ed2281c43e39b24d4197b9f57ee</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300343%26sid%3Dliteratum%253Aachs%26aulast%3DCoburn%26aufirst%3DC.%2BA.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKargman%26aufirst%3DS.%26aulast%3DKozlowski%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DNomeir%26aufirst%3DA.%2BA.%26aulast%3DSoll%26aufirst%3DR.%2BM.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520MK-8742%253A%2520an%2520HCV%2520NS5A%2520inhibitor%2520with%2520broad%2520genotype%2520activity%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D1930%26epage%3D1940%26doi%3D10.1002%2Fcmdc.201300343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coburn, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selyutin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblum, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavey, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizvi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shankar, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rokosz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMonagle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahser, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asante-Appiah, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J. A.</span><span> </span><span class="NLM_article-title">Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3800</span><span class="NLM_x">–</span> <span class="NLM_lpage">3805</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.05.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.bmcl.2016.05.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3800-3805&author=W.+Yuauthor=C.+A.+Coburnauthor=A.+G.+Nairauthor=M.+Wongauthor=L.+Tongauthor=M.+P.+Dwyerauthor=B.+Huauthor=B.+Zhongauthor=J.+Haoauthor=D.-Y.+Yangauthor=O.+Selyutinauthor=Y.+Jiangauthor=S.+B.+Rosenblumauthor=S.+H.+Kimauthor=B.+J.+Laveyauthor=G.+Zhouauthor=R.+Rizviauthor=B.+B.+Shankarauthor=Q.+Zengauthor=L.+Chenauthor=S.+Agrawalauthor=D.+Carrauthor=L.+Rokoszauthor=R.+Liuauthor=S.+Curryauthor=P.+McMonagleauthor=P.+Ingravalloauthor=F.+Lahserauthor=E.+Asante-Appiahauthor=A.+Nomeirauthor=J.+A.+Kozlowski&title=Alkyl+substituted+aminal+derivatives+of+HCV+NS5A+inhibitor+MK-8742&doi=10.1016%2Fj.bmcl.2016.05.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.05.041%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCoburn%26aufirst%3DC.%2BA.%26aulast%3DNair%26aufirst%3DA.%2BG.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DD.-Y.%26aulast%3DSelyutin%26aufirst%3DO.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DRosenblum%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DLavey%26aufirst%3DB.%2BJ.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DRizvi%26aufirst%3DR.%26aulast%3DShankar%26aufirst%3DB.%2BB.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DRokosz%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DCurry%26aufirst%3DS.%26aulast%3DMcMonagle%26aufirst%3DP.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DLahser%26aufirst%3DF.%26aulast%3DAsante-Appiah%26aufirst%3DE.%26aulast%3DNomeir%26aufirst%3DA.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DAlkyl%2520substituted%2520aminal%2520derivatives%2520of%2520HCV%2520NS5A%2520inhibitor%2520MK-8742%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3800%26epage%3D3805%26doi%3D10.1016%2Fj.bmcl.2016.05.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coburn, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblum, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selyutin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masse, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMonagle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asante-Appiah, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J. A.</span><span> </span><span class="NLM_article-title">Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3414</span><span class="NLM_x">–</span> <span class="NLM_lpage">3420</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.06.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.bmcl.2016.06.056" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3414-3420&author=W.+Yuauthor=C.+A.+Coburnauthor=A.+G.+Nairauthor=M.+Wongauthor=S.+B.+Rosenblumauthor=G.+Zhouauthor=M.+P.+Dwyerauthor=L.+Tongauthor=B.+Huauthor=B.+Zhongauthor=J.+Haoauthor=T.+Jiauthor=S.+Zanauthor=S.+H.+Kimauthor=Q.+Zengauthor=O.+Selyutinauthor=L.+Chenauthor=F.+Masseauthor=S.+Agrawalauthor=R.+Liuauthor=E.+Xiaauthor=Y.+Zhaiauthor=S.+Curryauthor=P.+McMonagleauthor=P.+Ingravalloauthor=E.+Asante-Appiahauthor=M.+Linauthor=J.+A.+Kozlowski&title=Aryl+or+heteroaryl+substituted+aminal+derivatives+of+HCV+NS5A+inhibitor+MK-8742&doi=10.1016%2Fj.bmcl.2016.06.056"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.06.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.06.056%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCoburn%26aufirst%3DC.%2BA.%26aulast%3DNair%26aufirst%3DA.%2BG.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DRosenblum%26aufirst%3DS.%2BB.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DT.%26aulast%3DZan%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DSelyutin%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DMasse%26aufirst%3DF.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DE.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DCurry%26aufirst%3DS.%26aulast%3DMcMonagle%26aufirst%3DP.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DAsante-Appiah%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DAryl%2520or%2520heteroaryl%2520substituted%2520aminal%2520derivatives%2520of%2520HCV%2520NS5A%2520inhibitor%2520MK-8742%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3414%26epage%3D3420%26doi%3D10.1016%2Fj.bmcl.2016.06.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Yu, W.; Tong, L.; Hu, B.; Zhong, B.; Hao, J.; Ji, T.; Zan, S.; Coburn, C. A.; Selyutin, O.; Chen, L.; Masse, F.; Rokosz, L.; Liu, R.; Curry, S.; McMonagle, P.; Ingravallo, P.; Asante-Appiah, E.; Chen, S.; Kozlowski, J. A.</span><span> </span><span class="NLM_article-title">Discovery of chromane containing HCV NS5A inhibitors with improved potency against resistance associate variants</span>. J. Med. Chem.<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">, </span>ASAP. DOI: <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01234</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01234" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=W.+Yu&author=L.+Tong&author=B.+Hu&author=B.+Zhong&author=J.+Hao&author=T.+Ji&author=S.+Zan&author=C.+A.+Coburn&author=O.+Selyutin&author=L.+Chen&author=F.+Masse&author=L.+Rokosz&author=R.+Liu&author=S.+Curry&author=P.+McMonagle&author=P.+Ingravallo&author=E.+Asante-Appiah&author=S.+Chen&author=J.+A.+Kozlowski&title=Discovery+of+chromane+containing+HCV+NS5A+inhibitors+with+improved+potency+against+resistance+associate+variants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01234%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520chromane%2520containing%2520HCV%2520NS5A%2520inhibitors%2520with%2520improved%2520potency%2520against%2520resistance%2520associate%2520variants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26doi%3D10.1021%2Facs.jmedchem.6b01234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coburn, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzola, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sha, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selyutin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblum, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavey, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keertikar, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masse, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMonagle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asante-Appiah, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J. A.</span><span> </span><span class="NLM_article-title">Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">4851</span><span class="NLM_x">–</span> <span class="NLM_lpage">4856</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.bmcl.2016.08.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=4851-4856&author=W.+Yuauthor=G.+Zhouauthor=C.+A.+Coburnauthor=Q.+Zengauthor=L.+Tongauthor=M.+P.+Dwyerauthor=L.+Chenauthor=R.+Mazzolaauthor=J.-H.+Kimauthor=D.+Shaauthor=O.+Selyutinauthor=S.+B.+Rosenblumauthor=B.+Laveyauthor=A.+G.+Nairauthor=S.+H.+Kimauthor=K.+M.+Keertikarauthor=F.+Masseauthor=S.+Agrawalauthor=R.+Liuauthor=E.+Xiaauthor=Y.+Zhaiauthor=S.+Curryauthor=P.+McMonagleauthor=P.+Ingravalloauthor=E.+Asante-Appiahauthor=S.+Chenauthor=J.+A.+Kozlowski&title=Substituted+tetracyclic+indole+core+derivatives+of+HCV+NS5A+inhibitor+MK-8742&doi=10.1016%2Fj.bmcl.2016.08.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DCoburn%26aufirst%3DC.%2BA.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DMazzola%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DSha%26aufirst%3DD.%26aulast%3DSelyutin%26aufirst%3DO.%26aulast%3DRosenblum%26aufirst%3DS.%2BB.%26aulast%3DLavey%26aufirst%3DB.%26aulast%3DNair%26aufirst%3DA.%2BG.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DKeertikar%26aufirst%3DK.%2BM.%26aulast%3DMasse%26aufirst%3DF.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DE.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DCurry%26aufirst%3DS.%26aulast%3DMcMonagle%26aufirst%3DP.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DAsante-Appiah%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DSubstituted%2520tetracyclic%2520indole%2520core%2520derivatives%2520of%2520HCV%2520NS5A%2520inhibitor%2520MK-8742%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D4851%26epage%3D4856%26doi%3D10.1016%2Fj.bmcl.2016.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coburn, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinke, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selyutin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblum, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fells, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asante-Appiah, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J. A.</span><span> </span><span class="NLM_article-title">Alternative Core Development Around the HCV NS5A Inhibitor MK-8742 Scaffold</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">5132</span><span class="NLM_x">–</span> <span class="NLM_lpage">5137</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.07.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.bmcl.2016.07.057" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5132-5137&author=L.+Tongauthor=W.+Yuauthor=C.+A.+Coburnauthor=P.+T.+Meinkeauthor=A.+G.+Nairauthor=M.+P.+Dwyerauthor=L.+Chenauthor=O.+Selyutinauthor=S.+B.+Rosenblumauthor=Y.+Jiangauthor=J.+Fellsauthor=B.+Huauthor=B.+Zhongauthor=R.+M.+Sollauthor=R.+Liuauthor=S.+Agrawalauthor=E.+Xiaauthor=Y.+Zhaiauthor=R.+Kongauthor=P.+Ingravalloauthor=A.+Nomeirauthor=E.+Asante-Appiahauthor=J.+A.+Kozlowski&title=Alternative+Core+Development+Around+the+HCV+NS5A+Inhibitor+MK-8742+Scaffold&doi=10.1016%2Fj.bmcl.2016.07.057"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.07.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.07.057%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCoburn%26aufirst%3DC.%2BA.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26aulast%3DNair%26aufirst%3DA.%2BG.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSelyutin%26aufirst%3DO.%26aulast%3DRosenblum%26aufirst%3DS.%2BB.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DFells%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DSoll%26aufirst%3DR.%2BM.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DXia%26aufirst%3DE.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DR.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DNomeir%26aufirst%3DA.%26aulast%3DAsante-Appiah%26aufirst%3DE.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DAlternative%2520Core%2520Development%2520Around%2520the%2520HCV%2520NS5A%2520Inhibitor%2520MK-8742%2520Scaffold%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5132%26epage%3D5137%26doi%3D10.1016%2Fj.bmcl.2016.07.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coburn, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selyutin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shankar, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblum, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruck, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMonagle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bystol, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahser, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asante-Appiah, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J. A.</span><span> </span><span class="NLM_article-title">Structure-Activity Relationships of Proline Modifications Around the Tetracyclic-indole Class of NS5A Inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">5354</span><span class="NLM_x">–</span> <span class="NLM_lpage">5360</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.08.097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.bmcl.2016.08.097" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5354-5360&author=L.+Tongauthor=W.+Yuauthor=C.+A.+Coburnauthor=L.+Chenauthor=O.+Selyutinauthor=Q.+Zengauthor=M.+P.+Dwyerauthor=A.+G.+Nairauthor=B.+B.+Shankarauthor=S.+H.+Kimauthor=D.-Y.+Yangauthor=S.+B.+Rosenblumauthor=R.+T.+Ruckauthor=I.+W.+Daviesauthor=B.+Huauthor=B.+Zhongauthor=J.+Haoauthor=T.+Jiauthor=S.+Zanauthor=R.+Liuauthor=S.+Agrawalauthor=D.+Carrauthor=S.+Curryauthor=P.+McMonagleauthor=K.+Bystolauthor=F.+Lahserauthor=P.+Ingravalloauthor=S.+Chenauthor=E.+Asante-Appiahauthor=J.+A.+Kozlowski&title=Structure-Activity+Relationships+of+Proline+Modifications+Around+the+Tetracyclic-indole+Class+of+NS5A+Inhibitors&doi=10.1016%2Fj.bmcl.2016.08.097"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.08.097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.08.097%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCoburn%26aufirst%3DC.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSelyutin%26aufirst%3DO.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DNair%26aufirst%3DA.%2BG.%26aulast%3DShankar%26aufirst%3DB.%2BB.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DYang%26aufirst%3DD.-Y.%26aulast%3DRosenblum%26aufirst%3DS.%2BB.%26aulast%3DRuck%26aufirst%3DR.%2BT.%26aulast%3DDavies%26aufirst%3DI.%2BW.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DT.%26aulast%3DZan%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DCurry%26aufirst%3DS.%26aulast%3DMcMonagle%26aufirst%3DP.%26aulast%3DBystol%26aufirst%3DK.%26aulast%3DLahser%26aufirst%3DF.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DAsante-Appiah%26aufirst%3DE.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DStructure-Activity%2520Relationships%2520of%2520Proline%2520Modifications%2520Around%2520the%2520Tetracyclic-indole%2520Class%2520of%2520NS5A%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5354%26epage%3D5360%26doi%3D10.1016%2Fj.bmcl.2016.08.097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Scheel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C.</span><span> </span><span class="NLM_article-title">Understanding the hepatitis C virus life cycle paves the way for highly effective therapies</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">837</span><span class="NLM_x">–</span> <span class="NLM_lpage">849</span><span class="refDoi"> DOI: 10.1038/nm.3248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1038%2Fnm.3248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=23836234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKru7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=837-849&author=T.+Scheelauthor=C.+Rice&title=Understanding+the+hepatitis+C+virus+life+cycle+paves+the+way+for+highly+effective+therapies&doi=10.1038%2Fnm.3248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the hepatitis C virus life cycle paves the way for highly effective therapies</span></div><div class="casAuthors">Scheel, Troels K. H.; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">837-849</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  More than two decades of intense research has provided a detailed understanding of hepatitis C virus (HCV), which chronically infects 2% of the world's population.  This effort has paved the way for the development of antiviral compds. to spare patients from life-threatening liver disease.  An exciting new era in HCV therapy dawned with the recent approval of two viral protease inhibitors, used in combination with pegylated interferon-α and ribavirin; however, this is just the beginning.  Multiple classes of antivirals with distinct targets promise highly efficient combinations, and interferon-free regimens with short treatment duration and fewer side effects are the future of HCV therapy.  Ongoing and future trials will det. the best antiviral combinations and whether the current seemingly rich pipeline is sufficient for successful treatment of all patients in the face of major challenges, such as HCV diversity, viral resistance, the influence of host genetics, advanced liver disease and other co-morbidities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpde8altGxkeLVg90H21EOLACvtfcHk0liFXdCjr2yO-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKru7rI&md5=dabc9fbc7dc0bc56115d5ede0d8ae072</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnm.3248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3248%26sid%3Dliteratum%253Aachs%26aulast%3DScheel%26aufirst%3DT.%26aulast%3DRice%26aufirst%3DC.%26atitle%3DUnderstanding%2520the%2520hepatitis%2520C%2520virus%2520life%2520cycle%2520paves%2520the%2520way%2520for%2520highly%2520effective%2520therapies%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D837%26epage%3D849%26doi%3D10.1038%2Fnm.3248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D.,  II</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">465</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span><span class="refDoi"> DOI: 10.1038/nature08960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1038%2Fnature08960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=20410884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=96-100&author=M.+Gaoauthor=R.+Nettlesauthor=M.+Belemaauthor=L.+Snyderauthor=V.+Nguyenauthor=R.+Fridellauthor=M.+Serrano-Wuauthor=D.+Langleyauthor=J.+Sunauthor=D.+O%E2%80%99Boyle&title=Chemical+genetics+strategy+identifies+an+HCV+NS5A+inhibitor+with+a+potent+clinical+effect&doi=10.1038%2Fnature08960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span></div><div class="casAuthors">Gao, Min; Nettles, Richard E.; Belema, Makonen; Snyder, Lawrence B.; Nguyen, Van N.; Fridell, Robert A.; Serrano-Wu, Michael H.; Langley, David R.; Sun, Jin-Hua; O'Boyle, Donald R., II; Lemm, Julie A.; Wang, Chunfu; Knipe, Jay O.; Chien, Caly; Colonno, Richard J.; Grasela, Dennis M.; Meanwell, Nicholas A.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7294</span>),
    <span class="NLM_cas:pages">96-100</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estd. to be approaching 200 million people.  Current therapy relies upon a combination of pegylated interferon-α and ribavirin, a poorly tolerated regimen typically assocd. with less than 50% sustained virol. response rate in those infected with genotype 1 virus.  The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B.  Here we describe the profile of BMS-790052, a small mol. inhibitor of the HCV NS5A protein that exhibits picomolar half-max. effective concns. (EC50) towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture.  In a phase I clin. trial in patients chronically infected with HCV, administration of a single 100-mg dose of BMS-790052 was assocd. with a 3.3 log10 redn. in mean viral load measured 24 h post-dose that was sustained for an addnl. 120 h in two patients infected with genotype 1b virus.  Genotypic anal. of samples taken at baseline, 24 and 144 h post-dose revealed that the major HCV variants obsd. had substitutions at amino-acid positions identified using the in vitro replicon system.  These results provide the first clin. validation of an inhibitor of HCV NS5A, a protein with no known enzymic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations of HCV inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAY7Lig0xT9LVg90H21EOLACvtfcHk0liFXdCjr2yO-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D&md5=620427e987f2bccd153270cde2ef5027</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1038%2Fnature08960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08960%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DNettles%26aufirst%3DR.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DSnyder%26aufirst%3DL.%26aulast%3DNguyen%26aufirst%3DV.%26aulast%3DFridell%26aufirst%3DR.%26aulast%3DSerrano-Wu%26aufirst%3DM.%26aulast%3DLangley%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%26atitle%3DChemical%2520genetics%2520strategy%2520identifies%2520an%2520HCV%2520NS5A%2520inhibitor%2520with%2520a%2520potent%2520clinical%2520effect%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D96%26epage%3D100%26doi%3D10.1038%2Fnature08960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nettles, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marbury, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldwater, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMicco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vutikullird, A.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1956</span><span class="NLM_x">–</span> <span class="NLM_lpage">1965</span><span class="refDoi"> DOI: 10.1002/hep.24609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1002%2Fhep.24609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=21837752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1956-1965&author=R.+Nettlesauthor=M.+Gaoauthor=M.+Bifanoauthor=E.+Chungauthor=A.+Perssonauthor=T.+Marburyauthor=R.+Goldwaterauthor=M.+DeMiccoauthor=M.+Rodriguez-Torresauthor=A.+Vutikullird&title=Multiple+ascending+dose+study+of+BMS-790052%2C+a+nonstructural+protein+5A+replication+complex+inhibitor%2C+in+patients+infected+with+hepatitis+C+virus+genotype+1&doi=10.1002%2Fhep.24609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1</span></div><div class="casAuthors">Nettles, Richard E.; Gao, Min; Bifano, Marc; Chung, Ellen; Persson, Anna; Marbury, Thomas C.; Goldwater, Ronald; DeMicco, Michael P.; Rodriguez-Torres, Maribel; Vutikullird, Apinya; Fuentes, Ernesto; Lawitz, Eric; Lopez-Talavera, Juan Carlos; Grasela, Dennis M.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1956-1965</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The antiviral activity, resistance profile, pharmacokinetics (PK), safety, and tolerability of BMS-790052, a nonstructural protein 5A (NS5A) replication complex inhibitor, were evaluated in a double-blind, placebo-controlled, sequential panel, multiple ascending dose study.  Thirty patients with chronic hepatitis C virus (HCV) genotype 1 infection were randomized to receive a 14-day course of BMS-790052 (1, 10, 30, 60, or 100 mg once daily or 30 mg twice daily) or placebo in a ratio of 4:1.  The mean max. decline from baseline in HCV RNA ranged from 2.8 to 4.1 log10 IU/mL; the placebo group showed no evidence of antiviral activity.  Most patients experienced viral rebound on or before day 7 of treatment with BMS-790052 monotherapy; viral rebound was assocd. with viral variants that had been previously implicated in resistance development in the in vitro replicon system.  The PK profile was supportive of once-daily dosing with median peak plasma concns. at 1-2 h postdose and mean terminal half-life of 12-15 h.  Steady state was achieved following 3-4 days of daily dosing.  BMS-790052 was well tolerated in all dose groups, with adverse events occurring with a similar frequency in BMS-790052- and placebo-treated groups.  There were no clin. relevant changes in vital signs, lab., or ECG parameters.  Conclusion: BMS-7590052 is the first NS5A replication complex inhibitor with multiple dose proof-of-concept in clinic.  At doses of 1-100 mg daily, BMS-790052 was well tolerated, had a PK profile supportive of once-daily dosing, and produced a rapid and substantial decrease in HCV-RNA levels in patients chronically infected with HCV genotype 1. (HEPATOl.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjY1mjsJbg-LVg90H21EOLACvtfcHk0liFXdCjr2yO-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsLrJ&md5=080f30aec3629e68b832fe6491c54d16</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1002%2Fhep.24609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24609%26sid%3Dliteratum%253Aachs%26aulast%3DNettles%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DBifano%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DMarbury%26aufirst%3DT.%26aulast%3DGoldwater%26aufirst%3DR.%26aulast%3DDeMicco%26aufirst%3DM.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DVutikullird%26aufirst%3DA.%26atitle%3DMultiple%2520ascending%2520dose%2520study%2520of%2520BMS-790052%252C%2520a%2520nonstructural%2520protein%25205A%2520replication%2520complex%2520inhibitor%252C%2520in%2520patients%2520infected%2520with%2520hepatitis%2520C%2520virus%2520genotype%25201%26jtitle%3DHepatology%26date%3D2011%26volume%3D54%26spage%3D1956%26epage%3D1965%26doi%3D10.1002%2Fhep.24609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachand, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavoie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2013</span><span class="NLM_x">–</span> <span class="NLM_lpage">2032</span><span class="refDoi"> DOI: 10.1021/jm401836p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401836p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVWhsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2013-2032&author=M.+Belemaauthor=V.+Nguyenauthor=C.+Bachandauthor=D.+Deonauthor=J.+Goodrichauthor=C.+Jamesauthor=R.+Lavoieauthor=O.+Lopezauthor=A.+Martelauthor=J.+Romine&title=Hepatitis+C+virus+NS5A+replication+complex+inhibitors%3A+the+discovery+of+daclatasvir&doi=10.1021%2Fjm401836p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir</span></div><div class="casAuthors">Belema, Makonen; Nguyen, Van N.; Bachand, Carol; Deon, Dan H.; Goodrich, Jason T.; James, Clint A.; Lavoie, Rico; Lopez, Omar D.; Martel, Alain; Romine, Jeffrey L.; Ruediger, Edward H.; Snyder, Lawrence B.; St. Laurent, Denis R.; Yang, Fukang; Zhu, Juliang; Wong, Henry S.; Langley, David R.; Adams, Stephen P.; Cantor, Glenn H.; Chimalakonda, Anjaneya; Fura, Aberra; Johnson, Benjamin M.; Knipe, Jay O.; Parker, Dawn D.; Santone, Kenneth S.; Fridell, Robert A.; Lemm, Julie A.; O'Boyle, Donald R., II; Colonno, Richard J.; Gao, Min; Meanwell, Nicholas A.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2013-2032</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The biphenyl derivs. I (R = NHCO2Me, NMe2) are prototypes of a novel class of NS5A replication complex inhibitors that demonstrate high inhibitory potency toward a panel of clin. relevant HCV strains encompassing genotypes 1-6.  However, these compds. exhibit poor systemic exposure in rat pharmacokinetic studies after oral dosing.  The structure-activity relationship investigations that improved the exposure properties of the parent bis-phenylimidazole chemotype, culminating in the identification of the highly potent NS5A replication complex inhibitor daclatasvir (II, X = 4,4'-biphenylene) are described.  An element crit. to success was the realization that the arylglycine cap of I (R = NHCO2Me) could be replaced with an alkylglycine deriv. and still maintain the high inhibitory potency of the series if accompanied with a stereoinversion, a finding that enabled a rapid optimization of exposure properties.  Compd. II had EC50 values of 50 and 9 pM toward genotype-1a and -1b replicons, resp., and oral bioavailabilities of 38-108% in preclin. species.  Compd. II provided clin. proof-of-concept for the NS5A replication complex inhibitor class, and regulatory approval to market it with the NS3/4A protease inhibitor asunaprevir for the treatment of HCV genotype-1b infection has recently been sought in Japan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYnJILm4L3mbVg90H21EOLACvtfcHk0litBrzDksTPZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVWhsr8%253D&md5=ca5c44e9b15fda7cb4632066ef2a673a</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1021%2Fjm401836p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401836p%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%26aulast%3DBachand%26aufirst%3DC.%26aulast%3DDeon%26aufirst%3DD.%26aulast%3DGoodrich%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DC.%26aulast%3DLavoie%26aufirst%3DR.%26aulast%3DLopez%26aufirst%3DO.%26aulast%3DMartel%26aufirst%3DA.%26aulast%3DRomine%26aufirst%3DJ.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitors%253A%2520the%2520discovery%2520of%2520daclatasvir%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2013%26epage%3D2032%26doi%3D10.1021%2Fjm401836p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lok, A.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A inhibitors and drug resistance mutations</span> <span class="citation_source-journal">Clin. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span><span class="refDoi"> DOI: 10.1016/j.cld.2012.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.cld.2012.09.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=111-121&author=A.+Lok&title=Hepatitis+C+virus+NS5A+inhibitors+and+drug+resistance+mutations&doi=10.1016%2Fj.cld.2012.09.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1016%2Fj.cld.2012.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cld.2012.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DLok%26aufirst%3DA.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520inhibitors%2520and%2520drug%2520resistance%2520mutations%26jtitle%3DClin.%2520Liver%2520Dis.%26date%3D2013%26volume%3D17%26spage%3D111%26epage%3D121%26doi%3D10.1016%2Fj.cld.2012.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pawlotsky, J.-M.</span><span> </span><span class="NLM_article-title">NS5A inhibitors in the treatment of hepatitis C</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">382</span><span class="refDoi"> DOI: 10.1016/j.jhep.2013.03.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.jhep.2013.03.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=23567084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVSltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2013&pages=375-382&author=J.-M.+Pawlotsky&title=NS5A+inhibitors+in+the+treatment+of+hepatitis+C&doi=10.1016%2Fj.jhep.2013.03.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">NS5A inhibitors in the treatment of hepatitis C</span></div><div class="casAuthors">Pawlotsky, Jean-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">375-382</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus infection is a major health problem worldwide and no vaccine has yet been developed against this virus.  In addn., currently approved pharmacotherapies achieve suboptimal cure rates and have side effects that result in non-compliance and premature treatment discontinuation.  Significant research has been devoted to developing direct-acting antiviral agents that inhibit key viral functions.  In particular, several novel drug candidates that inhibit the viral non-structural protein 5A (NS5A) have been demonstrated to possess high potency, pan-genotypic activity, and a high barrier to resistance.  Clin. trials using combination therapies contg. NS5A inhibitors have reported results that promise high cure rates and raise the possibility of developing interferon-free, all-oral regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjUOPI9xaUQ7Vg90H21EOLACvtfcHk0litBrzDksTPZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVSltrk%253D&md5=6692cd6e6c9d6b392ee977f9f9155913</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2013.03.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2013.03.030%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.-M.%26atitle%3DNS5A%2520inhibitors%2520in%2520the%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DJ.%2520Hepatol.%26date%3D2013%26volume%3D59%26spage%3D375%26epage%3D382%26doi%3D10.1016%2Fj.jhep.2013.03.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Belda, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Targett-Adams, P.</span><span> </span><span class="NLM_article-title">Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein</span> <span class="citation_source-journal">Virus Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">170</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1016/j.virusres.2012.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.virusres.2012.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=23009750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKru7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2012&pages=1-14&author=O.+Beldaauthor=P.+Targett-Adams&title=Small+molecule+inhibitors+of+the+hepatitis+C+virus-encoded+NS5A+protein&doi=10.1016%2Fj.virusres.2012.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein</span></div><div class="casAuthors">Belda, Oscar; Targett-Adams, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-14</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) is a modern-day pandemic; 2-3% of the world's population are thought to be infected with the virus and are subsequently at risk of developing end-stage liver diseases.  The traditional std. of care (SOC) for HCV-infected patients has been limited to a regimen of pegylated-interferon alpha (pegIFN) and ribavirin; displaying low cure rates in a majority of patients and severe side effects.  However, in 2011 the first direct-acting antivirals (DAA) were licensed to treat HCV-infected patients in combination with SOC, which served to elevate treatment response rates.  The HCV drug development pipeline is currently populated with many addnl. and improved DAAs; primarily mols. that target the virus-encoded protease or polymerase enzymes.  These mols. are being evaluated both in combination with the traditional SOC and together with other DAAs as all-oral pegIFN-free regimens with the ultimate goal of developing multiple DAA-contg. HCV therapies that do not rely on an pegIFN backbone.  A recent addn. to the arsenal of HCV inhibitors in development is represented by an entirely new DAA class; mols. that target the HCV-encoded non-enzymic NS5A protein.  NS5A is essential for HCV propagation and, although its actual functions are largely unknown, it is likely a key regulator of viral genome replication and virion assembly.  The protein is exquisitely sensitive to small mol.-mediated inhibition; NS5A-targeting mols. are probably the most potent antiviral mols. ever discovered and exhibit a no. of other attractive drug-like properties, including activity against many HCV genotypes/subtypes and once-daily dosing potential.  Although their mechanism of action is unclear, NS5A-targeting mols. are already proving their utility in clin. evaluation; particularly as components of pegIFN-sparring DAA combination regimens.  This review will aim to amalgamate our current understanding and knowledge of NS5A-targeting mols.; their discovery, properties, applications, and insight into their future impact as components of all-oral pegIFN-free DAA combination therapies to combat HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG1WoP20i-q7Vg90H21EOLACvtfcHk0litBrzDksTPZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKru7zO&md5=f2137b9130775af1b45bc72bd205dbfc</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2012.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2012.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DBelda%26aufirst%3DO.%26aulast%3DTargett-Adams%26aufirst%3DP.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus-encoded%2520NS5A%2520protein%26jtitle%3DVirus%2520Res.%26date%3D2012%26volume%3D170%26spage%3D1%26epage%3D14%26doi%3D10.1016%2Fj.virusres.2012.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cordek, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bechtel, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maynard, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmierski, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span> </span><span class="NLM_article-title">Targeting the NS5A protein of HCV: an emerging option</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">711</span><span class="refDoi"> DOI: 10.1358/dof.2011.036.09.1641618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1358%2Fdof.2011.036.09.1641618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=23378700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1eis7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=691-711&author=D.+G.+Cordekauthor=J.+T.+Bechtelauthor=A.+T.+Maynardauthor=W.+M.+Kazmierskiauthor=C.+E.+Cameron&title=Targeting+the+NS5A+protein+of+HCV%3A+an+emerging+option&doi=10.1358%2Fdof.2011.036.09.1641618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14dR"><div class="casContent"><span class="casTitleNuber">14d</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the protein NS5A protein of HCV: an emerging option</span></div><div class="casAuthors">Cordek, D. G.; Bechtel, J. T.; Maynard, A. T.; Kazmierski, W. M.; Cameron, C. E.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">691-711</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) infects more than 3% of the world's population, leading to an increased risk of cirrhosis and hepatocellular carcinoma.  The current std. of care, a combination of pegylated interferon alfa and ribavirin, is poorly tolerated and often ineffective against the most prevalent genotype of the virus, genotype 7.  The very recent approval of boceprevir and telaprevir, two HCV protease inhibitors, promises to significantly improve treatment options and outcomes.  In addn. to the viral protease NS3 and the viral polymerase NS5B, direct-acting antivirals are now in development against NS5A.  A multifunctional phosphoprotein, NS5A is essential to HCV genome replication, but has no known enzymic function.  Here we report how the design of small-mol. inhibitors against NS5A has evolved from promising monomers to highly potent dimeric compds. effective against many HCV genotypes.  We also highlight recent clin. data and how the inhibitors may bind to NS5A, itself capable of forming dimers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2lefIUXhmK7Vg90H21EOLACvtfcHk0lhvNTHyR_EwBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1eis7nE&md5=7e779d99491df4f8631c7848cb9e56dc</span></div><a href="/servlet/linkout?suffix=cit14d&amp;dbid=16384&amp;doi=10.1358%2Fdof.2011.036.09.1641618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2011.036.09.1641618%26sid%3Dliteratum%253Aachs%26aulast%3DCordek%26aufirst%3DD.%2BG.%26aulast%3DBechtel%26aufirst%3DJ.%2BT.%26aulast%3DMaynard%26aufirst%3DA.%2BT.%26aulast%3DKazmierski%26aufirst%3DW.%2BM.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26atitle%3DTargeting%2520the%2520NS5A%2520protein%2520of%2520HCV%253A%2520an%2520emerging%2520option%26jtitle%3DDrugs%2520Future%26date%3D2011%26volume%3D36%26spage%3D691%26epage%3D711%26doi%3D10.1358%2Fdof.2011.036.09.1641618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Schmitz, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, S.-L.</span><span> </span><span class="NLM_article-title">NS5A-From obscurity to new target for HCV therapy</span> <span class="citation_source-journal">Recent Pat. Anti-Infect. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span><span class="refDoi"> DOI: 10.2174/157489108784746597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.2174%2F157489108784746597" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=77-92&author=U.+Schmitzauthor=S.-L.+Tan&title=NS5A-From+obscurity+to+new+target+for+HCV+therapy&doi=10.2174%2F157489108784746597"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14e&amp;dbid=16384&amp;doi=10.2174%2F157489108784746597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157489108784746597%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitz%26aufirst%3DU.%26aulast%3DTan%26aufirst%3DS.-L.%26atitle%3DNS5A-From%2520obscurity%2520to%2520new%2520target%2520for%2520HCV%2520therapy%26jtitle%3DRecent%2520Pat.%2520Anti-Infect.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D77%26epage%3D92%26doi%3D10.2174%2F157489108784746597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Schinazi, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavegnano, C.</span><span> </span><span class="NLM_article-title">HCV drug discovery aimed at viral eradication</span> <span class="citation_source-journal">J. Viral Hepat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span><span class="refDoi"> DOI: 10.1111/j.1365-2893.2009.01246.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1111%2Fj.1365-2893.2009.01246.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=20040045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FnsFygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=77-90&author=R.+F.+Schinaziauthor=L.+Bassitauthor=C.+Gavegnano&title=HCV+drug+discovery+aimed+at+viral+eradication&doi=10.1111%2Fj.1365-2893.2009.01246.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">HCV drug discovery aimed at viral eradication</span></div><div class="casAuthors">Schinazi R F; Bassit L; Gavegnano C</div><div class="citationInfo"><span class="NLM_cas:title">Journal of viral hepatitis</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">77-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hepatitis C virus (HCV) causes significant morbidity and mortality worldwide with nearly 3% of the world population infected by this virus.  Fortunately, this virus does not establish latency, and hence it may be possible to eradicate it.  HCV is strongly associated with liver cirrhosis and hepatocellular carcinoma and is currently treated with pegylated interferon-alpha (peg-IFN-alpha) and ribavirin.  Unfortunately, these limited treatment options often produce significant side effects, and currently, complete eradication of virus with combined drug modalities has not yet been achieved for the majority of chronically HCV-infected individuals.  Restricted treatment options, lack of a universal cure for HCV and the link between chronic infection, liver cirrhosis and hepatocellular carcinoma necessitate design of novel drugs and treatment options.  Understanding the relationship between the immune response, viral clearance and inhibition of viral replication with pharmacology-based design can ultimately allow for complete eradication of HCV.  This review focuses upon significant novel preclinical and clinical specifically targeted antiviral therapy (STAT-C) drugs under development, highlights their mechanism of action, and discusses their impact on systemic viral loads and permanent clearance of infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxPMbaFdWlO4YPsCkJIw00fW6udTcc2eb6n0vrBqirr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FnsFygtg%253D%253D&md5=27a90c264b557eb92e7c266a9ae5b613</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2893.2009.01246.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2893.2009.01246.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DBassit%26aufirst%3DL.%26aulast%3DGavegnano%26aufirst%3DC.%26atitle%3DHCV%2520drug%2520discovery%2520aimed%2520at%2520viral%2520eradication%26jtitle%3DJ.%2520Viral%2520Hepat.%26date%3D2010%26volume%3D17%26spage%3D77%26epage%3D90%26doi%3D10.1111%2Fj.1365-2893.2009.01246.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Link, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squires, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrish, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matles, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mogalian, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mondou, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornpropst, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, M. C.</span><span> </span><span class="NLM_article-title">Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">2033</span><span class="NLM_x">–</span> <span class="NLM_lpage">2046</span><span class="refDoi"> DOI: 10.1021/jm401499g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401499g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2033-2046&issue=5&author=J.+O.+Linkauthor=J.+G.+Taylorauthor=L.+Xuauthor=M.+Mitchellauthor=H.+Guoauthor=H.+Liuauthor=D.+Katoauthor=T.+Kirschbergauthor=J.+Sunauthor=N.+Squiresauthor=J.+Parrishauthor=T.+Kellerauthor=Z.+Yangauthor=C.+Yangauthor=M.+Matlesauthor=Y.+Wangauthor=K.+Wangauthor=G.+Chengauthor=Y.+Tianauthor=E.+Mogalianauthor=E.+Mondouauthor=M.+Cornpropstauthor=J.+Perryauthor=M.+C.+Desai&title=Discovery+of+ledipasvir+%28GS-5885%29%3A+a+potent%2C+once-daily+oral+NS5A+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Fjm401499g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Link, John O.; Taylor, James G.; Xu, Lianhong; Mitchell, Michael; Guo, Hongyan; Liu, Hongtao; Kato, Darryl; Kirschberg, Thorsten; Sun, Jianyu; Squires, Neil; Parrish, Jay; Kellar, Terry; Yang, Zheng-Yu; Yang, Chris; Matles, Mike; Wang, Yujin; Wang, Kelly; Cheng, Guofeng; Tian, Yang; Mogalian, Erik; Mondou, Elsa; Cornpropst, Melanie; Perry, Jason; Desai, Manoj C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2033-2046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of highly potent NS5A inhibitors with an unsym. benzimidazole-difluorofluorene-imidazole core and distal [2.2.1]-azabicyclic ring system was discovered.  Optimization of antiviral potency and pharmacokinetics led to the identification of ledipasvir (GS-5885).  Ledipasvir (GT1a replicon EC50 = 31 pM) has an extended plasma half-life of 37-45 h in healthy volunteers and produces a rapid >3 log viral load redn. in monotherapy at oral doses of 3 mg or greater with once-daily dosing in genotype 1a HCV-infected patients. ledipasvir has been shown to be safe and efficacious, with SVR12 rates up to 100% when used in combination with direct-acting antivirals having complementary mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiLazFwyH5rrVg90H21EOLACvtfcHk0lhvNTHyR_EwBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltb3I&md5=30cec1d10b7b7dd02faae4fba4b88bd8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm401499g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401499g%26sid%3Dliteratum%253Aachs%26aulast%3DLink%26aufirst%3DJ.%2BO.%26aulast%3DTaylor%26aufirst%3DJ.%2BG.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DMitchell%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DKato%26aufirst%3DD.%26aulast%3DKirschberg%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DSquires%26aufirst%3DN.%26aulast%3DParrish%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DMatles%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DMogalian%26aufirst%3DE.%26aulast%3DMondou%26aufirst%3DE.%26aulast%3DCornpropst%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DJ.%26aulast%3DDesai%26aufirst%3DM.%2BC.%26atitle%3DDiscovery%2520of%2520ledipasvir%2520%2528GS-5885%2529%253A%2520a%2520potent%252C%2520once-daily%2520oral%2520NS5A%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D5%26spage%3D2033%26epage%3D2046%26doi%3D10.1021%2Fjm401499g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">DeGoey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randolph, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matulenko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motter, C.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Discovery of ABT-267, A Pan-genotypic inhibitor of HCV NS5A</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2047</span><span class="NLM_x">–</span> <span class="NLM_lpage">205</span><span class="refDoi"> DOI: 10.1021/jm401398x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401398x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2047-205&author=D.+DeGoeyauthor=J.+Randolphauthor=D.+Liuauthor=J.+Prattauthor=C.+Hutchinsauthor=P.+Donnerauthor=A.+Kruegerauthor=M.+Matulenkoauthor=S.+Patelauthor=C.+Motter&title=Discovery+of+ABT-267%2C+A+Pan-genotypic+inhibitor+of+HCV+NS5A&doi=10.1021%2Fjm401398x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A</span></div><div class="casAuthors">DeGoey, David A.; Randolph, John T.; Liu, Dachun; Pratt, John; Hutchins, Charles; Donner, Pamela; Krueger, A. Chris; Matulenko, Mark; Patel, Sachin; Motter, Christopher E.; Nelson, Lissa; Keddy, Ryan; Tufano, Michael; Caspi, Daniel D.; Krishnan, Preethi; Mistry, Neeta; Koev, Gennadiy; Reisch, Thomas J.; Mondal, Rubina; Pilot-Matias, Tami; Gao, Yi; Beno, David W. A.; Maring, Clarence J.; Molla, Akhter; Dumas, Emily; Campbell, Andrew; Williams, Laura; Collins, Christine; Wagner, Rolf; Kati, Warren M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2047-2057</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe here N-phenylpyrrolidine-based inhibitors of HCV NS5A with excellent potency, metabolic stability, and pharmacokinetics.  Compds. with 2S,5S stereochem. at the pyrrolidine ring provided improved genotype 1 (GT1) potency compared to the 2R,5R analogs.  Furthermore, the attachment of substituents at the 4-position of the central N-Ph group resulted in compds. with improved potency.  Substitution with tert-Bu, as in compd. 38 (ABT-267)(I), provided compds. with low-picomolar EC50 values and superior pharmacokinetics.  It was discovered that compd. 38 was a pan-genotypic HCV inhibitor, with an EC50 range of 1.7-19.3 pM against GT1a, -1b, -2a, -2b, -3a, -4a, and -5a and 366 pM against GT6a.  Compd. 38 decreased HCV RNA up to 3.10 log10 IU/mL during 3-day monotherapy in treatment-naive HCV GT1-infected subjects and is currently in phase 3 clin. trials in combination with an NS3 protease inhibitor with ritonavir (r) (ABT-450/r) and an NS5B non-nucleoside polymerase inhibitor (ABT-333), with and without ribavirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQLXZPjB144rVg90H21EOLACvtfcHk0liXVmPoIBBPaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKhsQ%253D%253D&md5=70f0d0f8e9751b533617fecc1b4a8016</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm401398x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401398x%26sid%3Dliteratum%253Aachs%26aulast%3DDeGoey%26aufirst%3DD.%26aulast%3DRandolph%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DPratt%26aufirst%3DJ.%26aulast%3DHutchins%26aufirst%3DC.%26aulast%3DDonner%26aufirst%3DP.%26aulast%3DKrueger%26aufirst%3DA.%26aulast%3DMatulenko%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DMotter%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520ABT-267%252C%2520A%2520Pan-genotypic%2520inhibitor%2520of%2520HCV%2520NS5A%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2047%26epage%3D205%26doi%3D10.1021%2Fjm401398x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Younossi, Z. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stepanova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feld, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hezode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nader, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, S.</span><span> </span><span class="NLM_article-title">Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1016/j.jhep.2016.02.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.jhep.2016.02.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=26956698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtValuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=33-39&author=Z.+M.+Younossiauthor=M.+Stepanovaauthor=J.+Feldauthor=S.+Zeuzemauthor=I.+Jacobsonauthor=K.+Agarwalauthor=C.+Hezodeauthor=F.+Naderauthor=L.+Henryauthor=S.+Hunt&title=Sofosbuvir%2Fvelpatasvir+improves+patient-reported+outcomes+in+HCV+patients%3A+results+from+ASTRAL-1+placebo-controlled+trial&doi=10.1016%2Fj.jhep.2016.02.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial</span></div><div class="casAuthors">Younossi, Zobair M.; Stepanova, Maria; Feld, Jordan; Zeuzem, Stefan; Jacobson, Ira; Agarwal, Kosh; Hezode, Christophe; Nader, Fatema; Henry, Linda; Hunt, Sharon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-39</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The new pan-genotypic regimen [sofosbuvir (SOF) and velpatasvir (VEL)] for hepatitis C virus (HCV) has been assocd. with high efficacy.  The aim of this study was to assess patient-reported outcomes (PROs) of this regimen.The PRO data (CLDQ-HCV, SF-36, FACIT-F, WPAI) came from the ASTRAL-1 study, a multicenter multinational blinded placebo-controlled phase 3 clin. trial of a fixed dose combination of SOF 400 mg and VEL 100 mg for patients with genotype 1, 2, 4, 5, and 6 compared to placebo for 12 wk.624 patients received active treatment [618 achieved sustained virol. response (SVR)], and 116 received placebo.  The baseline PRO scores were similar.  By treatment week 4, patients receiving SOF/VEL experienced improvements in general health (on av., +2.3 points), emotional well-being (+3.4), FACIT-F (+1.3), and all domains of CLDQ-HCV (+2.1 to +7.3) (all p <0.005).  On the other hand, the only PRO that improved in patients receiving placebo was the worry domain of CLDQ-HCV: +4.6 (p = 0.002).  By the end of treatment, improvement in PRO scores with SOF/VEL continued, and no improvement was noted in the placebo.  Improvement in PROs were also noted 12 and 24 wk post-treatment: +3.7, on av., in patients with SVR-12 after SOF/VEL vs. -2.6, on av., in the placebo arm (p <0.005).  Multivariate anal. showed that treatment-emergent changes in PROs were predicted by receiving SOF/VEL for some summary PRO score (p <0.005).This placebo-controlled trial shows that patients treated with SOF/VEL experience significant improvement of their PROs during treatment and after achieving SVR.In patients with chronic hepatitis C infection, health-related quality of life and work productivity are often impaired due to HCV-related fatigue.  Treatment of hepatitis C with interferon-based regimens, which was the std. of care for all HCV patients until recently, had substantial and potentially debilitating side effects.  These regimens caused addnl. impairment in health-related quality of life and work productivity during treatment and shortly after treatment cessation.  The newly developed interferon-free combination of sofosbuvir and velpatasvir has been shown to improve health-related quality of life during treatment, and lead to an improvement in a no. of indicators of patient-reported outcomes after successful clearance of HCV and achieving sustained virol. response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ-LX9rrAJ0bVg90H21EOLACvtfcHk0liXVmPoIBBPaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtValuro%253D&md5=b2260e84f37dcaef1d4bd3a0860518aa</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2016.02.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2016.02.042%26sid%3Dliteratum%253Aachs%26aulast%3DYounossi%26aufirst%3DZ.%2BM.%26aulast%3DStepanova%26aufirst%3DM.%26aulast%3DFeld%26aufirst%3DJ.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DJacobson%26aufirst%3DI.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DHezode%26aufirst%3DC.%26aulast%3DNader%26aufirst%3DF.%26aulast%3DHenry%26aufirst%3DL.%26aulast%3DHunt%26aufirst%3DS.%26atitle%3DSofosbuvir%252Fvelpatasvir%2520improves%2520patient-reported%2520outcomes%2520in%2520HCV%2520patients%253A%2520results%2520from%2520ASTRAL-1%2520placebo-controlled%2520trial%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D65%26spage%3D33%26epage%3D39%26doi%3D10.1016%2Fj.jhep.2016.02.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Yu, W.; Tong, L.; Kozlowski, J. A.; Selyutin, O.; Chen, L.; Kim, J.-H.; Sha, D.; Rizvi, R.; Shankar, B.; Hu, B.; Zhong, B.; Wai, D.; Hao, J.; Wei, W.; Ji, T.; Zan, S.</span><span> </span><span class="NLM_article-title">Preparation of thiazolyl-substituted tetracyclic compounds end-capped with peptide derivatives as antiviral agents for treating hepatitis C virus infection</span>. Patent WO 2014110687 A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=W.+Yu&author=L.+Tong&author=J.+A.+Kozlowski&author=O.+Selyutin&author=L.+Chen&author=J.-H.+Kim&author=D.+Sha&author=R.+Rizvi&author=B.+Shankar&author=B.+Hu&author=B.+Zhong&author=D.+Wai&author=J.+Hao&author=W.+Wei&author=T.+Ji&author=S.+Zan&title=Preparation+of+thiazolyl-substituted+tetracyclic+compounds+end-capped+with+peptide+derivatives+as+antiviral+agents+for+treating+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26atitle%3DPreparation%2520of%2520thiazolyl-substituted%2520tetracyclic%2520compounds%2520end-capped%2520with%2520peptide%2520derivatives%2520as%2520antiviral%2520agents%2520for%2520treating%2520hepatitis%2520C%2520virus%2520infection%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Neau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansette, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andronik, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">hydroxylation of the thiophene ring by hepatic monooxygenases</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1101</span><span class="NLM_x">–</span> <span class="NLM_lpage">1107</span><span class="refDoi"> DOI: 10.1016/0006-2952(90)90290-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2F0006-2952%2890%2990290-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1990&pages=1101-1107&author=E.+Neauauthor=P.+Dansetteauthor=V.+Andronikauthor=D.+Mansuy&title=hydroxylation+of+the+thiophene+ring+by+hepatic+monooxygenases&doi=10.1016%2F0006-2952%2890%2990290-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2890%2990290-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252890%252990290-2%26sid%3Dliteratum%253Aachs%26aulast%3DNeau%26aufirst%3DE.%26aulast%3DDansette%26aufirst%3DP.%26aulast%3DAndronik%26aufirst%3DV.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3Dhydroxylation%2520of%2520the%2520thiophene%2520ring%2520by%2520hepatic%2520monooxygenases%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1990%26volume%3D39%26spage%3D1101%26epage%3D1107%26doi%3D10.1016%2F0006-2952%2890%2990290-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">McMurtry, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, J.</span><span> </span><span class="NLM_article-title">renal and hepatic necrosis after metabolic activation of 2-substituted furans and thiophenes, including furosemide and cephaloridine</span> <span class="citation_source-journal">Toxicol. Appl. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span><span class="refDoi"> DOI: 10.1016/0041-008X(77)90005-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2F0041-008X%2877%2990005-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=595008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=1%3ACAS%3A528%3ADyaE1cXpvFSntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1977&pages=285-300&author=R.+McMurtryauthor=J.+Mitchell&title=renal+and+hepatic+necrosis+after+metabolic+activation+of+2-substituted+furans+and+thiophenes%2C+including+furosemide+and+cephaloridine&doi=10.1016%2F0041-008X%2877%2990005-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Renal and hepatic necrosis after metabolic activation of 2-substituted furans and thiophenes, including furosemide and cephaloridine</span></div><div class="casAuthors">McMurtry, Randolph J.; Mitchell, Jerry R.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">285-300</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    </div><div class="casAbstract">Single i.p. or i.v. injections of several 2-substituted furans and thiophenes, including furosemide (I)  [54-31-9] and cephaloridine (II)  [50-59-9], produced renal tubular necrosis or hepatic necrosis in mice and rats.  Pretreatment of animals with substances that altered drug-metabolizing enzymes usually altered the severity of the renal and hepatic necrosis produced by the furans and thiophenes and occasionally changed the target organ susceptibility to injury from 1 tissue to the other or the intraorgan zone of the lesion.  Studies with a tritiated nephrotoxic and hepatotoxic furan, 2-furamide  [609-38-1], showed direct correlations between the covalent binding of a chem. reactive metabolite of 2-furamide and the severity of renal and hepatic necrosis after pretreatment of mice with compds. that altered drug-metabolizing enzymes.  A comparison of the covalent binding of the toxic metabolite of 2-furamide to tissues in vivo vs. the covalent binding to hepatic and renal microsomal enzymes in vitro indicated that the renal necrosis was caused by the metabolic activation of 2-furamide in situ in the kidney.  The covalent binding to renal and hepatic microsomal enzymes in vitro was dependent on NADPH, O, and temp. and was inhibited by a CO-O atm.  Collectively, the data provide strong support for the hypothesis that the spectrum of tissue lesions produced in animals by many furans and thiophenes results from organ-specific metabolic transformation of parent drug to chem. reactive intermediates by cytochrome P-450 monooxygenases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5SVh1qYYpGLVg90H21EOLACvtfcHk0lhl8HAcgLtWog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXpvFSntA%253D%253D&md5=2d2082a218bc0e2c738bc06131e6d9be</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2F0041-008X%2877%2990005-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0041-008X%252877%252990005-9%26sid%3Dliteratum%253Aachs%26aulast%3DMcMurtry%26aufirst%3DR.%26aulast%3DMitchell%26aufirst%3DJ.%26atitle%3Drenal%2520and%2520hepatic%2520necrosis%2520after%2520metabolic%2520activation%2520of%25202-substituted%2520furans%2520and%2520thiophenes%252C%2520including%2520furosemide%2520and%2520cephaloridine%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D1977%26volume%3D42%26spage%3D285%26epage%3D300%26doi%3D10.1016%2F0041-008X%2877%2990005-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Dansette, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pons, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">Oxidative activation of the thiophene ring by hepatic enzymes</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">911</span><span class="NLM_x">–</span> <span class="NLM_lpage">918</span><span class="refDoi"> DOI: 10.1016/0006-2952(90)90207-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2F0006-2952%2890%2990207-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1990&pages=911-918&author=P.+Dansetteauthor=C.+Amarauthor=C.+Smithauthor=C.+Ponsauthor=D.+Mansuy&title=Oxidative+activation+of+the+thiophene+ring+by+hepatic+enzymes&doi=10.1016%2F0006-2952%2890%2990207-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2890%2990207-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252890%252990207-2%26sid%3Dliteratum%253Aachs%26aulast%3DDansette%26aufirst%3DP.%26aulast%3DAmar%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DPons%26aufirst%3DC.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DOxidative%2520activation%2520of%2520the%2520thiophene%2520ring%2520by%2520hepatic%2520enzymes%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1990%26volume%3D39%26spage%3D911%26epage%3D918%26doi%3D10.1016%2F0006-2952%2890%2990207-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Kozlowski, J. A.; Rosenblum, S. B.; Coburn, C. A.; Shankar, B. B.; Nair, A. G.; Chen, L.; Dwyer, M. P.; Jiang, Y.; Keertikar, K. M.; Lavey, B. J.; Selyutin, O. B.; Tong, L.; Wong, M.; Yang, D.-Y.; Yu, W.; Zhou, G.; Wu, H.; Hu, B.; Zhong, B.; Sun, F.; Ji, T.; Shen, C.</span><span> </span><span class="NLM_article-title">Preparation of tetracyclic indole derivatives for treatment of HCV infection</span>. Patent WO 2012040923 A1,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+A.+Kozlowski&author=S.+B.+Rosenblum&author=C.+A.+Coburn&author=B.+B.+Shankar&author=A.+G.+Nair&author=L.+Chen&author=M.+P.+Dwyer&author=Y.+Jiang&author=K.+M.+Keertikar&author=B.+J.+Lavey&author=O.+B.+Selyutin&author=L.+Tong&author=M.+Wong&author=D.-Y.+Yang&author=W.+Yu&author=G.+Zhou&author=H.+Wu&author=B.+Hu&author=B.+Zhong&author=F.+Sun&author=T.+Ji&author=C.+Shen&title=Preparation+of+tetracyclic+indole+derivatives+for+treatment+of+HCV+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DPreparation%2520of%2520tetracyclic%2520indole%2520derivatives%2520for%2520treatment%2520of%2520HCV%2520infection%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Tong, L.; Yu, W.; Kozlowski, J. A.; Chen, L.; Selyutin, O.; Kim, S. H.; Dwyer, M.; Hu, B.; Zhong, B.; Wai, D.; Hao, J.; Shen, C.; Lei, Z.; Wang, W.</span><span> </span><span class="NLM_article-title">Preparation of thiophene-substituted tetracyclic compounds end-capped with peptide derivatives as antiviral agents for treating hepatitis C virus infection</span>. Patent WO 2014110706 A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=L.+Tong&author=W.+Yu&author=J.+A.+Kozlowski&author=L.+Chen&author=O.+Selyutin&author=S.+H.+Kim&author=M.+Dwyer&author=B.+Hu&author=B.+Zhong&author=D.+Wai&author=J.+Hao&author=C.+Shen&author=Z.+Lei&author=W.+Wang&title=Preparation+of+thiophene-substituted+tetracyclic+compounds+end-capped+with+peptide+derivatives+as+antiviral+agents+for+treating+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DL.%26atitle%3DPreparation%2520of%2520thiophene-substituted%2520tetracyclic%2520compounds%2520end-capped%2520with%2520peptide%2520derivatives%2520as%2520antiviral%2520agents%2520for%2520treating%2520hepatitis%2520C%2520virus%2520infection%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="note"><p class="first last">Single crystal X-ray analysis for compound <b>40</b> is described in a patent entitled “Process for preparing substituted tetracyclic heterocycle compounds”. It was filed on June 4, 2015. This patent is expected to be published in December 2016.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Tong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girijavallabhan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prongay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saksena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralston, R.</span><span> </span><span class="NLM_article-title">Characterization of resistance mutations against HCV ketoamide protease inhibitors</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2007.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1016%2Fj.antiviral.2007.11.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=177-185&issue=3&author=X.+Tongauthor=S.+Bogenauthor=R.+Chaseauthor=V.+Girijavallabhanauthor=Z.+Guoauthor=F.+G.+Njorogeauthor=A.+Prongayauthor=A.+Saksenaauthor=A.+Skeltonauthor=E.+Xiaauthor=R.+Ralston&title=Characterization+of+resistance+mutations+against+HCV+ketoamide+protease+inhibitors&doi=10.1016%2Fj.antiviral.2007.11.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2007.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2007.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DX.%26aulast%3DBogen%26aufirst%3DS.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26aulast%3DProngay%26aufirst%3DA.%26aulast%3DSaksena%26aufirst%3DA.%26aulast%3DSkelton%26aufirst%3DA.%26aulast%3DXia%26aufirst%3DE.%26aulast%3DRalston%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520resistance%2520mutations%2520against%2520HCV%2520ketoamide%2520protease%2520inhibitors%26jtitle%3DAntiviral%2520Res.%26date%3D2008%26volume%3D77%26issue%3D3%26spage%3D177%26epage%3D185%26doi%3D10.1016%2Fj.antiviral.2007.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Lahser, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bystol, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMonagle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazuda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howe, A. Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asante-Appiah, E.</span><span> </span><span class="NLM_article-title">The combination of grazoprevir, a HCV NS3 protease inhibitor, and elbasvir, a HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2954</span><span class="NLM_x">–</span> <span class="NLM_lpage">2964</span><span class="refDoi"> DOI: 10.1128/AAC.00051-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;key=10.1128%2FAAC.00051-16" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=2954-2964&author=F.+C.+Lahserauthor=K.+Bystolauthor=S.+Curryauthor=P.+McMonagleauthor=E.+Xiaauthor=P.+Ingravalloauthor=R.+Chaseauthor=R.+Liuauthor=T.+Blackauthor=D.+Hazudaauthor=A.+Y.+M.+Howeauthor=E.+Asante-Appiah&title=The+combination+of+grazoprevir%2C+a+HCV+NS3+protease+inhibitor%2C+and+elbasvir%2C+a+HCV+NS5A+inhibitor%2C+demonstrates+a+high+genetic+barrier+to+resistance+in+HCV+genotype+1a+replicons&doi=10.1128%2FAAC.00051-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1128%2FAAC.00051-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00051-16%26sid%3Dliteratum%253Aachs%26aulast%3DLahser%26aufirst%3DF.%2BC.%26aulast%3DBystol%26aufirst%3DK.%26aulast%3DCurry%26aufirst%3DS.%26aulast%3DMcMonagle%26aufirst%3DP.%26aulast%3DXia%26aufirst%3DE.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DBlack%26aufirst%3DT.%26aulast%3DHazuda%26aufirst%3DD.%26aulast%3DHowe%26aufirst%3DA.%2BY.%2BM.%26aulast%3DAsante-Appiah%26aufirst%3DE.%26atitle%3DThe%2520combination%2520of%2520grazoprevir%252C%2520a%2520HCV%2520NS3%2520protease%2520inhibitor%252C%2520and%2520elbasvir%252C%2520a%2520HCV%2520NS5A%2520inhibitor%252C%2520demonstrates%2520a%2520high%2520genetic%2520barrier%2520to%2520resistance%2520in%2520HCV%2520genotype%25201a%2520replicons%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D2954%26epage%3D2964%26doi%3D10.1128%2FAAC.00051-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i77"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01310">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_64648"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01310">10.1021/acs.jmedchem.6b01310</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01310/suppl_file/jm6b01310_si_001.csv">CSV</a>)</p></li><li><p class="inline"><sup>1</sup>H NMR and LCMS spectra of final compounds and full characterization of compound <b>40</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01310/suppl_file/jm6b01310_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01310/suppl_file/jm6b01310_si_001.csv">jm6b01310_si_001.csv (8.26 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01310/suppl_file/jm6b01310_si_002.pdf">jm6b01310_si_002.pdf (8.05 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01310&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-1%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01310%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01310" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b04b29373c4c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
